A BILL 
To provide for lower prices for drugs through drug price 
negotiation, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Make Medicine Affordable Act’’. 
5
(b) TABLE OF CONTENTS.—The table of contents for 
6
this Act is as follows: 
7
Sec. 1. Short title; table of contents. 
TITLE I—LOWERING PRICES THROUGH DRUG PRICE 
NEGOTIATION 
17:03 Apr 19, 2022
H7497
2 
•HR 7497 IH
Sec. 101. Providing for lower prices for certain high-priced single source drugs. 
Sec. 102. Selected drug manufacturer excise tax imposed during noncompliance 
periods. 
Sec. 103. Funding. 
TITLE II—PRESCRIPTION DRUG INFLATION REBATES 
Sec. 201. Medicare part B rebate by manufacturers. 
Sec. 202. Medicare part D rebate by manufacturers. 
TITLE III—PART D IMPROVEMENTS AND MAXIMUM OUT-OF- 
Sec. 301. Medicare part D benefit redesign. 
Sec. 302. Maximum monthly cap on cost-sharing payments under prescription 
drug plans and MA–PD plans. 
TITLE IV—REPEAL OF CERTAIN PRESCRIPTION DRUG REBATE 
RULE 
Sec. 401. Prohibiting implementation of rule relating to eliminating the anti- 
kickback statute safe harbor protection for prescription drug 
rebates. 
TITLE V—MISCELLANEOUS 
Sec. 501. Appropriate cost-sharing for certain insulin products under Medicare 
part D. 
Sec. 502. Coverage of adult vaccines recommended by the Advisory Committee 
on Immunization Practices under Medicare part D. 
Sec. 503. Payment for biosimilar biological products during initial period. 
Sec. 504. Temporary increase in Medicare part B payment for certain bio-
similar biological products. 
Sec. 505. Improving access to adult vaccines under Medicaid and CHIP. 
TITLE VI—ADDITIONAL INSULIN POLICIES 
Sec. 601. ERISA requirements with respect to cost-sharing for certain insulin 
products. 
Sec. 602. Public Health Service Act requirements with respect to cost-sharing 
for insulin products. 
Sec. 603. IRC requirements with respect to cost-sharing for certain insulin 
products. 
17:03 Apr 19, 2022
H7497
3 
•HR 7497 IH
TITLE 
I—LOWERING 
PRICES 
1
THROUGH DRUG PRICE NE-
2
GOTIATION 
3
SEC. 101. PROVIDING FOR LOWER PRICES FOR CERTAIN 
4
HIGH-PRICED SINGLE SOURCE DRUGS. 
5
(a) PROGRAM TO LOWER PRICES
FOR CERTAIN 
6
HIGH-PRICED SINGLE SOURCE DRUGS.—Title XI of the 
7
Social Security Act is amended by adding after section 
8
1184 (42 U.S.C. 1320e–3) the following new part: 
9
‘‘PART E—PRICE NEGOTIATION PROGRAM TO 
10
LOWER PRICES FOR CERTAIN HIGH-PRICED 
11
SINGLE SOURCE DRUGS 
12
‘‘SEC. 1191. ESTABLISHMENT OF PROGRAM. 
13
‘‘(a) IN GENERAL.—The Secretary shall establish a 
14
Drug Price Negotiation Program (in this part referred to 
15
as the ‘program’). Under the program, with respect to 
16
each price applicability period, the Secretary shall— 
17
‘‘(1) publish a list of negotiation-eligible drugs 
18
and selected drugs in accordance with section 1192; 
19
‘‘(2) enter into agreements with manufacturers 
20
of selected drugs with respect to such period, in ac-
21
cordance with section 1193; 
22
‘‘(3) negotiate and, if applicable, renegotiate 
23
maximum fair prices for such selected drugs, in ac-
24
cordance with section 1194; and 
25
17:03 Apr 19, 2022
H7497
4 
•HR 7497 IH
‘‘(4) carry out the administrative duties de-
1
scribed in section 1196. 
2
‘‘(b) DEFINITIONS RELATING TO TIMING.—For pur-
3
poses of this part: 
4
‘‘(1) INITIAL PRICE APPLICABILITY YEAR.—The 
5
term ‘initial price applicability year’ means a year 
6
(beginning with 2025). 
7
‘‘(2) PRICE APPLICABILITY PERIOD.—The term 
8
‘price applicability period’ means, with respect to a 
9
qualifying single source drug, the period beginning 
10
with the first initial price applicability year with re-
11
spect to which such drug is a selected drug and end-
12
ing with the last year during which the drug is a se-
13
lected drug. 
14
‘‘(3) SELECTED
DRUG
PUBLICATION
DATE.— 
15
The term ‘selected drug publication date’ means, 
16
with respect to each initial price applicability year, 
17
February 1 of the year that begins 2 years prior to 
18
such year. 
19
‘‘(4) NEGOTIATION PERIOD.—The term ‘nego-
20
tiation period’ means, with respect to an initial price 
21
applicability year with respect to a selected drug, the 
22
period— 
23
‘‘(A) beginning on the sooner of— 
24
17:03 Apr 19, 2022
H7497
5 
•HR 7497 IH
‘‘(i) the date on which the manufac-
1
turer of the drug and the Secretary enter 
2
into an agreement under section 1193 with 
3
respect to such drug; or 
4
‘‘(ii) February 28 following the se-
5
lected drug publication date with respect to 
6
such selected drug; and 
7
‘‘(B) ending on November 1 of the year 
8
that begins 2 years prior to the initial price ap-
9
plicability year. 
10
‘‘(c) OTHER DEFINITIONS.—For purposes of this 
11
part: 
12
‘‘(1) MAXIMUM
FAIR
PRICE
ELIGIBLE
INDI-
13
VIDUAL.—The term ‘maximum fair price eligible in-
14
dividual’ means, with respect to a selected drug— 
15
‘‘(A) in the case such drug is dispensed to 
16
the individual at a pharmacy, by a mail order 
17
service, or by another dispenser, an individual 
18
who is enrolled under a prescription drug plan 
19
under part D of title XVIII or an MA–PD plan 
20
under part C of such title if coverage is pro-
21
vided under such plan for such selected drug; 
22
and 
23
‘‘(B) in the case such drug is furnished or 
24
administered to the individual by a hospital, 
25
17:03 Apr 19, 2022
H7497
6 
•HR 7497 IH
physician, or other provider of services or sup-
1
plier, an individual who is enrolled under part 
2
B of title XVIII, including an individual who is 
3
enrolled under an MA plan under part C of 
4
such title, if such selected drug is covered under 
5
such part. 
6
‘‘(2) MAXIMUM FAIR PRICE.—The term ‘max-
7
imum fair price’ means, with respect to a year dur-
8
ing a price applicability period and with respect to 
9
a selected drug (as defined in section 1192(c)) with 
10
respect to such period, the price published pursuant 
11
to section 1195 in the Federal Register for such 
12
drug and year. 
13
‘‘(3) UNIT.—The term ‘unit’ means, with re-
14
spect to a drug or biological, the lowest identifiable 
15
amount (such as a capsule or tablet, milligram of 
16
molecules, or grams) of the drug or biological that 
17
is dispensed or furnished. The determination of a 
18
unit, with respect to a drug or biological, pursuant 
19
to this paragraph shall not be subject to administra-
20
tive or judicial review. 
21
‘‘(4) TOTAL EXPENDITURES.—The term ‘total 
22
expenditures’ includes, in the case of expenditures 
23
with respect to part D of title XVIII, ingredient 
24
costs, dispensing fees, sales tax, and if applicable, 
25
17:03 Apr 19, 2022
H7497
7 
•HR 7497 IH
vaccine administration fees. The term ‘total expendi-
1
tures’ excludes, in the case of expenditures with re-
2
spect to part B of such title, expenditures for a drug 
3
or biological that are bundled or packaged into the 
4
payment for another service. 
5
‘‘SEC. 1192. SELECTION OF NEGOTIATION-ELIGIBLE DRUGS 
6
AS SELECTED DRUGS. 
7
‘‘(a) IN GENERAL.—Not later than the selected drug 
8
publication date with respect to an initial price applica-
9
bility year, in accordance with subsection (b), the Sec-
10
retary shall select and publish in the Federal Register a 
11
list of— 
12
‘‘(1)(A) with respect to the initial price applica-
13
bility year 2025, not more than 10 negotiation-eligi-
14
ble drugs described in subparagraph (A)(i) of sub-
15
section (d)(1), but not subparagraph (B) of such 
16
subsection, with respect to such year; 
17
‘‘(B) with respect to the initial price applica-
18
bility year 2026, not more than 15 negotiation-eligi-
19
ble drugs described in subparagraph (A)(i) of sub-
20
section (d)(1), but not subparagraph (B) of such 
21
subsection, with respect to such year; 
22
‘‘(C) with respect to the initial price applica-
23
bility year 2027, not more than 15 negotiation-eligi-
24
ble drugs described in subparagraph (A) of sub-
25
17:03 Apr 19, 2022
H7497
8 
•HR 7497 IH
section (d)(1), but not subparagraph (B) of such 
1
subsection, with respect to such year; and 
2
‘‘(D) with respect to the initial price applica-
3
bility year 2028 or a subsequent year, not more than 
4
20 negotiation-eligible drugs described in subpara-
5
graph (A) of subsection (d)(1), but not subpara-
6
graph (B) of such subsection, with respect to such 
7
year; and 
8
‘‘(2) all negotiation-eligible drugs described in 
9
subparagraph (B) of such subsection with respect to 
10
such year. 
11
Subject to subsection (c)(2) and section 1194(f)(5), each 
12
drug published on the list pursuant to the previous sen-
13
tence shall be subject to the negotiation process under sec-
14
tion 1194 for the negotiation period with respect to such 
15
initial price applicability year (and the renegotiation proc-
16
ess under such section as applicable for any subsequent 
17
year during the applicable price applicability period). 
18
‘‘(b) SELECTION OF DRUGS.— 
19
‘‘(1) IN GENERAL.—In carrying out subsection 
20
(a)(1), subject to paragraph (2), the Secretary shall, 
21
with respect to an initial price applicability year— 
22
‘‘(A) rank a combined list of negotiation-el-
23
igible drugs described in subsection (d)(1)(A) 
24
according to the total expenditures for such 
25
17:03 Apr 19, 2022
H7497
9 
•HR 7497 IH
drugs under parts B and D of title XVIII, as 
1
determined by the Secretary, during the most 
2
recent period of 12 months prior to the selected 
3
drug publication date (but ending not later 
4
than October 31 of the year prior to the year 
5
of such drug publication date), with respect to 
6
such year, for which data are available, with the 
7
negotiation-eligible drugs with the highest total 
8
expenditures being ranked the highest; and 
9
‘‘(B) select from such ranked combined list 
10
for inclusion on the published list described in 
11
subsection (a) with respect to such year the ne-
12
gotiation-eligible drugs with the highest such 
13
rankings. 
14
‘‘(2) HIGH SPEND PART D DRUGS FOR 2025 AND 
15
2026.—With respect to the initial price applicability 
16
year 2025 and with respect to the initial price appli-
17
cability year 2026, the Secretary shall apply para-
18
graph (1) as if the reference to ‘negotiation-eligible 
19
drugs described in subsection (d)(1)(A)’ were a ref-
20
erence to ‘negotiation-eligible drugs described in sub-
21
section (d)(1)(A)(i)’ and as if the reference to ‘total 
22
expenditures for such drugs under parts B and D of 
23
title XVIII’ were a reference to ‘total expenditures 
24
for such drugs under part D of title XVIII’. 
25
17:03 Apr 19, 2022
H7497
10 
•HR 7497 IH
‘‘(c) SELECTED DRUG.— 
1
‘‘(1) IN GENERAL.—For purposes of this part, 
2
consistent with subsection (e)(2) and subject to 
3
paragraph (2), each negotiation-eligible drug in-
4
cluded on the list published under subsection (a) 
5
with respect to an initial price applicability year 
6
shall be referred to as a ‘selected drug’ with respect 
7
to such year and each subsequent year beginning be-
8
fore the first year that begins after the date on 
9
which the Secretary determines at least one drug or 
10
biological product— 
11
‘‘(A) is approved or licensed (as applica-
12
ble)— 
13
‘‘(i) under section 505(j) of the Fed-
14
eral Food, Drug, and Cosmetic Act using 
15
such drug as the listed drug; or 
16
‘‘(ii) under section 351(k) of the Pub-
17
lic Health Service Act using such drug as 
18
the reference product; and 
19
‘‘(B) is marketed pursuant to such ap-
20
proval or licensure. 
21
‘‘(2) 
CLARIFICATION.—A 
negotiation-eligible 
22
drug— 
23
17:03 Apr 19, 2022
H7497
11 
•HR 7497 IH
‘‘(A) that is included on the list published 
1
under subsection (a) with respect to an initial 
2
price applicability year; and 
3
‘‘(B) for which the Secretary makes a de-
4
termination described in paragraph (1) before 
5
or during the negotiation period with respect to 
6
such initial price applicability year, 
7
shall not be subject to the negotiation process under 
8
section 1194 with respect to such negotiation period 
9
and shall continue to be considered a selected drug 
10
under this part with respect to the number of nego-
11
tiation-eligible drugs published on the list under sub-
12
section (a) with respect to such initial price applica-
13
bility year. 
14
‘‘(d) NEGOTIATION-ELIGIBLE DRUG.— 
15
‘‘(1) IN GENERAL.—For purposes of this part, 
16
subject to paragraph (2), the term ‘negotiation-eligi-
17
ble drug’ means, with respect to the selected drug 
18
publication date with respect to an initial price ap-
19
plicability year, a qualifying single source drug, as 
20
defined in subsection (e), that is described in either 
21
of the following subparagraphs (or, with respect to 
22
the initial price applicability year 2025 or 2026, that 
23
is described in subparagraph (A)(i) or (B)): 
24
17:03 Apr 19, 2022
H7497
12 
•HR 7497 IH
‘‘(A) HIGH SPEND DRUGS.—The qualifying 
1
single source drug is, determined in accordance 
2
with subsection (e)(2)— 
3
‘‘(i) among the 50 qualifying single 
4
source drugs with the highest total expend-
5
itures under part D of title XVIII, as de-
6
termined by the Secretary in accordance 
7
with paragraph (3), during the most recent 
8
period for which data are available of at 
9
least 12 months prior to the selected drug 
10
publication date (but ending no later than 
11
October 31 of the year prior to the year of 
12
such drug publication date), with respect 
13
to such year; or 
14
‘‘(ii) among the 50 qualifying single 
15
source drugs with the highest total expend-
16
itures under part B of title XVIII, as de-
17
termined by the Secretary in accordance 
18
with paragraph (3), during such most re-
19
cent period, as described in clause (i). 
20
‘‘(B) 
INSULIN.—The 
qualifying 
single 
21
source drug is described in subsection (e)(1)(C). 
22
‘‘(2) 
EXCEPTION
FOR
SMALL
BIOTECH 
23
DRUGS.— 
24
17:03 Apr 19, 2022
H7497
13 
•HR 7497 IH
‘‘(A) IN
GENERAL.—Subject to subpara-
1
graph (C), the term ‘negotiation-eligible drug’ 
2
shall not include, with respect to the initial 
3
price applicability years 2025, 2026, and 2027, 
4
a qualifying single source drug that meets ei-
5
ther of the following: 
6
‘‘(i) PART D DRUGS.—The total ex-
7
penditures for the qualifying single source 
8
drug under part D of title XVIII, as deter-
9
mined by the Secretary in accordance with 
10
paragraph (3), during 2021— 
11
‘‘(I) are equal to or less than 1 
12
percent of the total expenditures 
13
under such part D, as so determined, 
14
for all covered part D drugs during 
15
such year; and 
16
‘‘(II) are equal to at least 80 per-
17
cent of the total expenditures under 
18
such part D, as so determined, for all 
19
covered part D drugs for which the 
20
manufacturer of the drug has an 
21
agreement in effect under section 
22
1860D–14A during such year. 
23
‘‘(ii) PART B DRUGS.—The total ex-
24
penditures for the qualifying single source 
25
17:03 Apr 19, 2022
H7497
14 
•HR 7497 IH
drug under part B of title XVIII, as deter-
1
mined by the Secretary in accordance with 
2
paragraph (3), during 2021— 
3
‘‘(I) are equal to or less than 1 
4
percent of the total expenditures 
5
under such part B, as so determined, 
6
for all qualifying single source drugs 
7
covered under such part B during 
8
such year; and 
9
‘‘(II) are equal to at least 80 per-
10
cent of the total expenditures under 
11
such part B, as so determined, for all 
12
qualifying single source drugs of the 
13
manufacturer that are covered under 
14
such part B during such year. 
15
‘‘(B) CLARIFICATIONS RELATING TO MAN-
16
UFACTURERS.— 
17
‘‘(i) AGGREGATION
RULE.—All per-
18
sons treated as a single employer under 
19
subsection (a) or (b) of section 52 of the 
20
Internal Revenue Code of 1986 shall be 
21
treated as one manufacturer for purposes 
22
of this paragraph. 
23
‘‘(ii) LIMITATION.—A qualifying sin-
24
gle source drug described in subparagraph 
25
17:03 Apr 19, 2022
H7497
15 
•HR 7497 IH
(A) shall not include a qualifying single 
1
source drug of a manufacturer if such 
2
manufacturer is acquired after 2021 by 
3
another manufacturer that does not meet 
4
the definition of a specified manufacturer 
5
under section 1860D–14C(g)(4)(B)(ii), ef-
6
fective at the beginning of the plan year 
7
immediately following such acquisition or, 
8
in the case of an acquisition before 2024, 
9
effective January 1, 2024. 
10
‘‘(C) DRUGS
NOT
INCLUDED
AS
SMALL 
11
BIOTECH DRUGS.—The following shall not be 
12
considered a qualifying single source drug de-
13
scribed in subparagraph (A): 
14
‘‘(i) A vaccine that is licensed under 
15
section 351 of the Public Health Service 
16
Act and is marketed pursuant to such sec-
17
tion. 
18
‘‘(ii) A new formulation, such as an 
19
extended release formulation, of a quali-
20
fying single source drug. 
21
‘‘(iii) A qualifying single source drug 
22
described in subsection (e)(1)(C). 
23
‘‘(3) CLARIFICATIONS AND DETERMINATIONS.— 
24
17:03 Apr 19, 2022
H7497
16 
•HR 7497 IH
‘‘(A) PREVIOUSLY SELECTED DRUGS AND 
1
SMALL BIOTECH DRUGS EXCLUDED.—In apply-
2
ing clauses (i) and (ii) of paragraph (1)(A), the 
3
Secretary shall not consider or count— 
4
‘‘(i) drugs that are already selected 
5
drugs; and 
6
‘‘(ii) for initial price applicability 
7
years 2025, 2026, and 2027, qualifying 
8
single source drugs described in paragraph 
9
(2)(A). 
10
‘‘(B) USE
OF
DATA.—In determining 
11
whether a qualifying single source drug satisfies 
12
any of the criteria described in paragraph (1) 
13
or (2), the Secretary shall use data that is ag-
14
gregated across dosage forms and strengths of 
15
the drug, including new formulations of the 
16
drug, such as an extended release formulation, 
17
and not based on the specific formulation or 
18
package size or package type of the drug. 
19
‘‘(4) PUBLICATION.—Not later than the se-
20
lected drug publication date with respect to an ini-
21
tial price applicability year, the Secretary shall pub-
22
lish in the Federal Register a list of negotiation-eli-
23
gible drugs with respect to such selected drug publi-
24
cation date. 
25
17:03 Apr 19, 2022
H7497
17 
•HR 7497 IH
‘‘(e) QUALIFYING SINGLE SOURCE DRUG.— 
1
‘‘(1) IN GENERAL.—For purposes of this part, 
2
the term ‘qualifying single source drug’ means, with 
3
respect to an initial price applicability year, subject 
4
to paragraphs (2) and (3), a covered part D drug 
5
(as defined in section 1860D–2(e)) that is described 
6
in any of the following or a drug or biological prod-
7
uct covered under part B of title XVIII that is de-
8
scribed in any of the following: 
9
‘‘(A) DRUG PRODUCTS.—A drug— 
10
‘‘(i) that is approved under section 
11
505(c) of the Federal Food, Drug, and 
12
Cosmetic Act and is marketed pursuant to 
13
such approval; 
14
‘‘(ii) for which, as of the selected drug 
15
publication date with respect to such initial 
16
price applicability year, at least 7 years 
17
will have elapsed since the date of such ap-
18
proval; and 
19
‘‘(iii) that is not the listed drug for 
20
any drug that is approved and marketed 
21
under section 505(j) of such Act. 
22
‘‘(B) BIOLOGICAL PRODUCTS.—A biologi-
23
cal product— 
24
17:03 Apr 19, 2022
H7497
18 
•HR 7497 IH
‘‘(i) that is licensed under section 
1
351(a) of the Public Health Service Act 
2
and is marketed under section 351 of such 
3
Act; 
4
‘‘(ii) for which, as of the selected drug 
5
publication date with respect to such initial 
6
price applicability year, at least 11 years 
7
will have elapsed since the date of such li-
8
censure; and 
9
‘‘(iii) that is not the reference product 
10
for any biological product that is licensed 
11
and marketed under section 351(k) of such 
12
Act. 
13
‘‘(C) INSULIN
PRODUCT.—Any insulin 
14
product that is approved under section 505 of 
15
the Federal Food, Drug, and Cosmetic Act or 
16
licensed under section 351 of the Public Health 
17
Service Act and marketed pursuant to such ap-
18
proval or licensure, including any insulin prod-
19
uct that has been deemed to be licensed under 
20
section 351 of the Public Health Service Act 
21
pursuant to section 7002(e)(4) of the Biologics 
22
Price Competition and Innovation Act of 2009 
23
and is marketed pursuant to such section, re-
24
17:03 Apr 19, 2022
H7497
19 
•HR 7497 IH
gardless of whether such insulin product would 
1
be described in subparagraph (A) or (B). 
2
‘‘(2) TREATMENT
OF
AUTHORIZED
GENERIC 
3
DRUGS.— 
4
‘‘(A) IN GENERAL.—In the case of a quali-
5
fying single source drug described in subpara-
6
graph (A) or (B) of paragraph (1) that is the 
7
listed drug (as such term is used in section 
8
505(j) of the Federal Food, Drug, and Cos-
9
metic Act) or the reference product (as defined 
10
in section 351(i) of the Public Health Service 
11
Act), with respect to an authorized generic 
12
drug, in applying the provisions of this part, 
13
such authorized generic drug and such listed 
14
drug or reference product shall be treated as 
15
the same qualifying single source drug. 
16
‘‘(B) AUTHORIZED
GENERIC
DRUG
DE-
17
FINED.—For purposes of this paragraph, the 
18
term ‘authorized generic drug’ means— 
19
‘‘(i) in the case of a drug, an author-
20
ized generic drug (as such term is defined 
21
in section 505(t)(3) of the Federal Food, 
22
Drug, and Cosmetic Act); and 
23
‘‘(ii) in the case of a biological prod-
24
uct, a reference product (as such term is 
25
17:03 Apr 19, 2022
H7497
20 
•HR 7497 IH
defined in section 351(i) of the Public 
1
Health Service Act) that— 
2
‘‘(I) has been licensed under sec-
3
tion 351(a) of such Act; and 
4
‘‘(II) is marketed, sold, or dis-
5
tributed directly or indirectly to retail 
6
class of trade under a different label-
7
ing, packaging (other than repack-
8
aging as the reference product in blis-
9
ter packs, unit doses, or similar pack-
10
aging for use in institutions), product 
11
code, labeler code, trade name, or 
12
trade mark than the reference prod-
13
uct. 
14
‘‘(3) EXCLUSIONS.—In this part, the term 
15
‘qualifying single source drug’ does not include any 
16
of the following: 
17
‘‘(A) CERTAIN ORPHAN DRUGS.—A drug 
18
that is designated as a drug for only one rare 
19
disease or condition under section 526 of the 
20
Federal Food, Drug, and Cosmetic Act and for 
21
which the only approved indication (or indica-
22
tions) is for such disease or condition. 
23
‘‘(B) LOW SPEND MEDICARE DRUGS.—A 
24
drug or biological product (other than an insu-
25
17:03 Apr 19, 2022
H7497
21 
•HR 7497 IH
lin product described in paragraph (1)(C)) with 
1
respect to which the total expenditures under 
2
parts B and D of title XVIII, as determined by 
3
the Secretary, during the most recent period for 
4
which data are available of at least 12 months 
5
prior to the selected drug publication date (but 
6
ending no later than October 31 of the year 
7
prior to the year of such drug publication date), 
8
with respect to such year is less than— 
9
‘‘(i) 
with 
respect 
to 
2021, 
10
$200,000,000; or 
11
‘‘(ii) with respect to a subsequent 
12
year, the dollar amount specified in this 
13
subparagraph for the previous year in-
14
creased by the annual percentage increase 
15
in the consumer price index (all items; 
16
U.S. city average) as of December of such 
17
previous year. 
18
‘‘(f) NO ADMINISTRATIVE OR JUDICIAL REVIEW OF 
19
DETERMINATIONS AND SELECTIONS.—The determination 
20
of negotiation-eligible drugs under subsection (d) and the 
21
selection of drugs under this section are not subject to 
22
administrative or judicial review. 
23
17:03 Apr 19, 2022
H7497
22 
•HR 7497 IH
‘‘SEC. 1193. MANUFACTURER AGREEMENTS. 
1
‘‘(a) 
IN
GENERAL.—For 
purposes 
of 
section 
2
1191(a)(2), the Secretary shall enter into agreements with 
3
manufacturers of selected drugs with respect to a price 
4
applicability period, by not later than February 28 fol-
5
lowing the selected drug publication date with respect to 
6
such selected drug, under which— 
7
‘‘(1) during the negotiation period for the initial 
8
price applicability year for the selected drug, the 
9
Secretary and manufacturer, in accordance with sec-
10
tion 1194, negotiate to determine (and, by not later 
11
than the last date of such period, agree to) a max-
12
imum fair price for such selected drug of the manu-
13
facturer in order for the manufacturer to provide ac-
14
cess to such price— 
15
‘‘(A) to maximum fair price eligible indi-
16
viduals who with respect to such drug are de-
17
scribed 
in 
subparagraph 
(A) 
of 
section 
18
1191(c)(1) and are dispensed such drug (and to 
19
pharmacies, mail order services, and other dis-
20
pensers, with respect to such maximum fair 
21
price eligible individuals who are dispensed such 
22
drugs) during, subject to subparagraph (2), the 
23
price applicability period; and 
24
‘‘(B) to hospitals, physicians, and other 
25
providers of services and suppliers with respect 
26
17:03 Apr 19, 2022
H7497
23 
•HR 7497 IH
to maximum fair price eligible individuals who 
1
with respect to such drug are described in sub-
2
paragraph (B) of such section and are fur-
3
nished or administered such drug during, sub-
4
ject to subparagraph (2), the price applicability 
5
period; 
6
‘‘(2) the Secretary and the manufacturer shall, 
7
in accordance with section 1194, renegotiate (and, 
8
by not later than the last date of such period, agree 
9
to) the maximum fair price for such drug, in order 
10
for the manufacturer to provide access to such max-
11
imum fair price (as so renegotiated)— 
12
‘‘(A) to maximum fair price eligible indi-
13
viduals who with respect to such drug are de-
14
scribed 
in 
subparagraph 
(A) 
of 
section 
15
1191(c)(1) and are dispensed such drug (and to 
16
pharmacies, mail order services, and other dis-
17
pensers, with respect to such maximum fair 
18
price eligible individuals who are dispensed such 
19
drugs) during any year during the price appli-
20
cability period (beginning after such renegoti-
21
ation) with respect to such selected drug; and 
22
‘‘(B) to hospitals, physicians, and other 
23
providers of services and suppliers with respect 
24
to maximum fair price eligible individuals who 
25
17:03 Apr 19, 2022
H7497
24 
•HR 7497 IH
with respect to such drug are described in sub-
1
paragraph (B) of such section and are fur-
2
nished or administered such drug during any 
3
year described in subparagraph (A); 
4
‘‘(3) access to the maximum fair price (includ-
5
ing as renegotiated pursuant to paragraph (2)), with 
6
respect to such a selected drug, shall be provided by 
7
the manufacturer to— 
8
‘‘(A) maximum fair price eligible individ-
9
uals, who with respect to such drug are de-
10
scribed 
in 
subparagraph 
(A) 
of 
section 
11
1191(c)(1), at the pharmacy, mail order service, 
12
or other dispenser at the point-of-sale of such 
13
drug (and shall be provided by the manufac-
14
turer to the pharmacy, mail order service, or 
15
other dispenser, with respect to such maximum 
16
fair price eligible individuals who are dispensed 
17
such drugs), as described in paragraph (1)(A) 
18
or (2)(A), as applicable; and 
19
‘‘(B) hospitals, physicians, and other pro-
20
viders of services and suppliers with respect to 
21
maximum fair price eligible individuals who 
22
with respect to such drug are described in sub-
23
paragraph (B) of such section and are fur-
24
17:03 Apr 19, 2022
H7497
25 
•HR 7497 IH
nished or administered such drug, as described 
1
in paragraph (1)(B) or (2)(B), as applicable; 
2
‘‘(4) the manufacturer, subject to subsection 
3
(d), submits to the Secretary, through an online por-
4
tal established by the Secretary or other form and 
5
manner specified by the Secretary, for the negotia-
6
tion period for the price applicability period (and, if 
7
applicable, before any period of renegotiation pursu-
8
ant to section 1194(f)) with respect to such drug— 
9
‘‘(A) information on the non-Federal aver-
10
age manufacturer price for the drug for the ap-
11
plicable year or period; and 
12
‘‘(B) all other information that the Sec-
13
retary requires to carry out the negotiation (or 
14
renegotiation process) under this part, including 
15
information described in section 1194(e)(1); 
16
and 
17
‘‘(5) the manufacturer complies with require-
18
ments imposed by the Secretary for purposes of ad-
19
ministering the program, including with respect to 
20
the duties described in section 1196. 
21
‘‘(b) AGREEMENT IN EFFECT UNTIL DRUG IS NO 
22
LONGER A SELECTED DRUG.—An agreement entered into 
23
under this section shall be effective, with respect to a se-
24
17:03 Apr 19, 2022
H7497
26 
•HR 7497 IH
lected drug, until such drug is no longer considered a se-
1
lected drug under section 1192(c). 
2
‘‘(c) CONFIDENTIALITY OF INFORMATION.—Informa-
3
tion submitted to the Secretary under this part by a man-
4
ufacturer of a selected drug that is proprietary informa-
5
tion of such manufacturer (as determined by the Sec-
6
retary) shall be used only by the Secretary or disclosed 
7
to and used by the Comptroller General of the United 
8
States or the Medicare Payment Advisory Commission for 
9
purposes of carrying out this part. 
10
‘‘(d) IMPLEMENTATION FOR 2025 AND 2026.—Not-
11
withstanding any other provision of this part, the Sec-
12
retary shall implement this section for 2025 and 2026 by 
13
program instruction or otherwise. 
14
‘‘SEC. 1194. NEGOTIATION AND RENEGOTIATION PROCESS. 
15
‘‘(a) IN GENERAL.—For purposes of this part, under 
16
an agreement under section 1193 between the Secretary 
17
and a manufacturer of a selected drug, with respect to 
18
the period for which such agreement is in effect and in 
19
accordance with subsections (b), (c), and (d), the Sec-
20
retary and the manufacturer— 
21
‘‘(1) shall during the negotiation period with re-
22
spect to such drug, in accordance with this section, 
23
negotiate a maximum fair price for such drug for 
24
the purpose described in section 1193(a)(1); and 
25
17:03 Apr 19, 2022
H7497
27 
•HR 7497 IH
‘‘(2) renegotiate, in accordance with the process 
1
specified pursuant to subsection (f), such maximum 
2
fair price for such drug if such drug is a renegoti-
3
ation-eligible drug under such subsection. 
4
‘‘(b) NEGOTIATION PROCESS REQUIREMENTS.— 
5
‘‘(1) METHODOLOGY AND PROCESS.—The Sec-
6
retary shall develop and use a consistent method-
7
ology and process, in accordance with paragraph (2), 
8
for negotiations under subsection (a) that aims to 
9
achieve the lowest maximum fair price for each se-
10
lected drug. 
11
‘‘(2) SPECIFIC
ELEMENTS
OF
NEGOTIATION 
12
PROCESS.—As part of the negotiation process under 
13
this section, with respect to a selected drug and the 
14
negotiation period with respect to the initial price 
15
applicability year with respect to such drug, the fol-
16
lowing shall apply: 
17
‘‘(A) SUBMISSION OF INFORMATION.—Not 
18
later than March 1 of the year of the selected 
19
drug publication date, with respect to the se-
20
lected drug, the manufacturer of the drug shall 
21
submit to the Secretary, in accordance with sec-
22
tion 1193(a)(4), the information described in 
23
such section. 
24
17:03 Apr 19, 2022
H7497
28 
•HR 7497 IH
‘‘(B) INITIAL OFFER BY SECRETARY.—Not 
1
later than the June 1 following the selected 
2
drug publication date, the Secretary shall pro-
3
vide the manufacturer of a selected drug with 
4
a written initial offer that contains the Sec-
5
retary’s proposal for the maximum fair price of 
6
the drug and a list of the considerations de-
7
scribed in section 1194(e) that were used in de-
8
veloping such offer. 
9
‘‘(C) RESPONSE TO INITIAL OFFER.— 
10
‘‘(i) IN GENERAL.—Not later than 30 
11
days after the date of receipt of an initial 
12
offer under subparagraph (B), the manu-
13
facturer shall either accept such offer or 
14
propose a counteroffer to such offer. 
15
‘‘(ii) 
COUNTEROFFER
REQUIRE-
16
MENTS.—If a manufacturer proposes a 
17
counteroffer, such counteroffer— 
18
‘‘(I) shall be in writing; and 
19
‘‘(II) shall be justified based on 
20
the factors described in subsection (e). 
21
‘‘(D) RESPONSE
TO
COUNTEROFFER.— 
22
After receiving a counteroffer under subpara-
23
graph (C), the Secretary shall respond in writ-
24
ing to such counteroffer. 
25
17:03 Apr 19, 2022
H7497
29 
•HR 7497 IH
‘‘(E) DEADLINE.—All negotiations shall 
1
end prior to the first day of November following 
2
the selected drug publication date, with respect 
3
to the initial price applicability year. 
4
‘‘(F) LIMITATIONS ON OFFER AMOUNT.— 
5
In negotiating the maximum fair price of a se-
6
lected drug, with respect to an initial price ap-
7
plicability year for the selected drug, and, as 
8
applicable, in renegotiating the maximum fair 
9
price for such drug, with respect to a subse-
10
quent year during the price applicability period 
11
for such drug, the Secretary shall not offer (or 
12
agree to a counteroffer for) a maximum fair 
13
price for the selected drug that— 
14
‘‘(i) exceeds the ceiling determined 
15
under subsection (c) for the selected drug 
16
and year; or 
17
‘‘(ii) as applicable, is less than the 
18
floor determined under subsection (d) for 
19
the selected drug and year. 
20
‘‘(G) TREATMENT OF DETERMINATION.— 
21
The establishment of a maximum fair price 
22
under this section is not subject to administra-
23
tive or judicial review. 
24
‘‘(c) CEILING FOR MAXIMUM FAIR PRICE.— 
25
17:03 Apr 19, 2022
H7497
30 
•HR 7497 IH
‘‘(1) IN GENERAL.—The maximum fair price 
1
negotiated under this section for a selected drug, 
2
with respect to the first year of the price applica-
3
bility period with respect to such drug, shall not ex-
4
ceed the applicable percent described in paragraph 
5
(2), with respect to such drug, of the following: 
6
‘‘(A) INITIAL PRICE APPLICABILITY YEAR 
7
2025.—In the case of a selected drug with re-
8
spect to which such initial price applicability 
9
year is 2025, the average of the non-Federal 
10
average manufacturer price for such drug for 
11
the first 3 calendar quarters of 2021 (or, in the 
12
case that there is not a non-Federal average 
13
manufacturer price available for such drug for 
14
any of such first 3 calendar quarters of 2021, 
15
for the first full year following the market entry 
16
for such drug), increased by the percentage in-
17
crease in the consumer price index for all urban 
18
consumers (all items; United States city aver-
19
age) from September 2021 (or such first full 
20
year following the market entry), as applicable, 
21
to the year prior to the selected drug publica-
22
tion date with respect to such initial price appli-
23
cability year. 
24
17:03 Apr 19, 2022
H7497
31 
•HR 7497 IH
‘‘(B) INITIAL PRICE APPLICABILITY YEAR 
1
2026 AND SUBSEQUENT YEARS.—In the case of 
2
a selected drug with respect to which such ini-
3
tial price applicability year is 2026 or a subse-
4
quent year, the lower of— 
5
‘‘(i) the average of the non-Federal 
6
average manufacturer price for such drug 
7
for the first 3 calendar quarters of 2021 
8
(or, in the case that there is not a non- 
9
Federal average manufacturer price avail-
10
able for such drug for any of such first 3 
11
calendar quarters of 2021, for the first full 
12
year following the market entry for such 
13
drug), increased by the percentage increase 
14
in the consumer price index for all urban 
15
consumers (all items; United States city 
16
average) from September 2021 (or such 
17
first full year following the market entry), 
18
as applicable, to the year prior to the se-
19
lected drug publication date with respect to 
20
such initial price applicability year; or 
21
‘‘(ii) the non-Federal average manu-
22
facturer price for such drug for the year 
23
prior to the selected drug publication date 
24
17:03 Apr 19, 2022
H7497
32 
•HR 7497 IH
with respect to such initial price applica-
1
bility year. 
2
‘‘(2) APPLICABLE PERCENT DESCRIBED.—For 
3
purposes of paragraph (1), the applicable percent 
4
described in this paragraph is the following: 
5
‘‘(A) SHORT-MONOPOLY DRUGS.—With re-
6
spect to a selected drug (other than a post-ex-
7
clusivity drug and a long-monopoly drug), 75 
8
percent. 
9
‘‘(B) POST-EXCLUSIVITY DRUGS.—With re-
10
spect to a post-exclusivity drug, 65 percent. 
11
‘‘(C) LONG-MONOPOLY DRUGS.—With re-
12
spect to a long-monopoly drug, 40 percent. 
13
‘‘(3) POST-EXCLUSIVITY DRUG DEFINED.— 
14
‘‘(A) IN GENERAL.—In this part, subject 
15
to subparagraph (B), the term ‘post-exclusivity 
16
drug’ means, with respect to an initial price ap-
17
plicability year, a selected drug for which at 
18
least 12 years, but fewer than 16 years, have 
19
elapsed since the date of approval of such drug 
20
under section 505(c) of the Federal Food, 
21
Drug, and Cosmetic Act or since the date of li-
22
censure of such drug under section 351(a) of 
23
the Public Health Service Act, as applicable. 
24
17:03 Apr 19, 2022
H7497
33 
•HR 7497 IH
‘‘(B) EXCLUSIONS.—The term ‘post-exclu-
1
sivity drug’ shall not include any of the fol-
2
lowing: 
3
‘‘(i) A vaccine that is licensed under 
4
section 351 of the Public Health Service 
5
Act and marketed pursuant to such sec-
6
tion. 
7
‘‘(ii) A selected drug that had an 
8
agreement under this part with the Sec-
9
retary prior to the initial price applicability 
10
year 2030. 
11
‘‘(C) CLARIFICATION.—Nothing in sub-
12
paragraph (B)(ii) shall limit the transition of a 
13
selected drug described in paragraph (2)(A) to 
14
a long-monopoly drug if the selected drug meets 
15
the definition of a long-monopoly drug. 
16
‘‘(4) LONG-MONOPOLY DRUG DEFINED.— 
17
‘‘(A) IN GENERAL.—In this part, subject 
18
to subparagraph (B), the term ‘long-monopoly 
19
drug’ means, with respect to an initial price ap-
20
plicability year, a selected drug for which at 
21
least 16 years have elapsed since the date of 
22
approval of such drug under section 505(c) of 
23
the Federal Food, Drug, and Cosmetic Act or 
24
since the date of licensure of such drug under 
25
17:03 Apr 19, 2022
H7497
34 
•HR 7497 IH
section 351(a) of the Public Health Service Act, 
1
as applicable. 
2
‘‘(B) EXCLUSION.—The term ‘long-monop-
3
oly drug’ shall not include a vaccine that is li-
4
censed under section 351 of the Public Health 
5
Service Act and marketed pursuant to such sec-
6
tion. 
7
‘‘(5) NON-FEDERAL AVERAGE MANUFACTURER 
8
PRICE.—In this part, the term ‘non-Federal average 
9
manufacturer price’ has the meaning given such 
10
term in section 8126(h)(5) of title 38, United States 
11
Code. 
12
‘‘(d) TEMPORARY
FLOOR
FOR
SMALL
BIOTECH 
13
DRUGS.—In the case of a selected drug that is a quali-
14
fying single source drug described in section 1192(d)(2) 
15
and with respect to which the first initial price applica-
16
bility year of the price applicability period with respect to 
17
such drug is 2028 or 2029, the maximum fair price nego-
18
tiated under this section for such drug for such initial 
19
price applicability year may not be less than 66 percent 
20
of the average of the non-Federal average manufacturer 
21
price for such drug (as defined and applied in subsection 
22
(c)(4)) for the first 3 calendar quarters of 2021 (or, in 
23
the case that there is not a non-Federal average manufac-
24
turer price available for such drug for any of such first 
25
17:03 Apr 19, 2022
H7497
35 
•HR 7497 IH
3 calendar quarters of 2021, for the first full year fol-
1
lowing the market entry for such drug), increased by the 
2
percentage increase in the consumer price index for all 
3
urban consumers (all items; United States city average) 
4
from September 2021 (or such first full year following the 
5
market entry), as applicable, to the year prior to the se-
6
lected drug publication date with respect to the initial 
7
price applicability year. 
8
‘‘(e) CONSIDERATIONS.—For purposes of negotiating 
9
the maximum fair price of a selected drug under this part 
10
with the manufacturer of the drug, the Secretary shall 
11
consider the following factors (and, with respect to post- 
12
exclusivity drugs and long-monopoly drugs, shall not con-
13
sider factors other than those described in subparagraphs 
14
(B) and (C) of paragraph (1)): 
15
‘‘(1) 
MANUFACTURER-SPECIFIC
INFORMA-
16
TION.—The following information, with respect to 
17
such selected drug, including as submitted by the 
18
manufacturer: 
19
‘‘(A) Research and development costs of 
20
the manufacturer for the drug and the extent to 
21
which the manufacturer has recouped research 
22
and development costs. 
23
‘‘(B) Market data for the drug, including 
24
the distribution of sales across different pro-
25
17:03 Apr 19, 2022
H7497
36 
•HR 7497 IH
grams and purchasers and projected future rev-
1
enues for the drug. 
2
‘‘(C) Unit costs of production and distribu-
3
tion of the drug. 
4
‘‘(D) Prior Federal financial support for 
5
novel therapeutic discovery and development 
6
with respect to the drug. 
7
‘‘(E) Data on patents and on existing and 
8
pending exclusivity for the drug. 
9
‘‘(F) National sales data for the drug. 
10
‘‘(G) Information on clinical trials for the 
11
drug. 
12
‘‘(2) INFORMATION ON UNMET MEDICAL NEEDS 
13
AND ALTERNATIVE TREATMENTS.—The following in-
14
formation, with respect to such selected drug: 
15
‘‘(A) The extent to which the drug rep-
16
resents a therapeutic advance as compared to 
17
existing therapeutic alternatives and, to the ex-
18
tent such information is available, the costs of 
19
such existing therapeutic alternatives. 
20
‘‘(B) Information on approval by the Food 
21
and Drug Administration of alternative drug 
22
products or biological products. 
23
‘‘(C) Information on comparative effective-
24
ness analysis for such products, taking into 
25
17:03 Apr 19, 2022
H7497
37 
•HR 7497 IH
consideration the effects of such products on 
1
specific populations, such as individuals with 
2
disabilities, the elderly, the terminally ill, chil-
3
dren, and other patient populations. 
4
‘‘(D) The extent to which the drug ad-
5
dresses unmet medical needs for a condition for 
6
which treatment or diagnosis is not addressed 
7
adequately by available therapy. 
8
In considering information described in subpara-
9
graph (C), the Secretary shall not use evidence or 
10
findings from comparative clinical effectiveness re-
11
search in a manner that treats extending the life of 
12
an elderly, disabled, or terminally ill individual as of 
13
lower value than extending the life of an individual 
14
who is younger, nondisabled, or not terminally ill. 
15
‘‘(3) ADDITIONAL INFORMATION.—Information 
16
submitted to the Secretary, in accordance with a 
17
process specified by the Secretary, by other parties 
18
that are affected by the establishment of a maximum 
19
fair price for the selected drug. 
20
‘‘(f) RENEGOTIATION PROCESS.— 
21
‘‘(1) IN GENERAL.—In the case of a renegoti-
22
ation-eligible drug (as defined in paragraph (2)) that 
23
is selected under paragraph (3), the Secretary shall 
24
provide for a process of renegotiation (for years (be-
25
17:03 Apr 19, 2022
H7497
38 
•HR 7497 IH
ginning with 2027) during the price applicability pe-
1
riod, with respect to such drug) of the maximum fair 
2
price for such drug consistent with paragraph (4). 
3
‘‘(2) 
RENEGOTIATION-ELIGIBLE
DRUG
DE-
4
FINED.—In this section, the term ‘renegotiation-eli-
5
gible drug’ means a selected drug that is any of the 
6
following: 
7
‘‘(A) ADDITION OF NEW INDICATION.—A 
8
selected drug for which a new indication is 
9
added to the drug. 
10
‘‘(B) CHANGE OF STATUS TO A POST-EX-
11
CLUSIVITY DRUG.—A selected drug that is de-
12
scribed in section 1192(d)(1)(A) that— 
13
‘‘(i) is not a post-exclusivity drug or a 
14
long-monopoly drug; and 
15
‘‘(ii) for which there is a change in 
16
status to that of a post-exclusivity drug. 
17
‘‘(C) CHANGE OF STATUS TO A LONG-MO-
18
NOPOLY
DRUG.—A selected drug that is de-
19
scribed in section 1192(d)(1)(A) that— 
20
‘‘(i) is not a long-monopoly drug; and 
21
‘‘(ii) for which there is a change in 
22
status to that of a long-monopoly drug. 
23
‘‘(D) MATERIAL
CHANGES.—A selected 
24
drug for which the Secretary determines there 
25
17:03 Apr 19, 2022
H7497
39 
•HR 7497 IH
has been a material change of factors described 
1
in paragraph (1) or (2) of subsection (e). 
2
‘‘(3) SELECTION
OF
DRUGS
FOR
RENEGOTI-
3
ATION.—Each year the Secretary shall select among 
4
renegotiation-eligible drugs for renegotiation as fol-
5
lows: 
6
‘‘(A) ALL
NEGOTIA-
7
TION-ELIGIBLE
DRUGS.—The Secretary shall 
8
select all renegotiation-eligible drugs described 
9
in paragraph (2)(B). 
10
‘‘(B) ALL LONG-MONOPOLY NEGOTIATION- 
11
ELIGIBLE DRUGS.—The Secretary shall select 
12
all renegotiation-eligible drugs described in 
13
paragraph (2)(C). 
14
‘‘(C) REMAINING DRUGS.—Among the re-
15
maining renegotiation-eligible drugs described 
16
in subparagraphs (A) and (D) of paragraph (2), 
17
the Secretary shall select renegotiation-eligible 
18
drugs for which the Secretary expects renegoti-
19
ation is likely to result in a significant change 
20
in the maximum fair price otherwise negotiated. 
21
‘‘(4) RENEGOTIATION PROCESS.—The Secretary 
22
shall specify the process for renegotiation of max-
23
imum fair prices with the manufacturer of a renego-
24
tiation-eligible drug selected for renegotiation under 
25
17:03 Apr 19, 2022
H7497
40 
•HR 7497 IH
this subsection. Such process shall, to the extent 
1
practicable, be consistent with the methodology and 
2
process established under subsection (b) and in ac-
3
cordance with subsections (c) and (d), and for pur-
4
poses of applying subsections (c) and (d), the ref-
5
erence to the first initial price applicability year of 
6
the price applicability period with respect to such 
7
drug shall be treated as the first initial price appli-
8
cability year of such period for which the maximum 
9
fair price established pursuant to such renegotiation 
10
applies, including for applying subsection (c)(2)(B) 
11
in the case of renegotiation-eligible drugs described 
12
in paragraph (3)(A) of this subsection and sub-
13
section (c)(2)(C) in the case of renegotiation-eligible 
14
drugs described in paragraph (3)(B) of this sub-
15
section. 
16
‘‘(5) CLARIFICATION.—A renegotiation-eligible 
17
drug for which the Secretary makes a determination 
18
described in section 1192(c)(1) before or during the 
19
period of renegotiation shall not be subject to the re-
20
negotiation process under this section. 
21
‘‘(6) NO
ADMINISTRATIVE
OR
JUDICIAL
RE-
22
VIEW.—The determination of renegotiation-eligible 
23
drugs under paragraph (2) and the selection of re-
24
17:03 Apr 19, 2022
H7497
41 
•HR 7497 IH
negotiation-eligible drugs under paragraph (3) are 
1
not subject to administrative or judicial review. 
2
‘‘(g) REQUEST FOR INFORMATION.—For purposes of 
3
negotiating and, as applicable, renegotiating (including for 
4
purposes of determining whether to renegotiate) the max-
5
imum fair price of a selected drug under this part with 
6
the manufacturer of the drug, with respect to a price ap-
7
plicability period, and other relevant data for purposes of 
8
this section— 
9
‘‘(1) the Secretary shall, not later than the se-
10
lected drug publication date with respect to the ini-
11
tial price applicability year of such period, request 
12
drug pricing information from the manufacturer of 
13
such selected drug, including information described 
14
in subsection (e)(1); and 
15
‘‘(2) by not later than March 1 following the se-
16
lected drug publication date, the manufacturer of 
17
such selected drug shall submit to the Secretary 
18
such requested information in such form and man-
19
ner as the Secretary requires. 
20
The Secretary shall request, from the manufacturer or 
21
others, all additional information needed to carry out the 
22
negotiation and renegotiation process under this section. 
23
‘‘(h) CLARIFICATION.—In no case shall the maximum 
24
fair price negotiated under this section for a selected drug 
25
17:03 Apr 19, 2022
H7497
42 
•HR 7497 IH
that is a qualifying single source drug described in sub-
1
paragraph (A) or (B) of section 1192(e)(1) apply before— 
2
‘‘(1) in the case the selected drug is a quali-
3
fying single source drug described in such subpara-
4
graph (A), the date that is 9 years after the date on 
5
which the drug was approved under section 505(c) 
6
of the Federal Food, Drug, and Cosmetic Act; and 
7
‘‘(2) in the case the selected drug is a quali-
8
fying single source drug described in such subpara-
9
graph (B), the date that is 13 years after the date 
10
on which the drug was licensed under section 351(a) 
11
of the Public Health Service Act. 
12
‘‘(i) IMPLEMENTATION FOR 2025 AND 2026.—Not-
13
withstanding any other provision of this part, the Sec-
14
retary shall implement this section for 2025 and 2026 by 
15
program instruction or otherwise. 
16
‘‘SEC. 1195. PUBLICATION OF MAXIMUM FAIR PRICES. 
17
‘‘(a) IN GENERAL.—With respect to an initial price 
18
applicability year and a selected drug with respect to such 
19
year— 
20
‘‘(1) not later than November 15 of the year 
21
that is 2 years prior to such initial price applicability 
22
year, the Secretary shall publish on CMS.gov the 
23
maximum fair price for such drug negotiated under 
24
this part with the manufacturer of such drug; 
25
17:03 Apr 19, 2022
H7497
43 
•HR 7497 IH
‘‘(2) not later than November 30 of the year 
1
that is 2 years prior to such initial price applicability 
2
year, the Secretary shall publish in the Federal Reg-
3
ister the maximum fair price for such drug described 
4
in paragraph (1); and 
5
‘‘(3) not later than March 1 of the year prior 
6
to such initial price applicability year, the Secretary 
7
shall publish in the Federal Register, subject to sec-
8
tion 1193(c) and based on the considerations as de-
9
scribed in section 1194(e), the explanation for the 
10
maximum fair price for such drug described in para-
11
graphs (1) and (2). 
12
‘‘(b) UPDATES.— 
13
‘‘(1) 
SUBSEQUENT
YEAR
MAXIMUM
FAIR 
14
PRICES.—For a selected drug, for each year subse-
15
quent to first initial price applicability year of the 
16
price applicability period with respect to such drug, 
17
with respect to which an agreement for such drug is 
18
in effect under section 1193, not later than Novem-
19
ber 30 of the year that is 2 years prior to such sub-
20
sequent year, the Secretary shall publish in the Fed-
21
eral Register the maximum fair price applicable to 
22
such drug and year, which shall be— 
23
‘‘(A) subject to subparagraph (B), the 
24
amount equal to the maximum fair price pub-
25
17:03 Apr 19, 2022
H7497
44 
•HR 7497 IH
lished for such drug for the previous year, in-
1
creased by the annual percentage increase in 
2
the consumer price index for all urban con-
3
sumers (all items; U.S. city average) as of Sep-
4
tember of such previous year; or 
5
‘‘(B) in the case the maximum fair price 
6
for such drug was renegotiated, for the first 
7
year for which such price as so renegotiated ap-
8
plies, such renegotiated maximum fair price. 
9
‘‘(2) PRICES NEGOTIATED AFTER DEADLINE.— 
10
In the case of a selected drug with respect to an ini-
11
tial price applicability year for which the maximum 
12
fair price is determined under this part after the 
13
date of publication under this section, the Secretary 
14
shall publish such maximum fair price in the Fed-
15
eral Register by not later than 30 days after the 
16
date such maximum price is so determined. 
17
‘‘SEC. 1196. ADMINISTRATIVE DUTIES; COORDINATION PRO-
18
VISIONS. 
19
‘‘(a) ADMINISTRATIVE DUTIES.— 
20
‘‘(1) IN
GENERAL.—For purposes of section 
21
1191, the administrative duties described in this sec-
22
tion are the following: 
23
17:03 Apr 19, 2022
H7497
45 
•HR 7497 IH
‘‘(A) The establishment of procedures to 
1
ensure that the maximum fair price for a se-
2
lected drug is applied before— 
3
‘‘(i) any coverage or financial assist-
4
ance under other health benefit plans or 
5
programs that provide coverage or finan-
6
cial assistance for the purchase or provi-
7
sion of prescription drug coverage on be-
8
half of maximum fair price eligible individ-
9
uals; and 
10
‘‘(ii) any other discounts. 
11
‘‘(B) The establishment of procedures to 
12
compute and apply the maximum fair price 
13
across different strengths and dosage forms of 
14
a selected drug and not based on the specific 
15
formulation or package size or package type of 
16
the drug. 
17
‘‘(C) The establishment of procedures to 
18
carry out the provisions of this part, as applica-
19
ble, with respect to— 
20
‘‘(i) maximum fair price eligible indi-
21
viduals who are enrolled under a prescrip-
22
tion drug plan under part D of title XVIII 
23
or an MA–PD plan under part C of such 
24
title; and 
25
17:03 Apr 19, 2022
H7497
46 
•HR 7497 IH
‘‘(ii) maximum fair price eligible indi-
1
viduals who are enrolled under part B of 
2
such title, including who are enrolled under 
3
an MA plan under part C of such title. 
4
‘‘(D) The establishment of a negotiation 
5
process and renegotiation process in accordance 
6
with section 1194, including a process for ac-
7
quiring information described in subsection (e) 
8
of such section. 
9
‘‘(E) The establishment of an online portal 
10
which manufacturers shall be required to use to 
11
submit 
information 
described 
in 
section 
12
1194(b)(2)(A). 
13
‘‘(F) The sharing with the Secretary of the 
14
Treasury of such information as is necessary to 
15
determine the tax imposed by section 4192 of 
16
the Internal Revenue Code of 1986 (relating to 
17
enforcement of this part). 
18
‘‘(G) The establishment of an attestation 
19
and verification process for purposes of apply-
20
ing section 1192(d)(2)(B). 
21
‘‘(2) MONITORING
COMPLIANCE.—The Sec-
22
retary shall monitor compliance by a manufacturer 
23
with the terms of an agreement under section 1193, 
24
17:03 Apr 19, 2022
H7497
47 
•HR 7497 IH
including by establishing a mechanism through 
1
which violations of such terms shall be reported. 
2
‘‘(b) IMPLEMENTATION FOR 2025 AND 2026.—Not-
3
withstanding any other provision of this part, the Sec-
4
retary shall implement this section for 2025 and 2026 by 
5
program instruction or otherwise. 
6
‘‘SEC. 1197. CIVIL MONETARY PENALTY. 
7
‘‘(a) VIOLATIONS RELATING TO OFFERING OF MAX-
8
IMUM FAIR PRICE.—Any manufacturer of a selected drug 
9
that has entered into an agreement under section 1193, 
10
with respect to a year during the price applicability period 
11
with respect to such drug, that does not provide access 
12
to a price that is not more than the maximum fair price 
13
(or a lesser price) for such drug for such year— 
14
‘‘(1) to a maximum fair price eligible individual 
15
who with respect to such drug is described in sub-
16
paragraph (A) of section 1191(c)(1) and who is dis-
17
pensed such drug during such year (and to phar-
18
macies, mail order services, and other dispensers, 
19
with respect to such maximum fair price eligible in-
20
dividuals who are dispensed such drugs); or 
21
‘‘(2) to a hospital, physician, or other provider 
22
of services or supplier with respect to maximum fair 
23
price eligible individuals who with respect to such 
24
drug is described in subparagraph (B) of such sec-
25
17:03 Apr 19, 2022
H7497
48 
•HR 7497 IH
tion and is furnished or administered such drug by 
1
such hospital, physician, or provider or supplier dur-
2
ing such year, 
3
shall be subject to a civil monetary penalty equal to ten 
4
times the amount equal to the product of the number of 
5
units of such drug so furnished, dispensed, or adminis-
6
tered during such year and the difference between the 
7
price for such drug made available for such year by such 
8
manufacturer with respect to such individual or hospital, 
9
physician, provider of services, or supplier and the max-
10
imum fair price for such drug for such year. 
11
‘‘(b) VIOLATIONS OF CERTAIN TERMS OF AGREE-
12
MENT.—Any manufacturer of a selected drug that has en-
13
tered into an agreement under section 1193, with respect 
14
to a year during the price applicability period with respect 
15
to such drug, that is in violation of a requirement imposed 
16
pursuant to section 1193(a)(5), including the requirement 
17
to submit information pursuant to section 1193(a)(4), 
18
shall be subject to a civil monetary penalty equal to 
19
$1,000,000 for each day of such violation. 
20
‘‘(c) FALSE INFORMATION.—Any manufacturer that 
21
knowingly provides false information for the attestation 
22
process or verification process established pursuant to sec-
23
tion 1196(a)(1)(H), shall be subject to a civil monetary 
24
17:03 Apr 19, 2022
H7497
49 
•HR 7497 IH
penalty equal to $100,000,000 for each item of such false 
1
information. 
2
‘‘(d) APPLICATION.—The provisions of section 1128A 
3
(other than subsections (a) and (b)) shall apply to a civil 
4
monetary penalty under this section in the same manner 
5
as such provisions apply to a penalty or proceeding under 
6
section 1128A(a).’’. 
7
(b) APPLICATION OF MAXIMUM FAIR PRICES AND 
8
CONFORMING AMENDMENTS.— 
9
(1) UNDER MEDICARE.— 
10
(A) APPLICATION
TO
PAYMENTS
UNDER 
11
PART B.—Section 1847A(b)(1)(B) of the Social 
12
Security Act (42 U.S.C. 1395w–3a(b)(1)(B)) is 
13
amended by inserting ‘‘or in the case of such a 
14
drug or biological that is a selected drug (as re-
15
ferred to in section 1192(c)), with respect to a 
16
price applicability period (as defined in section 
17
1191(b)(2)), 106 percent of the maximum fair 
18
price (as defined in section 1191(c)(2)) applica-
19
ble for such drug and a year during such pe-
20
riod’’ after ‘‘paragraph (4)’’. 
21
(B) APPLICATION
UNDER
MA
OF
COST- 
22
SHARING FOR PART B DRUGS BASED OFF OF 
23
NEGOTIATED
PRICE.—Section 
24
1852(a)(1)(B)(iv) of the Social Security Act 
25
17:03 Apr 19, 2022
H7497
50 
•HR 7497 IH
(42 U.S.C. 1395w–22(a)(1)(B)(iv)) is amend-
1
ed— 
2
(i) by redesignating subclause (VII) as 
3
subclause (VIII); and 
4
(ii) by inserting after subclause (VI) 
5
the following subclause: 
6
‘‘(VII) A drug or biological that 
7
is a selected drug (as referred to in 
8
section 1192(c)).’’. 
9
(C) EXCEPTION TO PART D NON-INTER-
10
FERENCE.—Section 1860D–11(i) of the Social 
11
Security Act (42 U.S.C. 1395w–111(i)) is 
12
amended— 
13
(i) in paragraph (1), by striking 
14
‘‘and’’ at the end; 
15
(ii) in paragraph (2), by striking ‘‘or 
16
institute a price structure for the reim-
17
bursement of covered part D drugs’’ and 
18
inserting ‘‘for covered part D drugs; and’’; 
19
and 
20
(iii) by adding at the end the fol-
21
lowing: 
22
‘‘(3) may not institute a price structure for the 
23
reimbursement of covered part D drugs, except as 
24
provided under part E of title XI.’’. 
25
17:03 Apr 19, 2022
H7497
51 
•HR 7497 IH
(D) APPLICATION AS NEGOTIATED PRICE 
1
UNDER PART D.—Section 1860D–2(d)(1) of the 
2
Social 
Security 
Act 
(42 
U.S.C. 
1395w– 
3
102(d)(1)) is amended— 
4
(i) in subparagraph (B), by inserting 
5
‘‘, subject to subparagraph (D),’’ after 
6
‘‘negotiated prices’’; and 
7
(ii) by adding at the end the following 
8
new subparagraph: 
9
‘‘(D) APPLICATION
OF
MAXIMUM
FAIR 
10
PRICE FOR SELECTED DRUGS.—In applying this 
11
section, in the case of a covered part D drug 
12
that is a selected drug (as referred to in section 
13
1192(c)), with respect to a price applicability 
14
period (as defined in section 1191(b)(2)), the 
15
negotiated prices used for payment (as de-
16
scribed in this subsection) shall be no greater 
17
than the maximum fair price (as defined in sec-
18
tion 1191(c)(2)) for such drug and for each 
19
year during such period plus any dispensing 
20
fees for such drug.’’. 
21
(E) COVERAGE
OF
SELECTED
DRUGS.— 
22
Section 1860D–4(b)(3) of the Social Security 
23
Act (42 U.S.C. 1395w–104(b)(3)) is amended 
24
17:03 Apr 19, 2022
H7497
52 
•HR 7497 IH
by adding at the end the following new sub-
1
paragraph: 
2
‘‘(I) REQUIRED INCLUSION OF SELECTED 
3
DRUGS.—For 2025 and each subsequent year, 
4
the PDP sponsor offering a prescription drug 
5
plan shall include each covered part D drug 
6
that is a selected drug under section 1192 for 
7
which an agreement for such drug is in effect 
8
under section 1193 with respect to the year.’’. 
9
(F) INFORMATION
FROM
PRESCRIPTION 
10
DRUG PLANS AND MA–PD PLANS REQUIRED.— 
11
(i) PRESCRIPTION DRUG PLANS.—Sec-
12
tion 1860D–12(b) of the Social Security 
13
Act (42 U.S.C. 1395w–112(b)) is amended 
14
by adding at the end the following new 
15
paragraph: 
16
‘‘(8) PROVISION OF INFORMATION RELATED TO 
17
MAXIMUM FAIR PRICES.—Each contract entered into 
18
with a PDP sponsor under this part with respect to 
19
a prescription drug plan offered by such sponsor 
20
shall require the sponsor to provide information to 
21
the Secretary as requested by the Secretary in ac-
22
cordance with section 1194(g).’’. 
23
(ii) 
MA–PD 
PLANS.—Section 
24
1857(f)(3) of the Social Security Act (42 
25
17:03 Apr 19, 2022
H7497
53 
•HR 7497 IH
U.S.C. 1395w–27(f)(3)) is amended by 
1
adding at the end the following new sub-
2
paragraph: 
3
‘‘(E) PROVISION
OF
INFORMATION
RE-
4
LATED
TO
MAXIMUM
FAIR
PRICES.—Section 
5
1860D–12(b)(8).’’. 
6
(2) 
DRUG
PRICE
NEGOTIATION
PROGRAM 
7
PRICES
INCLUDED
IN
BEST
PRICE.—Section 
8
1927(c)(1)(C) of the Social Security Act (42 U.S.C. 
9
1396r–8(c)(1)(C)) is amended— 
10
(A) in clause (i)(VI), by striking ‘‘any 
11
prices charged’’ and inserting ‘‘subject to clause 
12
(ii)(V), any prices charged’’; and 
13
(B) in clause (ii)— 
14
(i) in subclause (III), by striking at 
15
the end ‘‘; and’’; 
16
(ii) in subclause (IV), by striking at 
17
the end the period and inserting ‘‘; and’’; 
18
and 
19
(iii) by adding at the end the fol-
20
lowing new subclause: 
21
‘‘(V) in the case of a rebate pe-
22
riod and a covered outpatient drug 
23
that is a selected drug (as referred to 
24
in section 1192(c)) during such rebate 
25
17:03 Apr 19, 2022
H7497
54 
•HR 7497 IH
period, shall be inclusive of the max-
1
imum fair price (as defined in section 
2
1191(c)(2)) for such drug with re-
3
spect to such period.’’. 
4
SEC. 102. SELECTED DRUG MANUFACTURER EXCISE TAX 
5
IMPOSED DURING NONCOMPLIANCE PERI-
6
ODS. 
7
(a) IN GENERAL.—Chapter 32 of the Internal Rev-
8
enue Code of 1986 is amended by adding at the end the 
9
following new subchapter: 
10
‘‘Subchapter E—Other Items 
11
‘‘Sec. 4192. Selected drugs during noncompliance periods. 
‘‘SEC. 4192. SELECTED DRUGS DURING NONCOMPLIANCE 
12
PERIODS. 
13
‘‘(a) IN GENERAL.—There is hereby imposed on the 
14
sale by the manufacturer, producer, or importer of any 
15
selected drug during a day described in subsection (b) a 
16
tax in an amount such that the applicable percentage is 
17
equal to the ratio of— 
18
‘‘(1) such tax, divided by 
19
‘‘(2) the sum of such tax and the price for 
20
which so sold. 
21
‘‘(b) NONCOMPLIANCE PERIODS.—A day is described 
22
in this subsection with respect to a selected drug if it is 
23
a day during one of the following periods: 
24
17:03 Apr 19, 2022
H7497
55 
•HR 7497 IH
‘‘(1) The period beginning on the March 1st 
1
immediately following the selected drug publication 
2
date and ending on the first date during which the 
3
manufacturer of the drug has in place an agreement 
4
described in subsection (a) of section 1193 of the 
5
Social Security Act with respect to such drug. 
6
‘‘(2) The period beginning on the November 
7
2nd immediately following the March 1st described 
8
in paragraph (1) and ending on the first date during 
9
which the manufacturer of the drug and the Sec-
10
retary have agreed to a maximum fair price under 
11
such agreement. 
12
‘‘(3) In the case of a selected drug with respect 
13
to which the Secretary of Health and Human Serv-
14
ices has specified a renegotiation period under such 
15
agreement, the period beginning on the first date 
16
after the last date of such renegotiation period and 
17
ending on the first date during which the manufac-
18
turer of the drug has agreed to a renegotiated max-
19
imum fair price under such agreement. 
20
‘‘(4) With respect to information that is re-
21
quired to be submitted to the Secretary of Health 
22
and Human Services under such agreement, the pe-
23
riod beginning on the date on which such Secretary 
24
17:03 Apr 19, 2022
H7497
56 
•HR 7497 IH
certifies that such information is overdue and ending 
1
on the date that such information is so submitted. 
2
‘‘(c) APPLICABLE PERCENTAGE.—For purposes of 
3
this section, the term ‘applicable percentage’ means— 
4
‘‘(1) in the case of sales of a selected drug dur-
5
ing the first 90 days described in subsection (b) with 
6
respect to such drug, 65 percent, 
7
‘‘(2) in the case of sales of such drug during 
8
the 91st day through the 180th day described in 
9
subsection (b) with respect to such drug, 75 percent, 
10
‘‘(3) in the case of sales of such drug during 
11
the 181st day through the 270th day described in 
12
subsection (b) with respect to such drug, 85 percent, 
13
and 
14
‘‘(4) in the case of sales of such drug during 
15
any subsequent day, 95 percent. 
16
‘‘(d) SELECTED DRUG.—For purposes of this sec-
17
tion— 
18
‘‘(1) IN GENERAL.—The term ‘selected drug’ 
19
means any selected drug (within the meaning of sec-
20
tion 1192 of the Social Security Act) which is manu-
21
factured or produced in the United States or entered 
22
into the United States for consumption, use, or 
23
warehousing. 
24
17:03 Apr 19, 2022
H7497
57 
•HR 7497 IH
‘‘(2) UNITED
STATES.—The term ‘United 
1
States’ has the meaning given such term by section 
2
4612(a)(4). 
3
‘‘(3) COORDINATION WITH RULES FOR POSSES-
4
SIONS OF THE UNITED STATES.—Rules similar to 
5
the rules of paragraphs (2) and (4) of section 
6
4132(c) shall apply for purposes of this section. 
7
‘‘(e) OTHER DEFINITIONS.—For purposes of this 
8
section, the terms ‘selected drug publication date’ and 
9
‘maximum fair price’ have the meaning given such terms 
10
in section 1191 of the Social Security Act. 
11
‘‘(f) ANTI-ABUSE RULE.—In the case of a sale which 
12
was timed for the purpose of avoiding the tax imposed by 
13
this section, the Secretary may treat such sale as occur-
14
ring during a day described in subsection (b).’’. 
15
(b) NO DEDUCTION FOR EXCISE TAX PAYMENTS.— 
16
Section 275(a)(6) of the Internal Revenue Code of 1986 
17
is amended by inserting ‘‘or by section 4192’’ before the 
18
period at the end. 
19
(c) CERTAIN EXEMPTIONS FROM TAX NOT APPLICA-
20
BLE.— 
21
(1) Section 4221(a) of the Internal Revenue 
22
Code of 1986 is amended by adding at the end the 
23
following: ‘‘In the case of the tax imposed by section 
24
17:03 Apr 19, 2022
H7497
58 
•HR 7497 IH
4192, paragraphs (3), (4), (5), and (6) shall not 
1
apply.’’. 
2
(2) Section 6416(b)(2) of such Code is amend-
3
ed by adding at the end the following: ‘‘In the case 
4
of the tax imposed by section 4192, subparagraphs 
5
(B), (C), (D), and (E) shall not apply.’’. 
6
(d) CLERICAL AMENDMENT.—The table of sub-
7
chapters for chapter 32 of such Code is amended by add-
8
ing at the end the following new item: 
9
‘‘SUBCHAPTER E. OTHER ITEMS’’. 
(e) EFFECTIVE DATE.—The amendments made by 
10
this section shall apply to sales after the date of the enact-
11
ment of this Act. 
12
SEC. 103. FUNDING. 
13
In addition to amounts otherwise available, there is 
14
appropriated for fiscal year 2022, out of any money in 
15
the Treasury not otherwise appropriated, to remain avail-
16
able until expended— 
17
(1) $300,000,000 to carry out the provisions of, 
18
including the amendments made by, this part in fis-
19
cal year 2022; 
20
(2) $300,000,000 to carry out the provisions of, 
21
including the amendments made by, this part in fis-
22
cal year 2023; 
23
17:03 Apr 19, 2022
H7497
59 
•HR 7497 IH
(3) $300,000,000 to carry out the provisions of, 
1
including the amendments made by, this part in fis-
2
cal year 2024; 
3
(4) $300,000,000 to carry out the provisions of, 
4
including the amendments made by, this part in fis-
5
cal year 2025; 
6
(5) $300,000,000 to carry out the provisions of, 
7
including the amendments made by, this part in fis-
8
cal year 2026; 
9
(6) $300,000,000 to carry out the provisions of, 
10
including the amendments made by, this part in fis-
11
cal year 2027; 
12
(7) $300,000,000 to carry out the provisions of, 
13
including the amendments made by, this part in fis-
14
cal year 2028; 
15
(8) $300,000,000 to carry out the provisions of, 
16
including the amendments made by, this part in fis-
17
cal year 2029; 
18
(9) $300,000,000 to carry out the provisions of, 
19
including the amendments made by, this part in fis-
20
cal year 2030; and 
21
(10) $300,000,000 to carry out the provisions 
22
of, including the amendments made by, this part in 
23
fiscal year 2031. 
24
17:03 Apr 19, 2022
H7497
60 
•HR 7497 IH
TITLE II—PRESCRIPTION DRUG 
1
INFLATION REBATES 
2
SEC. 201. MEDICARE PART B REBATE BY MANUFACTURERS. 
3
(a) IN GENERAL.—Section 1847A of the Social Secu-
4
rity Act (42 U.S.C. 1395w–3a) is amended— 
5
(1) by redesignating subsection (h) as sub-
6
section (i) and by inserting after subsection (g) the 
7
following subsection: 
8
‘‘(h) REBATE
BY MANUFACTURERS
FOR SINGLE 
9
SOURCE DRUGS
AND BIOLOGICALS WITH PRICES IN-
10
CREASING FASTER THAN INFLATION.— 
11
‘‘(1) REQUIREMENTS.— 
12
‘‘(A) SECRETARIAL PROVISION OF INFOR-
13
MATION.—Not later than 6 months after the 
14
end of each calendar quarter beginning on or 
15
after July 1, 2023, the Secretary shall, for each 
16
part B rebatable drug, report to each manufac-
17
turer of such part B rebatable drug the fol-
18
lowing for such calendar quarter: 
19
‘‘(i) Information on the total number 
20
of billing units of the billing and payment 
21
code described in subparagraph (A)(i) of 
22
paragraph (3) with respect to such drug 
23
and calendar quarter. 
24
17:03 Apr 19, 2022
H7497
61 
•HR 7497 IH
‘‘(ii) Information on the amount (if 
1
any) of the excess average sales price in-
2
crease described in subparagraph (A)(ii) of 
3
such paragraph for such drug and calendar 
4
quarter. 
5
‘‘(iii) The rebate amount specified 
6
under such paragraph for such part B 
7
rebatable drug and calendar quarter. 
8
‘‘(B) MANUFACTURER
REQUIREMENT.— 
9
For each calendar quarter beginning on or after 
10
July 1, 2023, the manufacturer of a part B 
11
rebatable drug shall, for such drug, not later 
12
than 30 days after the date of receipt from the 
13
Secretary of the information described in sub-
14
paragraph (A) for such calendar quarter, pro-
15
vide to the Secretary a rebate that is equal to 
16
the amount specified in paragraph (3) for such 
17
drug for such calendar quarter. 
18
‘‘(2) PART B REBATABLE DRUG DEFINED.— 
19
‘‘(A) IN GENERAL.—In this subsection, the 
20
term ‘part B rebatable drug’ means a single 
21
source drug or biological (as defined in sub-
22
paragraph (D) of subsection (c)(6)), including a 
23
biosimilar biological product (as defined in sub-
24
paragraph (H) of such subsection) but exclud-
25
17:03 Apr 19, 2022
H7497
62 
•HR 7497 IH
ing a qualifying biosimilar biological product 
1
(as defined in subsection (b)(8)(B)(iii)), that 
2
would be payable under this part if such drug 
3
were furnished to an individual enrolled under 
4
this part, except such term shall not include 
5
such a drug or biological— 
6
‘‘(i) if, as determined by the Sec-
7
retary, the average total allowed charges 
8
for such drug or biological under this part 
9
for a year per individual that uses such a 
10
drug or biological are less than, subject to 
11
subparagraph (B), $100; or 
12
‘‘(ii) that is a vaccine described in 
13
subparagraph (A) or (B) of section 
14
1861(s)(10). 
15
‘‘(B) INCREASE.—The dollar amount ap-
16
plied under subparagraph (A)(i)— 
17
‘‘(i) for 2024, shall be the dollar 
18
amount specified under such subparagraph 
19
for 2023, increased by the percentage in-
20
crease in the consumer price index for all 
21
urban consumers (United States city aver-
22
age) for the 12-month period ending with 
23
June of the previous year; and 
24
17:03 Apr 19, 2022
H7497
63 
•HR 7497 IH
‘‘(ii) for a subsequent year, shall be 
1
the dollar amount specified in this clause 
2
(or clause (i)) for the previous year (with-
3
out application of subparagraph (C)), in-
4
creased by the percentage increase in the 
5
consumer price index for all urban con-
6
sumers (United States city average) for 
7
the 12-month period ending with June of 
8
the previous year. 
9
‘‘(C) ROUNDING.—Any dollar amount de-
10
termined under subparagraph (B) that is not a 
11
multiple of $10 shall be rounded to the nearest 
12
multiple of $10. 
13
‘‘(3) REBATE AMOUNT.— 
14
‘‘(A) IN GENERAL.—For purposes of para-
15
graph (1), the amount specified in this para-
16
graph for a part B rebatable drug assigned to 
17
a billing and payment code for a calendar quar-
18
ter is, subject to subparagraphs (B) and (G) 
19
and paragraph (4), the amount equal to the 
20
product of— 
21
‘‘(i) the total number of billing units 
22
determined under subparagraph (B) for 
23
the billing and payment code of such drug; 
24
and 
25
17:03 Apr 19, 2022
H7497
64 
•HR 7497 IH
‘‘(ii) the amount (if any) by which— 
1
‘‘(I) the amount equal to— 
2
‘‘(aa) in the case of a part B 
3
rebatable drug described in para-
4
graph 
(1)(B) 
of 
section 
5
1847A(b), 106 percent of the 
6
amount determined under para-
7
graph (4) of such section for 
8
such drug during the calendar 
9
quarter; or 
10
‘‘(bb) in the case of a part B 
11
rebatable drug described in para-
12
graph (1)(C) of such section, the 
13
payment 
amount 
under 
such 
14
paragraph for such drug during 
15
the calendar quarter; exceeds 
16
‘‘(II) the inflation-adjusted pay-
17
ment amount determined under sub-
18
paragraph (C) for such part B 
19
rebatable drug during the calendar 
20
quarter. 
21
‘‘(B) 
TOTAL
NUMBER
OF
BILLING 
22
UNITS.—For purposes of subparagraph (A)(i), 
23
the total number of billing units with respect to 
24
17:03 Apr 19, 2022
H7497
65 
•HR 7497 IH
a part B rebatable drug is determined as fol-
1
lows: 
2
‘‘(i) Determine the total number of 
3
units equal to— 
4
‘‘(I) the total number of units, as 
5
reported under subsection (c)(1)(B) 
6
for each National Drug Code of such 
7
drug during the calendar quarter that 
8
is two calendar quarters prior to the 
9
calendar quarter as described in sub-
10
paragraph (A), minus 
11
‘‘(II) the total number of units 
12
with respect to each National Drug 
13
Code of such drug for which payment 
14
was made under a State plan under 
15
title XIX (or waiver of such plan), as 
16
reported by States under section 
17
1927(b)(2)(A) for the rebate period 
18
that is the same calendar quarter as 
19
described in subclause (I). 
20
‘‘(ii) Convert the units determined 
21
under clause (i) to billing units for the bill-
22
ing and payment code of such drug, using 
23
a methodology similar to the methodology 
24
used under this section, by dividing the 
25
17:03 Apr 19, 2022
H7497
66 
•HR 7497 IH
units determined under clause (i) for each 
1
National Drug Code of such drug by the 
2
billing unit for the billing and payment 
3
code of such drug. 
4
‘‘(iii) Compute the sum of the billing 
5
units for each National Drug Code of such 
6
drug in clause (ii). 
7
‘‘(C) DETERMINATION OF INFLATION-AD-
8
JUSTED PAYMENT AMOUNT.—The inflation-ad-
9
justed payment amount determined under this 
10
subparagraph for a part B rebatable drug for 
11
a calendar quarter is— 
12
‘‘(i) the payment amount for the bill-
13
ing and payment code for such drug in the 
14
payment amount benchmark quarter (as 
15
defined in subparagraph (D)); increased by 
16
‘‘(ii) the percentage by which the re-
17
bate period CPI–U (as defined in subpara-
18
graph (F)) for the calendar quarter ex-
19
ceeds the benchmark period CPI–U (as de-
20
fined in subparagraph (E)). 
21
‘‘(D) 
PAYMENT
AMOUNT
BENCHMARK 
22
QUARTER.—The term ‘payment amount bench-
23
mark quarter’ means the calendar quarter im-
24
17:03 Apr 19, 2022
H7497
67 
•HR 7497 IH
mediately prior to the calendar quarter begin-
1
ning October 1, 2021. 
2
‘‘(E) BENCHMARK
PERIOD
CPI–U.—The 
3
term ‘benchmark period CPI–U’ means the con-
4
sumer price index for all urban consumers 
5
(United States city average) for the last month 
6
of the calendar quarter beginning October 1, 
7
2021. 
8
‘‘(F) REBATE PERIOD CPI–U.—The term 
9
‘rebate period CPI–U’ means, with respect to a 
10
calendar quarter described in subparagraph 
11
(C), the greater of the benchmark period CPI– 
12
U and the consumer price index for all urban 
13
consumers (United States city average) for the 
14
first month of the calendar quarter that is two 
15
calendar quarters prior to such described cal-
16
endar quarter. 
17
‘‘(G) EXEMPTION
FOR
SHORTAGES
AND 
18
SEVERE
SUPPLY
CHAIN
DISRUPTIONS.—The 
19
Secretary shall reduce or waive the amount 
20
under subparagraph (A) with respect to a part 
21
B rebatable drug that is described as currently 
22
in shortage on the shortage list in effect under 
23
section 506E of the Federal Food, Drug, and 
24
Cosmetic Act or in the case of a biosimilar bio-
25
17:03 Apr 19, 2022
H7497
68 
•HR 7497 IH
logical product, when the Secretary determines 
1
there are severe supply chain disruptions. 
2
‘‘(4) SPECIAL TREATMENT OF CERTAIN DRUGS 
3
AND EXEMPTION.— 
4
‘‘(A) SUBSEQUENTLY APPROVED DRUGS.— 
5
In the case of a part B rebatable drug first ap-
6
proved or licensed by the Food and Drug Ad-
7
ministration after March 1, 2021, clause (i) of 
8
paragraph (3)(C) shall be applied as if the term 
9
‘payment amount benchmark quarter’ were de-
10
fined under paragraph (3)(D) as the third full 
11
calendar quarter after the day on which the 
12
drug was first marketed and clause (ii) of para-
13
graph (3)(C) shall be applied as if the term 
14
‘benchmark period CPI–U’ were defined under 
15
paragraph (3)(E) as if the reference to ‘the last 
16
month of the calendar quarter immediately 
17
prior to the calendar quarter beginning October 
18
1, 2021’ under such paragraph were a reference 
19
to ‘the first month of the first full calendar 
20
quarter after the day on which the drug was 
21
first marketed’. 
22
‘‘(B) TIMELINE
FOR
PROVISION
OF
RE-
23
BATES
FOR
SUBSEQUENTLY
APPROVED 
24
DRUGS.—In the case of a part B rebatable drug 
25
17:03 Apr 19, 2022
H7497
69 
•HR 7497 IH
first approved or licensed by the Food and 
1
Drug Administration after March 1, 2021, 
2
paragraph (1)(B) shall be applied as if the ref-
3
erence to ‘July 1, 2023’ under such paragraph 
4
were a reference to the later of the 6th full cal-
5
endar quarter after the day on which the drug 
6
was first marketed or July 1, 2023. 
7
‘‘(C) SELECTED DRUGS.—In the case of a 
8
part B rebatable drug that is a selected drug 
9
(as defined in section 1192(c)) for a price appli-
10
cability 
period 
(as 
defined 
in 
section 
11
1191(b)(2)), in the case such drug is deter-
12
mined (pursuant to such section 1192(c)) to no 
13
longer be a selected drug, beginning the first 
14
calendar quarter after the price applicability pe-
15
riod with respect to such drug, clause (i) of 
16
paragraph (3)(C) shall be applied as if the term 
17
‘payment amount benchmark quarter’ were de-
18
fined under paragraph (3)(D) as the calendar 
19
quarter beginning January 1 of the last year 
20
beginning during such price applicability period 
21
with respect to such selected drug and clause 
22
(ii) of paragraph (3)(C) shall be applied as if 
23
the term ‘benchmark period CPI–U’ were de-
24
fined under paragraph (3)(E) as if the ref-
25
17:03 Apr 19, 2022
H7497
70 
•HR 7497 IH
erence to ‘the last month of the calendar quar-
1
ter immediately prior to the calendar quarter 
2
beginning October 1, 2021’ under such para-
3
graph were a reference to the March of the year 
4
preceding such last year. 
5
‘‘(5) APPLICATION TO BENEFICIARY COINSUR-
6
ANCE.—In the case of a part B rebatable drug, if 
7
the payment amount described in paragraph 
8
(3)(A)(ii)(I) (or, in the case of a part B rebatable 
9
drug that is a selected drug (as defined in section 
10
1192(c)), the payment amount described in sub-
11
section (b)(1)(B) for such drug) for a calendar quar-
12
ter exceeds the inflation adjusted payment for such 
13
quarter— 
14
‘‘(A) in computing the amount of any coin-
15
surance applicable under this part to an indi-
16
vidual to whom such drug is furnished, the 
17
computation of such coinsurance shall be equal 
18
to 20 percent of the inflation-adjusted payment 
19
amount determined under paragraph (3)(C) for 
20
such part B rebatable drug; and 
21
‘‘(B) the amount of such coinsurance for 
22
such calendar quarter, as computed under sub-
23
paragraph (A), shall be applied as a percent, as 
24
determined by the Secretary, to the payment 
25
17:03 Apr 19, 2022
H7497
71 
•HR 7497 IH
amount that would otherwise apply under sub-
1
paragraph (B) or (C) of subsection (b)(1). 
2
‘‘(6) REBATE DEPOSITS.—Amounts paid as re-
3
bates under paragraph (1)(B) shall be deposited into 
4
the Federal Supplementary Medical Insurance Trust 
5
Fund established under section 1841. 
6
‘‘(7) CIVIL MONEY PENALTY.—If a manufac-
7
turer of a part B rebatable drug has failed to com-
8
ply with the requirements under paragraph (1)(B) 
9
for such drug for a calendar quarter, the manufac-
10
turer shall be subject to, in accordance with a proc-
11
ess established by the Secretary pursuant to regula-
12
tions, a civil money penalty in an amount equal to 
13
at least 125 percent of the amount specified in para-
14
graph (3) for such drug for such calendar quarter. 
15
The provisions of section 1128A (other than sub-
16
sections (a) (with respect to amounts of penalties or 
17
additional assessments) and (b)) shall apply to a 
18
civil money penalty under this paragraph in the 
19
same manner as such provisions apply to a penalty 
20
or proceeding under section 1128A(a).’’; and 
21
(2) in subsection (i), as redesignated by para-
22
graph (1)— 
23
(A) in paragraph (4), by striking at the 
24
end ‘‘and’’; 
25
17:03 Apr 19, 2022
H7497
72 
•HR 7497 IH
(B) in paragraph (5), by striking at the 
1
end the period and inserting a semicolon; and 
2
(C) by adding at the end the following new 
3
paragraphs: 
4
‘‘(6) the determination of units under sub-
5
section (h); 
6
‘‘(7) the determination of whether a drug is a 
7
part B rebatable drug under subsection (h); 
8
‘‘(8) the calculation of the rebate amount under 
9
subsection (h); 
10
‘‘(9) the computation of coinsurance under sub-
11
section (h)(5); and 
12
‘‘(10) the computation of amounts paid under 
13
section 1833(a)(1)(EE).’’. 
14
(b) AMOUNTS PAYABLE; COST-SHARING.—Section 
15
1833 of the Social Security Act (42 U.S.C. 1395l) is 
16
amended— 
17
(1) in subsection (a)(1)— 
18
(A) in subparagraph (G), by inserting ‘‘, 
19
subject 
to 
subsection 
(i)(9),’’ 
after 
‘‘the 
20
amounts paid’’; 
21
(B) in subparagraph (S), by striking ‘‘with 
22
respect to’’ and inserting ‘‘subject to subpara-
23
graph (EE), with respect to’’; 
24
17:03 Apr 19, 2022
H7497
73 
•HR 7497 IH
(C) by striking ‘‘and (DD)’’ and inserting 
1
‘‘(DD)’’; and 
2
(D) by inserting before the semicolon at 
3
the end the following: ‘‘, and (EE) with respect 
4
to a part B rebatable drug (as defined in para-
5
graph (2) of section 1847A(h)) for which the 
6
payment amount for a calendar quarter under 
7
paragraph (3)(A)(ii)(I) of such section (or, in 
8
the case of a part B rebatable drug that is a 
9
selected drug (as defined in section 1192(c)) for 
10
which, the payment amount described in section 
11
1847A(b)(1)(B)) for such drug for such quarter 
12
exceeds the inflation-adjusted payment under 
13
paragraph (3)(A)(ii)(II) of such section for 
14
such quarter, the amounts paid shall be equal 
15
to the percent of the payment amount under 
16
paragraph (3)(A)(ii)(I) of such section or sec-
17
tion 1847A(b)(1)(B), as applicable, that equals 
18
the difference between (i) 100 percent, and (ii) 
19
the 
percent 
applied 
under 
section 
20
1847A(h)(5)(B)’’; 
21
(2) in subsection (i), by adding at the end the 
22
following new paragraph: 
23
‘‘(9) In the case of a part B rebatable drug (as de-
24
fined in paragraph (2) of section 1847A(h)) for which pay-
25
17:03 Apr 19, 2022
H7497
74 
•HR 7497 IH
ment under this subsection is not packaged into a payment 
1
for a service furnished on or after July 1, 2023, under 
2
the revised payment system under this subsection, in lieu 
3
of calculation of coinsurance and the amount of payment 
4
otherwise applicable under this subsection, the provisions 
5
of section 1847A(h)(5) and paragraph (1)(EE) of sub-
6
section (a), shall, as determined appropriate by the Sec-
7
retary, apply under this subsection in the same manner 
8
as such provisions of section 1847A(h)(5) and subsection 
9
(a) apply under such section and subsection.’’; and 
10
(3) in subsection (t)(8), by adding at the end 
11
the following new subparagraph: 
12
‘‘(F) PART B REBATABLE DRUGS.—In the 
13
case of a part B rebatable drug (as defined in 
14
paragraph (2) of section 1847A(h), except if 
15
such drug does not have a copayment amount 
16
as a result of application of subparagraph (E)) 
17
for which payment under this part is not pack-
18
aged into a payment for a covered OPD service 
19
(or group of services) furnished on or after July 
20
1, 2023, and the payment for such drug under 
21
this subsection is the same as the amount for 
22
a 
calendar 
quarter 
under 
paragraph 
23
(3)(A)(ii)(I) of section 1847A(h), under the sys-
24
tem under this subsection, in lieu of calculation 
25
17:03 Apr 19, 2022
H7497
75 
•HR 7497 IH
of the copayment amount and the amount of 
1
payment otherwise applicable under this sub-
2
section (other than the application of the limita-
3
tion described in subparagraph (C)), the provi-
4
sions of section 1847A(h)(5) and paragraph 
5
(1)(EE) of subsection (a), shall, as determined 
6
appropriate by the Secretary, apply under this 
7
subsection in the same manner as such provi-
8
sions of section 1847A(h)(5) and subsection (a) 
9
apply under such section and subsection.’’. 
10
(c) CONFORMING AMENDMENTS.— 
11
(1) TO
PART
B
ASP
CALCULATION.—Section 
12
1847A(c)(3) of the Social Security Act (42 U.S.C. 
13
1395w–3a(c)(3)) is amended by inserting ‘‘sub-
14
section (h) or’’ before ‘‘section 1927’’. 
15
(2) EXCLUDING PART B DRUG INFLATION RE-
16
BATE
FROM
BEST
PRICE.—Section 
17
1927(c)(1)(C)(ii)(I) of the Social Security Act (42 
18
U.S.C. 1396r–8(c)(1)(C)(ii)(I)) is amended by in-
19
serting ‘‘or section 1847A(h)’’ after ‘‘this section’’. 
20
(3) COORDINATION WITH MEDICAID REBATE IN-
21
FORMATION DISCLOSURE.—Section 1927(b)(3)(D)(i) 
22
of the Social Security Act (42 U.S.C. 1396r– 
23
8(b)(3)(D)(i)) is amended by inserting ‘‘and the re-
24
bate’’ after ‘‘the payment amount’’. 
25
17:03 Apr 19, 2022
H7497
76 
•HR 7497 IH
(4) EXCLUDING PART B DRUG INFLATION RE-
1
BATES
FROM
AVERAGE
MANUFACTURER
PRICE.— 
2
Section 1927(k)(1)(B)(i) of the Social Security Act 
3
(42 U.S.C. 1396r–8(k)(1)(B)(i)), as previously 
4
amended, is further amended— 
5
(A) in subclause (IV), by striking ‘‘and’’; 
6
(B) in subclause (V), by striking the period 
7
at the end and inserting a semicolon; and 
8
(C) by adding at the end the following new 
9
subclause: 
10
‘‘(VI) rebates paid by manufac-
11
turers under section 1847A(h); and’’. 
12
(d) FUNDING.—In addition to amounts otherwise 
13
available, there are appropriated to the Centers for Medi-
14
care & Medicaid Services, out of any money in the Treas-
15
ury not otherwise appropriated, $12,500,000 for fiscal 
16
year 2022 and $7,500,000 for each of fiscal years 2023 
17
through 2031, to remain available until expended, to carry 
18
out the provisions of, including the amendments made by, 
19
this section. 
20
SEC. 202. MEDICARE PART D REBATE BY MANUFACTURERS. 
21
(a) IN GENERAL.—Part D of title XVIII of the Social 
22
Security Act is amended by inserting after section 1860D– 
23
14A (42 U.S.C. 1395w–114a) the following new section: 
24
17:03 Apr 19, 2022
H7497
77 
•HR 7497 IH
‘‘SEC. 1860D–14B. MANUFACTURER REBATE FOR CERTAIN 
1
DRUGS WITH PRICES INCREASING FASTER 
2
THAN INFLATION. 
3
‘‘(a) REQUIREMENTS.— 
4
‘‘(1) SECRETARIAL
PROVISION
OF
INFORMA-
5
TION.—Not later than 9 months after the end of 
6
each applicable year (as defined in subsection 
7
(g)(7)), subject to paragraph (3), the Secretary 
8
shall, for each part D rebatable drug, report to each 
9
manufacturer of such part D rebatable drug the fol-
10
lowing for such year: 
11
‘‘(A) The amount (if any) of the excess an-
12
nual manufacturer price increase described in 
13
subsection (b)(1)(A)(ii) for each dosage form 
14
and strength with respect to such drug and 
15
year. 
16
‘‘(B) The rebate amount specified under 
17
subsection (b) for each dosage form and 
18
strength with respect to such drug and year. 
19
‘‘(2) MANUFACTURER
REQUIREMENTS.—For 
20
each applicable year, the manufacturer of a part D 
21
rebatable drug, for each dosage form and strength 
22
with respect to such drug, not later than 30 days 
23
after the date of receipt from the Secretary of the 
24
information described in paragraph (1) for such 
25
year, shall provide to the Secretary a rebate that is 
26
17:03 Apr 19, 2022
H7497
78 
•HR 7497 IH
equal to the amount specified in subsection (b) for 
1
such dosage form and strength with respect to such 
2
drug for such year. 
3
‘‘(3) TRANSITION RULE FOR REPORTING.—The 
4
Secretary may, for each rebatable covered part D 
5
drug, delay the timeframe for reporting the informa-
6
tion and rebate amount described in subparagraphs 
7
(A) and (B) of such paragraph for the applicable 
8
year of 2023 until not later than September 30, 
9
2025. 
10
‘‘(b) REBATE AMOUNT.— 
11
‘‘(1) IN GENERAL.— 
12
‘‘(A) CALCULATION.—For purposes of this 
13
section, the amount specified in this subsection 
14
for a dosage form and strength with respect to 
15
a part D rebatable drug and applicable year is, 
16
subject to subparagraph (C), paragraph (5)(B), 
17
and paragraph (6), the amount equal to the 
18
product of— 
19
‘‘(i) subject to subparagraph (B) of 
20
this paragraph, the total number of units 
21
that are used to calculate the average man-
22
ufacturer price of such dosage form and 
23
strength with respect to such part D 
24
rebatable drug, as reported by the manu-
25
17:03 Apr 19, 2022
H7497
79 
•HR 7497 IH
facturer of such drug under section 1927 
1
for each month, with respect to such year; 
2
and 
3
‘‘(ii) the amount (if any) by which— 
4
‘‘(I) the annual manufacturer 
5
price (as determined in paragraph 
6
(2)) paid for such dosage form and 
7
strength with respect to such part D 
8
rebatable drug for the year; exceeds 
9
‘‘(II) the inflation-adjusted pay-
10
ment amount determined under para-
11
graph (3) for such dosage form and 
12
strength with respect to such part D 
13
rebatable drug for the year. 
14
‘‘(B) EXCLUDED UNITS.—For purposes of 
15
subparagraph (A)(i), the Secretary shall exclude 
16
from the total number of units for a dosage 
17
form and strength with respect to a part D 
18
rebatable drug, with respect to an applicable 
19
year, the following: 
20
‘‘(i) Units of each dosage form and 
21
strength of such part D rebatable drug for 
22
which payment was made under a State 
23
plan under title XIX (or waiver of such 
24
17:03 Apr 19, 2022
H7497
80 
•HR 7497 IH
plan), as reported by States under section 
1
1927(b)(2)(A). 
2
‘‘(ii) Units of each dosage form and 
3
strength of such part D rebatable drug for 
4
which a rebate is paid under section 
5
1847A(h). 
6
‘‘(C) EXEMPTION
FOR
SHORTAGES
AND 
7
SEVERE
SUPPLY
CHAIN
DISRUPTIONS.—The 
8
Secretary shall reduce or waive the amount 
9
under subparagraph (A) with respect to a part 
10
D rebatable drug that is described as currently 
11
in shortage on the shortage list in effect under 
12
section 506E of the Federal Food, Drug, and 
13
Cosmetic Act or in the case of a generic drug, 
14
when the Secretary determines there are severe 
15
supply chain disruptions. 
16
‘‘(2) DETERMINATION OF ANNUAL MANUFAC-
17
TURER PRICE.—The annual manufacturer price de-
18
termined under this paragraph for a dosage form 
19
and strength, with respect to a part D rebatable 
20
drug and an applicable year, is the sum of the prod-
21
ucts of— 
22
‘‘(A) the average manufacturer price (as 
23
defined in subsection (g)(6)) of such dosage 
24
form and strength, as calculated for a unit of 
25
17:03 Apr 19, 2022
H7497
81 
•HR 7497 IH
such drug, with respect to each of the calendar 
1
quarters of such year; and 
2
‘‘(B) the ratio of— 
3
‘‘(i) the total number of units of such 
4
dosage form and strength reported under 
5
section 1927 with respect to each such cal-
6
endar quarter of such year; to 
7
‘‘(ii) the total number of units of such 
8
dosage form and strength reported under 
9
section 1927 with respect to such year, as 
10
determined by the Secretary. 
11
‘‘(3) DETERMINATION OF INFLATION-ADJUSTED 
12
PAYMENT AMOUNT.—The inflation-adjusted payment 
13
amount determined under this paragraph for a dos-
14
age form and strength with respect to a part D 
15
rebatable drug for an applicable year, subject to 
16
paragraph (5), is— 
17
‘‘(A) the benchmark year manufacturer 
18
price determined under paragraph (4) for such 
19
dosage form and strength with respect to such 
20
drug and year; increased by 
21
‘‘(B) the percentage by which the applica-
22
ble year CPI–U (as defined in subsection 
23
(g)(5)) for the year exceeds the benchmark pe-
24
riod CPI–U (as defined in subsection (g)(4)). 
25
17:03 Apr 19, 2022
H7497
82 
•HR 7497 IH
‘‘(4) DETERMINATION
OF
BENCHMARK
YEAR 
1
MANUFACTURER PRICE.—The benchmark year man-
2
ufacturer price determined under this paragraph for 
3
a dosage form and strength, with respect to a part 
4
D rebatable drug and an applicable year, is the sum 
5
of the products of— 
6
‘‘(A) the average manufacturer price (as 
7
defined in subsection (g)(6)) of such dosage 
8
form and strength, as calculated for a unit of 
9
such drug, with respect to each of the calendar 
10
quarters of the payment amount benchmark 
11
year (as defined in subsection (g)(3)); and 
12
‘‘(B) the ratio of— 
13
‘‘(i) the total number of units re-
14
ported under section 1927 of such dosage 
15
form and strength with respect to each 
16
such calendar quarter of such payment 
17
amount benchmark year; to 
18
‘‘(ii) the total number of units re-
19
ported under section 1927 of such dosage 
20
form and strength with respect to such 
21
payment amount benchmark year. 
22
‘‘(5) SPECIAL TREATMENT OF CERTAIN DRUGS 
23
AND EXEMPTION.— 
24
17:03 Apr 19, 2022
H7497
83 
•HR 7497 IH
‘‘(A) SUBSEQUENTLY APPROVED DRUGS.— 
1
In the case of a part D rebatable drug first ap-
2
proved or licensed by the Food and Drug Ad-
3
ministration after October 1, 2021, subpara-
4
graphs (A) and (B) of paragraph (4) shall be 
5
applied as if the term ‘payment amount bench-
6
mark year’ were defined under subsection 
7
(g)(3) as the first calendar year beginning after 
8
the day on which the drug was first marketed 
9
by any manufacturer and subparagraph (B) of 
10
paragraph (3) shall be applied as if the term 
11
‘benchmark period CPI–U’ were defined under 
12
subsection (g)(4) as if the reference to ‘the 
13
month immediately prior to October 2021’ 
14
under such subsection were a reference to ‘Jan-
15
uary of the first year beginning after the date 
16
on which the drug was first marketed by any 
17
manufacturer’. 
18
‘‘(B) TREATMENT
OF
NEW
FORMULA-
19
TIONS.— 
20
‘‘(i) IN GENERAL.—In the case of a 
21
part D rebatable drug that is a line exten-
22
sion of a part D rebatable drug that is an 
23
oral solid dosage form, the Secretary shall 
24
establish a formula for determining the re-
25
17:03 Apr 19, 2022
H7497
84 
•HR 7497 IH
bate amount under paragraph (1) and the 
1
inflation adjusted payment amount under 
2
paragraph (3) with respect to such part D 
3
rebatable drug and an applicable year, con-
4
sistent with the formula applied under sub-
5
section (c)(2)(C) of section 1927 for deter-
6
mining a rebate obligation for a rebate pe-
7
riod under such section. 
8
‘‘(ii) LINE EXTENSION DEFINED.—In 
9
this subparagraph, the term ‘line exten-
10
sion’ means, with respect to a part D 
11
rebatable drug, a new formulation of the 
12
drug, such as an extended release formula-
13
tion, but does not include an abuse-deter-
14
rent formulation of the drug (as deter-
15
mined by the Secretary), regardless of 
16
whether such abuse-deterrent formulation 
17
is an extended release formulation. 
18
‘‘(C) SELECTED DRUGS.—In the case of a 
19
part D rebatable drug that is a selected drug 
20
(as defined in section 1192(c)) for a price appli-
21
cability 
period 
(as 
defined 
in 
section 
22
1191(b)(2)), in the case such drug is deter-
23
mined (pursuant to such section 1192(c)) to no 
24
longer be a selected drug, for each applicable 
25
17:03 Apr 19, 2022
H7497
85 
•HR 7497 IH
year beginning after the price applicability pe-
1
riod with respect to such drug, subparagraphs 
2
(A) and (B) of paragraph (4) shall be applied 
3
as if the term ‘payment amount benchmark 
4
year’ were defined under subsection (g)(3) as 
5
the last year beginning during such price appli-
6
cability period with respect to such selected 
7
drug and subparagraph (B) of paragraph (3) 
8
shall be applied as if the term ‘benchmark pe-
9
riod CPI–U’ were defined under subsection 
10
(g)(4) as if the reference to ‘the month imme-
11
diately prior to October 1, 2021’ under such 
12
subsection were a reference to January of the 
13
last year beginning during such price applica-
14
bility period with respect to such drug. 
15
‘‘(6) RECONCILIATION
IN
CASE
OF
REVISED 
16
AMP REPORTS.—The Secretary shall provide for a 
17
method and process under which, in the case of a 
18
manufacturer of a part D rebatable drug that sub-
19
mits revisions to information submitted under sec-
20
tion 1927 by the manufacturer with respect to such 
21
drug, the Secretary determines, pursuant to such re-
22
visions, adjustments, if any, to the calculation of the 
23
amount specified in this subsection for a dosage 
24
form and strength with respect to such part D 
25
17:03 Apr 19, 2022
H7497
86 
•HR 7497 IH
rebatable drug and an applicable year and reconciles 
1
any overpayments or underpayments in amounts 
2
paid as rebates under this subsection. Any identified 
3
underpayment shall be rectified by the manufacturer 
4
not later than 30 days after the date of receipt from 
5
the Secretary of information on such underpayment. 
6
‘‘(c) REBATE DEPOSITS.—Amounts paid as rebates 
7
under subsection (b) shall be deposited into the Medicare 
8
Prescription Drug Account in the Federal Supplementary 
9
Medical Insurance Trust Fund established under section 
10
1841. 
11
‘‘(d) INFORMATION.—For purposes of carrying out 
12
this section, the Secretary shall use information submitted 
13
by manufacturers under section 1927(b)(3) and informa-
14
tion submitted by States under section 1927(b)(2)(A). 
15
‘‘(e) CIVIL MONEY PENALTY.—If a manufacturer of 
16
a part D rebatable drug has failed to comply with the re-
17
quirement under subsection (a)(2) with respect to such 
18
drug for an applicable year, the manufacturer shall be 
19
subject to, in accordance with a process established by the 
20
Secretary pursuant to regulations, a civil money penalty 
21
in an amount equal to 125 percent of the amount specified 
22
in subsection (b) for such drug for such year. The provi-
23
sions of section 1128A (other than subsections (a) (with 
24
respect to amounts of penalties or additional assessments) 
25
17:03 Apr 19, 2022
H7497
87 
•HR 7497 IH
and (b)) shall apply to a civil money penalty under this 
1
subsection in the same manner as such provisions apply 
2
to a penalty or proceeding under section 1128A(a). 
3
‘‘(f) NO ADMINISTRATIVE OR JUDICIAL REVIEW.— 
4
There shall be no administrative or judicial review of the 
5
following: 
6
‘‘(1) The determination of units under this sec-
7
tion. 
8
‘‘(2) The determination of whether a drug is a 
9
part D rebatable drug under this section. 
10
‘‘(3) The calculation of the rebate amount 
11
under this section. 
12
‘‘(g) DEFINITIONS.—In this section: 
13
‘‘(1) PART D REBATABLE DRUG.— 
14
‘‘(A) IN
GENERAL.—The term ‘part D 
15
rebatable drug’ means a drug or biological that 
16
would (without application of this section) be a 
17
covered part D drug, except such term shall, 
18
with respect to an applicable year, not include 
19
such a drug or biological if the average annual 
20
total cost under this part for such year per in-
21
dividual who uses such a drug or biological, as 
22
determined by the Secretary, is less than, sub-
23
ject to subparagraph (B), $100, as determined 
24
by the Secretary using the most recent data 
25
17:03 Apr 19, 2022
H7497
88 
•HR 7497 IH
available or, if data is not available, as esti-
1
mated by the Secretary. 
2
‘‘(B) INCREASE.—The dollar amount ap-
3
plied under subparagraph (A)— 
4
‘‘(i) for 2024, shall be the dollar 
5
amount specified under such subparagraph 
6
for 2023, increased by the percentage in-
7
crease in the consumer price index for all 
8
urban consumers (United States city aver-
9
age) for the 12-month period beginning 
10
with January of 2023; and 
11
‘‘(ii) for a subsequent year, shall be 
12
the dollar amount specified in this sub-
13
paragraph for the previous year, increased 
14
by the percentage increase in the consumer 
15
price index for all urban consumers 
16
(United States city average) for the 12- 
17
month period beginning with January of 
18
the previous year. 
19
Any dollar amount specified under this sub-
20
paragraph that is not a multiple of $10 shall be 
21
rounded to the nearest multiple of $10. 
22
‘‘(2) UNIT.—The term ‘unit’ means, with re-
23
spect to a part D rebatable drug, the lowest dispen-
24
sable amount (such as a capsule or tablet, milligram 
25
17:03 Apr 19, 2022
H7497
89 
•HR 7497 IH
of molecules, or grams) of the part D rebatable 
1
drug, as reported under section 1927. 
2
‘‘(3) PAYMENT AMOUNT BENCHMARK YEAR.— 
3
The term ‘payment amount benchmark year’ means 
4
the year ending in the month immediately prior to 
5
October 1, 2021. 
6
‘‘(4) BENCHMARK
PERIOD
CPI–U.—The term 
7
‘benchmark period CPI–U’ means the consumer 
8
price index for all urban consumers (United States 
9
city average) for the month immediately prior to Oc-
10
tober 2021. 
11
‘‘(5) APPLICABLE YEAR CPI–U.—The term ‘ap-
12
plicable year CPI–U’ means, with respect to an ap-
13
plicable year, the consumer price index for all urban 
14
consumers (United States city average) for January 
15
of such year. 
16
‘‘(6) AVERAGE
MANUFACTURER
PRICE.—The 
17
term ‘average manufacturer price’ has the meaning, 
18
with respect to a part D rebatable drug of a manu-
19
facturer, given such term in section 1927(k)(1), with 
20
respect to a covered outpatient drug of a manufac-
21
turer for a rebate period under section 1927. 
22
‘‘(7) APPLICABLE YEAR.—The term ‘applicable 
23
year’ means a calendar year beginning with 2023. 
24
17:03 Apr 19, 2022
H7497
90 
•HR 7497 IH
‘‘(h) IMPLEMENTATION FOR 2023 AND 2024.—Not-
1
withstanding any other provision of this section, the Sec-
2
retary shall implement this section for 2023 and 2024 by 
3
program instruction or otherwise.’’. 
4
(b) CONFORMING AMENDMENTS.— 
5
(1) TO
PART
B
ASP
CALCULATION.—Section 
6
1847A(c)(3) of the Social Security Act (42 U.S.C. 
7
1395w–3a(c)(3)), as amended by section 201(c)(1), 
8
is further amended by striking ‘‘subsection (h) or 
9
section 1927’’ and inserting ‘‘subsection (h), section 
10
1927, or section 1860D–14B’’. 
11
(2) EXCLUDING PART D DRUG INFLATION RE-
12
BATE
FROM
BEST
PRICE.—Section 
13
1927(c)(1)(C)(ii)(I) of the Social Security Act (42 
14
U.S.C. 1396r–8(c)(1)(C)(ii)(I)), as amended by sec-
15
tion 201(c)(2), is further amended by striking ‘‘or 
16
section 
1847A(h)’’ 
and 
inserting 
‘‘, 
section 
17
1847A(h), or section 1860D–14B’’. 
18
(3) COORDINATION WITH MEDICAID REBATE IN-
19
FORMATION DISCLOSURE.—Section 1927(b)(3)(D)(i) 
20
of the Social Security Act (42 U.S.C. 1396r– 
21
8(b)(3)(D)(i)), as amended by section 201(c)(3), is 
22
further amended by striking ‘‘or to carry out section 
23
1847B’’ and inserting ‘‘or to carry out section 
24
1847B or section 1860D–14B’’. 
25
17:03 Apr 19, 2022
H7497
91 
•HR 7497 IH
(4) EXCLUDING PART D DRUG INFLATION RE-
1
BATES
FROM
AVERAGE
MANUFACTURER
PRICE.— 
2
Section 1927(k)(1)(B)(i) of the Social Security Act 
3
(42 U.S.C. 1396r–8(k)(1)(B)(i)), as previously 
4
amended, is further amended by adding at the end 
5
the following new subclause: 
6
‘‘(VII) rebates paid by manufac-
7
turers under section 1860D–14B.’’. 
8
(c) FUNDING.—In addition to amounts otherwise 
9
available, there are appropriated to the Centers for Medi-
10
care & Medicaid Services, out of any money in the Treas-
11
ury not otherwise appropriated, $12,500,000 for fiscal 
12
year 2022 and $7,500,000 for each of fiscal years 2023 
13
through 2031, to remain available until expended, to carry 
14
out the provisions of, including the amendments made by, 
15
this section. 
16
TITLE 
III—PART 
D 
IMPROVE-
17
MENTS AND MAXIMUM OUT- 
18
OF-POCKET CAP FOR MEDI-
19
CARE BENEFICIARIES 
20
SEC. 301. MEDICARE PART D BENEFIT REDESIGN. 
21
(a) 
BENEFIT
STRUCTURE
REDESIGN.—Section 
22
1860D–2(b) of the Social Security Act (42 U.S.C. 1395w– 
23
102(b)) is amended— 
24
(1) in paragraph (2)— 
25
17:03 Apr 19, 2022
H7497
92 
•HR 7497 IH
(A) in subparagraph (A), in the matter 
1
preceding clause (i), by inserting ‘‘for a year 
2
preceding 2024 and for costs above the annual 
3
deductible specified in paragraph (1) and up to 
4
the annual out-of-pocket threshold specified in 
5
paragraph (4)(B) for 2024 and each subsequent 
6
year’’ after ‘‘paragraph (3)’’; 
7
(B) in subparagraph (C)— 
8
(i) in clause (i), in the matter pre-
9
ceding subclause (I), by inserting ‘‘for a 
10
year preceding 2024,’’ after ‘‘paragraph 
11
(4),’’; and 
12
(ii) in clause (ii)(III), by striking 
13
‘‘and each subsequent year’’ and inserting 
14
‘‘through 2023’’; and 
15
(C) in subparagraph (D)— 
16
(i) in clause (i)— 
17
(I) in the matter preceding sub-
18
clause (I), by inserting ‘‘for a year 
19
preceding 2024,’’ after ‘‘paragraph 
20
(4),’’; and 
21
(II) in subclause (I)(bb), by 
22
striking ‘‘a year after 2018’’ and in-
23
serting ‘‘each of years 2019 through 
24
2023’’; and 
25
17:03 Apr 19, 2022
H7497
93 
•HR 7497 IH
(ii) in clause (ii)(V), by striking 
1
‘‘2019 and each subsequent year’’ and in-
2
serting ‘‘each of years 2019 through 
3
2023’’; 
4
(2) in paragraph (3)(A)— 
5
(A) in the matter preceding clause (i), by 
6
inserting ‘‘for a year preceding 2024,’’ after 
7
‘‘and (4),’’; and 
8
(B) in clause (ii), by striking ‘‘for a subse-
9
quent year’’ and inserting ‘‘for each of years 
10
2007 through 2023’’; and 
11
(3) in paragraph (4)— 
12
(A) in subparagraph (A)— 
13
(i) in clause (i)— 
14
(I) by redesignating subclauses 
15
(I) and (II) as items (aa) and (bb), 
16
respectively, and moving the margin 
17
of each such redesignated item 2 ems 
18
to the right; 
19
(II) in the matter preceding item 
20
(aa), as redesignated by subclause (I), 
21
by striking ‘‘is equal to the greater 
22
of—’’ and inserting ‘‘is equal to— 
23
‘‘(I) for a year preceding 2024, 
24
the greater of—’’; 
25
17:03 Apr 19, 2022
H7497
94 
•HR 7497 IH
(III) by striking the period at the 
1
end of item (bb), as redesignated by 
2
subclause (I), and inserting ‘‘; and’’; 
3
and 
4
(IV) by adding at the end the fol-
5
lowing: 
6
‘‘(II) for 2024 and each suc-
7
ceeding year, $0.’’; and 
8
(ii) in clause (ii)— 
9
(I) by striking ‘‘clause (i)(I)’’ and 
10
inserting ‘‘clause (i)(I)(aa)’’; and 
11
(II) by adding at the end the fol-
12
lowing new sentence: ‘‘The Secretary 
13
shall continue to calculate the dollar 
14
amounts specified in clause (i)(I)(aa), 
15
including with the adjustment under 
16
this clause, after 2023 for purposes of 
17
section 1860D–14(a)(1)(D)(iii).’’; 
18
(B) in subparagraph (B)— 
19
(i) in clause (i)— 
20
(I) in subclause (V), by striking 
21
‘‘or’’ at the end; 
22
(II) in subclause (VI)— 
23
(aa) by striking ‘‘for a sub-
24
sequent year’’ and inserting ‘‘for 
25
17:03 Apr 19, 2022
H7497
95 
•HR 7497 IH
each of years 2021 through 
1
2023’’; and 
2
(bb) by striking the period 
3
at the end and inserting a semi-
4
colon; and 
5
(III) by adding at the end the 
6
following new subclauses: 
7
‘‘(VII) for 2024, is equal to 
8
$2,000; or 
9
‘‘(VIII) for a subsequent year, is 
10
equal to the amount specified in this 
11
subparagraph for the previous year, 
12
increased by the annual percentage in-
13
crease described in paragraph (6) for 
14
the year involved.’’; and 
15
(ii) in clause (ii), by striking ‘‘clause 
16
(i)(II)’’ and inserting ‘‘clause (i)’’; 
17
(C) in subparagraph (C)(i), by striking 
18
‘‘and for amounts’’ and inserting ‘‘and, for a 
19
year preceding 2024, for amounts’’; and 
20
(D) in subparagraph (E), by striking ‘‘In 
21
applying’’ and inserting ‘‘For each of years 
22
2011 through 2023, in applying’’. 
23
17:03 Apr 19, 2022
H7497
96 
•HR 7497 IH
(b) REINSURANCE
PAYMENT
AMOUNT.—Section 
1
1860D–15(b) of the Social Security Act (42 U.S.C. 
2
1395w–115(b)) is amended— 
3
(1) in paragraph (1)— 
4
(A) by striking ‘‘equal to 80 percent’’ and 
5
inserting ‘‘equal to— 
6
‘‘(A) for a year preceding 2024, 80 per-
7
cent’’; 
8
(B) in subparagraph (A), as added by sub-
9
paragraph (A), by striking the period at the 
10
end and inserting ‘‘; and’’; and 
11
(C) by adding at the end the following new 
12
subparagraph: 
13
‘‘(B) for 2024 and each subsequent year, 
14
the sum of— 
15
‘‘(i) an amount equal to 20 percent of 
16
such allowable reinsurance costs attrib-
17
utable to that portion of gross prescription 
18
drug costs as specified in paragraph (3) in-
19
curred in the coverage year after such indi-
20
vidual has incurred costs that exceed the 
21
annual out-of-pocket threshold specified in 
22
section 1860D–2(b)(4)(B) with respect to 
23
applicable drugs (as defined in section 
24
1860D–14C(g)(2)); and 
25
17:03 Apr 19, 2022
H7497
97 
•HR 7497 IH
‘‘(ii) an amount equal to 40 percent of 
1
such allowable reinsurance costs attrib-
2
utable to that portion of gross prescription 
3
drug costs as specified in paragraph (3) in-
4
curred in the coverage year after such indi-
5
vidual has incurred costs that exceed the 
6
annual out-of-pocket threshold specified in 
7
section 1860D–2(b)(4)(B) with respect to 
8
covered part D drugs that are not applica-
9
ble drugs (as so defined).’’; 
10
(2) in paragraph (2)— 
11
(A) by striking ‘‘COSTS.—For purposes’’ 
12
and inserting ‘‘COSTS.— 
13
‘‘(A) IN
GENERAL.—Subject to subpara-
14
graph (B), for purposes’’; and 
15
(B) by adding at the end the following new 
16
subparagraph: 
17
‘‘(B) INCLUSION OF MANUFACTURER DIS-
18
COUNTS ON APPLICABLE DRUGS.—For purposes 
19
of applying subparagraph (A), the term ‘allow-
20
able reinsurance costs’ shall include the portion 
21
of the negotiated price (as defined in section 
22
1860D–14C(g)(6)) of an applicable drug (as 
23
defined in section 1860D–14C(g)(2)) that was 
24
paid by a manufacturer under the manufacturer 
25
17:03 Apr 19, 2022
H7497
98 
•HR 7497 IH
discount program under section 1860D–14C.’’; 
1
and 
2
(3) in paragraph (3)— 
3
(A) in the first sentence, by striking ‘‘For 
4
purposes’’ and inserting ‘‘Subject to paragraph 
5
(2)(B), for purposes’’; and 
6
(B) in the second sentence, by inserting 
7
‘‘(or, with respect to 2024 and subsequent 
8
years, in the case of an applicable drug, as de-
9
fined in section 1860D–14C(g)(2), by a manu-
10
facturer)’’ after ‘‘by the individual or under the 
11
plan’’. 
12
(c) REDUCED COST-SHARING; BENEFICIARY PRE-
13
MIUM PERCENTAGE.— 
14
(1) COST-SHARING.— 
15
(A) 
IN
GENERAL.—Section 
1860D– 
16
2(b)(2)(A) of the Social Security Act (42 
17
U.S.C. 1395w–102(b)(2)(A)) is amended— 
18
(i) in the subparagraph header, by 
19
striking ‘‘25 PERCENT COINSURANCE’’ and 
20
inserting ‘‘COINSURANCE’’; 
21
(ii) in clause (i), by inserting ‘‘(or, for 
22
2024 and each subsequent year, 23 per-
23
cent)’’ after ‘‘25 percent’’; and 
24
17:03 Apr 19, 2022
H7497
99 
•HR 7497 IH
(iii) in clause (ii), by inserting ‘‘(or, 
1
for 2024 and each subsequent year, 23 
2
percent)’’ after ‘‘25 percent’’. 
3
(B) CONFORMING
AMENDMENT.—Section 
4
1860D–14(a)(2)(D) of the Social Security Act 
5
(42 U.S.C. 1395w–114(a)(2)(D)) is amended 
6
by inserting ‘‘(or, for 2024 and each subsequent 
7
year, instead of coinsurance of ‘23 percent’)’’ 
8
after ‘‘instead of coinsurance of ‘25 percent’ ’’. 
9
(2) BENEFICIARY PREMIUM PERCENTAGE.— 
10
(A) 
IN
GENERAL.—Section 
1860D– 
11
13(a)(3)(A) of the Social Security Act (42 
12
U.S.C. 1395w–113(a)(3)(A)) is amended by in-
13
serting ‘‘(or, for 2024 and each subsequent 
14
year, 23.5 percent)’’ after ‘‘25.5 percent’’. 
15
(B) CONFORMING AMENDMENTS.— 
16
(i) Section 1860D–11(g)(6) of the So-
17
cial Security Act (42 U.S.C. 1395w– 
18
111(g)(6)) is amended by inserting ‘‘(or, 
19
for 2024 and each subsequent year, 23.5 
20
percent)’’ after ‘‘25.5 percent’’. 
21
(ii) Section 1860D–13(a)(7)(B)(i) of 
22
the Social Security Act (42 U.S.C. 1395w– 
23
113(a)(7)(B)(i)) is amended— 
24
17:03 Apr 19, 2022
H7497
100 
•HR 7497 IH
(I) in subclause (I), by inserting 
1
‘‘(or, for 2024 and each subsequent 
2
year, 23.5 percent)’’ after ‘‘25.5 per-
3
cent’’; and 
4
(II) in subclause (II), by insert-
5
ing ‘‘(or, for 2024 and each subse-
6
quent year, 23.5 percent)’’ after ‘‘25.5 
7
percent’’. 
8
(iii) Section 1860D–15(a) of the So-
9
cial Security Act (42 U.S.C. 1395w– 
10
115(a)) is amended by inserting ‘‘(or, for 
11
2024 and each subsequent year, 76.5 per-
12
cent)’’ after ‘‘74.5 percent’’. 
13
(d) MANUFACTURER DISCOUNT PROGRAM.— 
14
(1) IN GENERAL.—Part D of title XVIII of the 
15
Social Security Act (42 U.S.C. 1395w–101 through 
16
42 U.S.C. 1395w–153), as amended by section 202, 
17
is further amended by inserting after section 
18
1860D–14B the following new sections: 
19
‘‘SEC. 1860D–14C. MANUFACTURER DISCOUNT PROGRAM. 
20
‘‘(a) ESTABLISHMENT.—The Secretary shall estab-
21
lish a manufacturer discount program (in this section re-
22
ferred to as the ‘program’). Under the program, the Sec-
23
retary shall enter into agreements described in subsection 
24
(b) with manufacturers and provide for the performance 
25
17:03 Apr 19, 2022
H7497
101 
•HR 7497 IH
of the duties described in subsection (c). The Secretary 
1
shall establish a model agreement for use under the pro-
2
gram by not later than January 1, 2023, in consultation 
3
with manufacturers, and allow for comment on such model 
4
agreement. 
5
‘‘(b) TERMS OF AGREEMENT.— 
6
‘‘(1) IN GENERAL.— 
7
‘‘(A) AGREEMENT.—An agreement under 
8
this section shall require the manufacturer to 
9
provide, in accordance with this section, dis-
10
counted prices for applicable drugs of the man-
11
ufacturer that are dispensed to applicable bene-
12
ficiaries on or after January 1, 2024. 
13
‘‘(B) CLARIFICATION.—Nothing in this 
14
section shall be construed as affecting— 
15
‘‘(i) the application of a coinsurance 
16
of 23 percent of the negotiated price, as 
17
applied under paragraph (2)(A) of section 
18
1860D–2(b), for costs described in such 
19
paragraph; or 
20
‘‘(ii) the application of the copayment 
21
amount described in paragraph (4)(A) of 
22
such section, with respect to costs de-
23
scribed in such paragraph. 
24
‘‘(C) TIMING OF AGREEMENT.— 
25
17:03 Apr 19, 2022
H7497
102 
•HR 7497 IH
‘‘(i) SPECIAL
RULE
FOR
2024.—In 
1
order for an agreement with a manufac-
2
turer to be in effect under this section with 
3
respect to the period beginning on January 
4
1, 2024, and ending on December 31, 
5
2024, the manufacturer shall enter into 
6
such agreement not later than 30 days 
7
after the date of the establishment of a 
8
model agreement under subsection (a). 
9
‘‘(ii) 
2025 
AND
SUBSEQUENT 
10
YEARS.—In order for an agreement with a 
11
manufacturer to be in effect under this 
12
section with respect to plan year 2025 or 
13
a subsequent plan year, the manufacturer 
14
shall enter into such agreement not later 
15
than a calendar quarter or semi-annual 
16
deadline established by the Secretary. 
17
‘‘(2) PROVISION OF APPROPRIATE DATA.—Each 
18
manufacturer with an agreement in effect under this 
19
section shall collect and have available appropriate 
20
data, as determined by the Secretary, to ensure that 
21
it can demonstrate to the Secretary compliance with 
22
the requirements under the program. 
23
‘‘(3) COMPLIANCE
WITH
REQUIREMENTS
FOR 
24
ADMINISTRATION
OF
PROGRAM.—Each manufac-
25
17:03 Apr 19, 2022
H7497
103 
•HR 7497 IH
turer with an agreement in effect under this section 
1
shall comply with requirements imposed by the Sec-
2
retary or a third party with a contract under sub-
3
section (d)(3), as applicable, for purposes of admin-
4
istering the program, including any determination 
5
under subparagraph (A) of subsection (c)(1) or pro-
6
cedures established under such subsection (c)(1). 
7
‘‘(4) LENGTH OF AGREEMENT.— 
8
‘‘(A) IN GENERAL.—An agreement under 
9
this section shall be effective for an initial pe-
10
riod of not less than 12 months and shall be 
11
automatically renewed for a period of not less 
12
than 1 year unless terminated under subpara-
13
graph (B). 
14
‘‘(B) TERMINATION.— 
15
‘‘(i) BY THE SECRETARY.—The Sec-
16
retary shall provide for termination of an 
17
agreement under this section for a knowing 
18
and willful violation of the requirements of 
19
the agreement or other good cause shown. 
20
Such termination shall not be effective ear-
21
lier than 30 days after the date of notice 
22
to the manufacturer of such termination. 
23
The Secretary shall provide, upon request, 
24
a manufacturer with a hearing concerning 
25
17:03 Apr 19, 2022
H7497
104 
•HR 7497 IH
such a termination, and such hearing shall 
1
take place prior to the effective date of the 
2
termination with sufficient time for such 
3
effective date to be repealed if the Sec-
4
retary determines appropriate. 
5
‘‘(ii) BY A MANUFACTURER.—A man-
6
ufacturer may terminate an agreement 
7
under this section for any reason. Any 
8
such termination shall be effective, with re-
9
spect to a plan year— 
10
‘‘(I) if the termination occurs be-
11
fore January 31 of a plan year, as of 
12
the day after the end of the plan year; 
13
and 
14
‘‘(II) if the termination occurs on 
15
or after January 31 of a plan year, as 
16
of the day after the end of the suc-
17
ceeding plan year. 
18
‘‘(iii) EFFECTIVENESS
OF
TERMI-
19
NATION.—Any termination under this sub-
20
paragraph shall not affect discounts for 
21
applicable drugs of the manufacturer that 
22
are due under the agreement before the ef-
23
fective date of its termination. 
24
17:03 Apr 19, 2022
H7497
105 
•HR 7497 IH
‘‘(iv) NOTICE TO THIRD PARTY.—The 
1
Secretary shall provide notice of such ter-
2
mination to a third party with a contract 
3
under subsection (d)(3) within not less 
4
than 30 days before the effective date of 
5
such termination. 
6
‘‘(c) DUTIES DESCRIBED.—The duties described in 
7
this subsection are the following: 
8
‘‘(1) ADMINISTRATION OF PROGRAM.—Admin-
9
istering the program, including— 
10
‘‘(A) the determination of the amount of 
11
the discounted price of an applicable drug of a 
12
manufacturer; 
13
‘‘(B) the establishment of procedures to 
14
ensure that, not later than the applicable num-
15
ber of calendar days after the dispensing of an 
16
applicable drug by a pharmacy or mail order 
17
service, the pharmacy or mail order service is 
18
reimbursed for an amount equal to the dif-
19
ference between— 
20
‘‘(i) the negotiated price of the appli-
21
cable drug; and 
22
‘‘(ii) the discounted price of the appli-
23
cable drug; 
24
17:03 Apr 19, 2022
H7497
106 
•HR 7497 IH
‘‘(C) the establishment of procedures to 
1
ensure that the discounted price for an applica-
2
ble drug under this section is applied before any 
3
coverage or financial assistance under other 
4
health benefit plans or programs that provide 
5
coverage or financial assistance for the pur-
6
chase or provision of prescription drug coverage 
7
on behalf of applicable beneficiaries as specified 
8
by the Secretary; and 
9
‘‘(D) providing a reasonable dispute resolu-
10
tion mechanism to resolve disagreements be-
11
tween manufacturers, applicable beneficiaries, 
12
and the third party with a contract under sub-
13
section (d)(3). 
14
‘‘(2) MONITORING COMPLIANCE.— 
15
‘‘(A) IN
GENERAL.—The Secretary shall 
16
monitor compliance by a manufacturer with the 
17
terms of an agreement under this section. 
18
‘‘(B) NOTIFICATION.—If a third party 
19
with a contract under subsection (d)(3) deter-
20
mines that the manufacturer is not in compli-
21
ance with such agreement, the third party shall 
22
notify the Secretary of such noncompliance for 
23
appropriate enforcement under subsection (e). 
24
17:03 Apr 19, 2022
H7497
107 
•HR 7497 IH
‘‘(3) COLLECTION OF DATA FROM PRESCRIP-
1
TION DRUG PLANS AND MA–PD PLANS.—The Sec-
2
retary may collect appropriate data from prescrip-
3
tion drug plans and MA–PD plans in a timeframe 
4
that allows for discounted prices to be provided for 
5
applicable drugs under this section. 
6
‘‘(d) ADMINISTRATION.— 
7
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
8
the Secretary shall provide for the implementation of 
9
this section, including the performance of the duties 
10
described in subsection (c). 
11
‘‘(2) LIMITATION.—In providing for the imple-
12
mentation of this section, the Secretary shall not re-
13
ceive or distribute any funds of a manufacturer 
14
under the program. 
15
‘‘(3) CONTRACT
WITH
THIRD
PARTIES.—The 
16
Secretary shall enter into a contract with 1 or more 
17
third parties to administer the requirements estab-
18
lished by the Secretary in order to carry out this 
19
section. At a minimum, the contract with a third 
20
party under the preceding sentence shall require 
21
that the third party— 
22
‘‘(A) receive and transmit information be-
23
tween the Secretary, manufacturers, and other 
24
17:03 Apr 19, 2022
H7497
108 
•HR 7497 IH
individuals or entities the Secretary determines 
1
appropriate; 
2
‘‘(B) receive, distribute, or facilitate the 
3
distribution of funds of manufacturers to ap-
4
propriate individuals or entities in order to 
5
meet the obligations of manufacturers under 
6
agreements under this section; 
7
‘‘(C) provide adequate and timely informa-
8
tion to manufacturers, consistent with the 
9
agreement with the manufacturer under this 
10
section, as necessary for the manufacturer to 
11
fulfill its obligations under this section; and 
12
‘‘(D) permit manufacturers to conduct 
13
periodic audits, directly or through contracts, of 
14
the data and information used by the third 
15
party to determine discounts for applicable 
16
drugs of the manufacturer under the program. 
17
‘‘(4) 
PERFORMANCE
REQUIREMENTS.—The 
18
Secretary shall establish performance requirements 
19
for a third party with a contract under paragraph 
20
(3) and safeguards to protect the independence and 
21
integrity of the activities carried out by the third 
22
party under the program under this section. 
23
17:03 Apr 19, 2022
H7497
109 
•HR 7497 IH
‘‘(5) IMPLEMENTATION.—The Secretary shall 
1
implement the program under this section for 2024 
2
and 2025 by program instruction or otherwise. 
3
‘‘(e) ENFORCEMENT.— 
4
‘‘(1) AUDITS.—Each manufacturer with an 
5
agreement in effect under this section shall be sub-
6
ject to periodic audit by the Secretary. 
7
‘‘(2) CIVIL MONEY PENALTY.— 
8
‘‘(A) IN GENERAL.—A manufacturer that 
9
fails to provide discounted prices for applicable 
10
drugs of the manufacturer dispensed to applica-
11
ble beneficiaries in accordance with such agree-
12
ment shall be subject to a civil money penalty 
13
for each such failure in an amount the Sec-
14
retary determines is equal to the sum of— 
15
‘‘(i) the amount that the manufac-
16
turer would have paid with respect to such 
17
discounts under the agreement, which will 
18
then be used to pay the discounts which 
19
the manufacturer had failed to provide; 
20
and 
21
‘‘(ii) 25 percent of such amount. 
22
‘‘(B) APPLICATION.—The provisions of 
23
section 1128A (other than subsections (a) and 
24
(b)) shall apply to a civil money penalty under 
25
17:03 Apr 19, 2022
H7497
110 
•HR 7497 IH
this paragraph in the same manner as such 
1
provisions apply to a penalty or proceeding 
2
under section 1128A(a). 
3
‘‘(f) CLARIFICATION REGARDING AVAILABILITY OF 
4
OTHER COVERED PART D DRUGS.—Nothing in this sec-
5
tion shall prevent an applicable beneficiary from pur-
6
chasing a covered part D drug that is not an applicable 
7
drug (including a generic drug or a drug that is not on 
8
the formulary of the prescription drug plan or MA–PD 
9
plan that the applicable beneficiary is enrolled in). 
10
‘‘(g) DEFINITIONS.—In this section: 
11
‘‘(1) APPLICABLE
BENEFICIARY.—The term 
12
‘applicable beneficiary’ means an individual who, on 
13
the date of dispensing a covered part D drug— 
14
‘‘(A) is enrolled in a prescription drug plan 
15
or an MA–PD plan; 
16
‘‘(B) is not enrolled in a qualified retiree 
17
prescription drug plan; and 
18
‘‘(C) has incurred costs, as determined in 
19
accordance with section 1860D–2(b)(4)(C) as if 
20
clause (iii) of such section included a reference 
21
to costs reimbursed through insurance, a group 
22
health plan, or certain other third-party pay-
23
ment arrangements, for covered part D drugs 
24
in the year that exceed— 
25
17:03 Apr 19, 2022
H7497
111 
•HR 7497 IH
‘‘(i) in the case of an individual not 
1
described in clause (ii) or (iii), the annual 
2
deductible for such year, as specified in 
3
section 1860D–2(b)(1); 
4
‘‘(ii) in the case of a subsidy eligible 
5
individual described in section 1860D– 
6
14(a)(1), the annual deductible for such 
7
year, as specified in subparagraph (B) of 
8
such section; and 
9
‘‘(iii) in the case of a subsidy eligible 
10
individual described in section 1860D– 
11
14(a)(2), the annual deductible for such 
12
year, as specified in subparagraph (B) of 
13
such section. 
14
‘‘(2) APPLICABLE DRUG.—The term ‘applicable 
15
drug’, with respect to an applicable beneficiary— 
16
‘‘(A) means a covered part D drug— 
17
‘‘(i) approved under a new drug appli-
18
cation under section 505(c) of the Federal 
19
Food, Drug, and Cosmetic Act or, in the 
20
case of a biologic product, licensed under 
21
section 351 of the Public Health Service 
22
Act; and 
23
‘‘(ii)(I) if the PDP sponsor of the pre-
24
scription drug plan or the MA organization 
25
17:03 Apr 19, 2022
H7497
112 
•HR 7497 IH
offering the MA–PD plan uses a for-
1
mulary, which is on the formulary of the 
2
prescription drug plan or MA–PD plan 
3
that the applicable beneficiary is enrolled 
4
in; 
5
‘‘(II) if the PDP sponsor of the pre-
6
scription drug plan or the MA organization 
7
offering the MA–PD plan does not use a 
8
formulary, for which benefits are available 
9
under the prescription drug plan or MA– 
10
PD plan that the applicable beneficiary is 
11
enrolled in; or 
12
‘‘(III) is provided through an excep-
13
tion or appeal; and 
14
‘‘(B) does not include a selected drug (as 
15
referred to under section 1192(c)) during a 
16
price applicability period (as defined in section 
17
1191(b)(2)) with respect to such drug. 
18
‘‘(3) APPLICABLE
NUMBER
OF
CALENDAR 
19
DAYS.—The term ‘applicable number of calendar 
20
days’ means— 
21
‘‘(A) with respect to claims for reimburse-
22
ment submitted electronically, 14 days; and 
23
‘‘(B) with respect to claims for reimburse-
24
ment submitted otherwise, 30 days. 
25
17:03 Apr 19, 2022
H7497
113 
•HR 7497 IH
‘‘(4) DISCOUNTED PRICE.— 
1
‘‘(A) IN GENERAL.—The term ‘discounted 
2
price’ means, subject to subparagraphs (B) and 
3
(C), with respect to an applicable drug of a 
4
manufacturer dispensed during a year to an ap-
5
plicable beneficiary— 
6
‘‘(i) who has not incurred costs, as de-
7
termined 
in 
accordance 
with 
section 
8
1860D–2(b)(4)(C), for covered part D 
9
drugs in the year that are equal to or ex-
10
ceed the annual out-of-pocket threshold 
11
specified in section 1860D–2(b)(4)(B)(i) 
12
for the year, 90 percent of the negotiated 
13
price of such drug; and 
14
‘‘(ii) who has incurred such costs, as 
15
so determined, in the year that are equal 
16
to or exceed such threshold for the year, 
17
80 percent of the negotiated price of such 
18
drug. 
19
‘‘(B) PHASE-IN FOR CERTAIN DRUGS DIS-
20
PENSED TO LIS BENEFICIARIES.— 
21
‘‘(i) IN GENERAL.—In the case of an 
22
applicable drug of a specified manufacturer 
23
(as defined in clause (ii)) that is marketed 
24
as of the date of enactment of this sub-
25
17:03 Apr 19, 2022
H7497
114 
•HR 7497 IH
paragraph and dispensed for an applicable 
1
beneficiary who is a subsidy eligible indi-
2
vidual (as defined in section 1860D– 
3
14(a)(3)), the term ‘discounted price’ 
4
means the specified LIS percent (as de-
5
fined in clause (iii)) of the negotiated price 
6
of the applicable drug of the manufacturer. 
7
‘‘(ii) SPECIFIED MANUFACTURER.— 
8
‘‘(I) IN GENERAL.—In this sub-
9
paragraph, subject to subclause (II), 
10
the 
term 
‘specified 
manufacturer’ 
11
means a manufacturer of an applica-
12
ble drug for which, in 2021— 
13
‘‘(aa) the manufacturer had 
14
a coverage gap discount agree-
15
ment under section 1860D–14A; 
16
‘‘(bb) the total expenditures 
17
for all of the specified drugs of 
18
the manufacturer covered by 
19
such agreement or agreements 
20
for such year and covered under 
21
this part during such year rep-
22
resented less than 1.0 percent of 
23
the total expenditures under this 
24
17:03 Apr 19, 2022
H7497
115 
•HR 7497 IH
part for all covered Part D drugs 
1
during such year; and 
2
‘‘(cc) the total expenditures 
3
for all of the specified drugs of 
4
the manufacturer that are single 
5
source drugs and biological prod-
6
ucts covered under part B during 
7
such year represented less than 
8
1.0 percent of the total expendi-
9
tures under part B for all drugs 
10
or biological products covered 
11
under such part during such 
12
year. 
13
‘‘(II) SPECIFIED DRUGS.— 
14
‘‘(aa) 
IN
GENERAL.—For 
15
purposes of this clause, the term 
16
‘specified drug’ means, with re-
17
spect to a specified manufac-
18
turer, for 2021, an applicable 
19
drug that is produced, prepared, 
20
propagated, 
compounded, 
con-
21
verted, or processed by the man-
22
ufacturer. 
23
‘‘(bb) 
AGGREGATION 
24
RULE.—All persons treated as a 
25
17:03 Apr 19, 2022
H7497
116 
•HR 7497 IH
single employer under subsection 
1
(a) or (b) of section 52 of the In-
2
ternal Revenue Code of 1986 
3
shall be treated as one manufac-
4
turer for purposes of this sub-
5
paragraph. For purposes of mak-
6
ing a determination pursuant to 
7
the previous sentence, an agree-
8
ment under this section shall re-
9
quire that a manufacturer pro-
10
vide and attest to such informa-
11
tion as specified by the Secretary 
12
as necessary. 
13
‘‘(III) LIMITATION.—The term 
14
‘specified manufacturer’ shall not in-
15
clude a manufacturer described in 
16
subclause (I) if such manufacturer is 
17
acquired after 2021 by another manu-
18
facturer that is not a specified manu-
19
facturer, effective at the beginning of 
20
the plan year immediately following 
21
such acquisition or, in the case of an 
22
acquisition before 2024, effective Jan-
23
uary 1, 2024. 
24
17:03 Apr 19, 2022
H7497
117 
•HR 7497 IH
‘‘(iii) SPECIFIED
LIS
PERCENT.—In 
1
this subparagraph, the ‘specified LIS per-
2
cent’ means, with respect to a year— 
3
‘‘(I) for an applicable drug dis-
4
pensed for an applicable beneficiary 
5
described in clause (i) who has not in-
6
curred costs, as determined in accord-
7
ance with section 1860D–2(b)(4)(C), 
8
for covered part D drugs in the year 
9
that are equal to or exceed the annual 
10
out-of-pocket threshold specified in 
11
section 1860D–2(b)(4)(B)(i) for the 
12
year— 
13
‘‘(aa) for 2024, 99 percent; 
14
‘‘(bb) for 2025, 98 percent; 
15
‘‘(cc) for 2026, 95 percent; 
16
‘‘(dd) for 2027, 92 percent; 
17
and 
18
‘‘(ee) for 2028 and each 
19
subsequent year, 90 percent; and 
20
‘‘(II) for an applicable drug dis-
21
pensed for an applicable beneficiary 
22
described in clause (i) who has in-
23
curred costs, as determined in accord-
24
ance with section 1860D–2(b)(4)(C), 
25
17:03 Apr 19, 2022
H7497
118 
•HR 7497 IH
for covered part D drugs in the year 
1
that are equal to or exceed the annual 
2
out-of-pocket threshold specified in 
3
section 1860D–2(b)(4)(B)(i) for the 
4
year— 
5
‘‘(aa) for 2024, 99 percent; 
6
‘‘(bb) for 2025, 98 percent; 
7
‘‘(cc) for 2026, 95 percent; 
8
‘‘(dd) for 2027, 92 percent; 
9
‘‘(ee) for 2028, 90 percent; 
10
‘‘(ff) for 2029, 85 percent; 
11
and 
12
‘‘(gg) for 2030 and each 
13
subsequent year, 80 percent. 
14
‘‘(C) PHASE-IN
FOR
SPECIFIED
SMALL 
15
MANUFACTURERS.— 
16
‘‘(i) IN GENERAL.—In the case of an 
17
applicable drug of a specified small manu-
18
facturer (as defined in clause (ii)) that is 
19
marketed as of the date of enactment of 
20
this subparagraph and dispensed for an 
21
applicable beneficiary, the term ‘discounted 
22
price’ means the specified small manufac-
23
turer percent (as defined in clause (iii)) of 
24
17:03 Apr 19, 2022
H7497
119 
•HR 7497 IH
the negotiated price of the applicable drug 
1
of the manufacturer. 
2
‘‘(ii) SPECIFIED
SMALL
MANUFAC-
3
TURER.— 
4
‘‘(I) IN GENERAL.—In this sub-
5
paragraph, subject to subclause (III), 
6
the term ‘specified small manufac-
7
turer’ means a manufacturer of an 
8
applicable drug for which, in 2021— 
9
‘‘(aa) the manufacturer is a 
10
specified manufacturer (as de-
11
fined in subparagraph (B)(ii)); 
12
and 
13
‘‘(bb) the total expenditures 
14
under part D for any one of the 
15
specified 
small 
manufacturer 
16
drugs of the manufacturer that 
17
are covered by the agreement or 
18
agreements 
under 
section 
19
1860D–14A of such manufac-
20
turer for such year and covered 
21
under this part during such year 
22
are equal to or more than 80 per-
23
cent of the total expenditures 
24
under this part for all specified 
25
17:03 Apr 19, 2022
H7497
120 
•HR 7497 IH
small manufacturer drugs of the 
1
manufacturer that are covered by 
2
such agreement or agreements 
3
for such year and covered under 
4
this part during such year. 
5
‘‘(II) SPECIFIED
SMALL
MANU-
6
FACTURER DRUGS.— 
7
‘‘(aa) 
IN
GENERAL.—For 
8
purposes of this clause, the term 
9
‘specified 
small 
manufacturer 
10
drugs’ means, with respect to a 
11
specified small manufacturer, for 
12
2021, an applicable drug that is 
13
produced, prepared, propagated, 
14
compounded, converted, or proc-
15
essed by the manufacturer. 
16
‘‘(bb) 
AGGREGATION 
17
RULE.—All persons treated as a 
18
single employer under subsection 
19
(a) or (b) of section 52 of the In-
20
ternal Revenue Code of 1986 
21
shall be treated as one manufac-
22
turer for purposes of this sub-
23
paragraph. For purposes of mak-
24
ing a determination pursuant to 
25
17:03 Apr 19, 2022
H7497
121 
•HR 7497 IH
the previous sentence, an agree-
1
ment under this section shall re-
2
quire that a manufacturer pro-
3
vide and attest to such informa-
4
tion as specified by the Secretary 
5
as necessary. 
6
‘‘(III) LIMITATION.—The term 
7
‘specified small manufacturer’ shall 
8
not include a manufacturer described 
9
in subclause (I) if such manufacturer 
10
is acquired after 2021 by another 
11
manufacturer that is not a specified 
12
small manufacturer, effective at the 
13
beginning of the plan year imme-
14
diately following such acquisition or, 
15
in the case of an acquisition before 
16
2024, effective January 1, 2024. 
17
‘‘(iii) SPECIFIED
SMALL
MANUFAC-
18
TURER PERCENT.—In this subparagraph, 
19
the term ‘specified small manufacturer per-
20
cent’ means, with respect to a year— 
21
‘‘(I) for an applicable drug dis-
22
pensed for an applicable beneficiary 
23
who has not incurred costs, as deter-
24
mined in accordance with section 
25
17:03 Apr 19, 2022
H7497
122 
•HR 7497 IH
1860D–2(b)(4)(C), for covered part D 
1
drugs in the year that are equal to or 
2
exceed 
the 
annual 
out-of-pocket 
3
threshold specified in section 1860D– 
4
2(b)(4)(B)(i) for the year— 
5
‘‘(aa) for 2024, 99 percent; 
6
‘‘(bb) for 2025, 98 percent; 
7
‘‘(cc) for 2026, 95 percent; 
8
‘‘(dd) for 2027, 92 percent; 
9
and 
10
‘‘(ee) for 2028 and each 
11
subsequent year, 90 percent; and 
12
‘‘(II) for an applicable drug dis-
13
pensed for an applicable beneficiary 
14
who has incurred costs, as determined 
15
in accordance with section 1860D– 
16
2(b)(4)(C), for covered part D drugs 
17
in the year that are equal to or exceed 
18
the annual out-of-pocket threshold 
19
specified 
in 
section 
1860D– 
20
2(b)(4)(B)(i) for the year— 
21
‘‘(aa) for 2024, 99 percent; 
22
‘‘(bb) for 2025, 98 percent; 
23
‘‘(cc) for 2026, 95 percent; 
24
‘‘(dd) for 2027, 92 percent; 
25
17:03 Apr 19, 2022
H7497
123 
•HR 7497 IH
‘‘(ee) for 2028, 90 percent; 
1
‘‘(ff) for 2029, 85 percent; 
2
and 
3
‘‘(gg) for 2030 and each 
4
subsequent year, 80 percent. 
5
‘‘(D) TOTAL
EXPENDITURES.—For pur-
6
poses of this paragraph, the term ‘total expend-
7
itures’ includes, in the case of expenditures with 
8
respect to part D, ingredient costs, dispensing 
9
fees, sales tax, and, if applicable, vaccine ad-
10
ministration fees. The term ‘total expenditures’ 
11
excludes, in the case of expenditures with re-
12
spect to part B, expenditures for a drug or bio-
13
logical that are bundled or packaged into the 
14
payment for another service. 
15
‘‘(E) 
SPECIAL
CASE
FOR
CERTAIN 
16
CLAIMS.— 
17
‘‘(i) 
CLAIMS
SPANNING
DEDUCT-
18
IBLE.—In the case where the entire 
19
amount of the negotiated price of an indi-
20
vidual claim for an applicable drug with re-
21
spect to an applicable beneficiary does not 
22
fall above the annual deductible specified 
23
in section 1860D–2(b)(1) for the year, the 
24
manufacturer of the applicable drug shall 
25
17:03 Apr 19, 2022
H7497
124 
•HR 7497 IH
provide the discounted price under this 
1
section on only the portion of the nego-
2
tiated price of the applicable drug that 
3
falls above such annual deductible. 
4
‘‘(ii) CLAIMS SPANNING OUT-OF-POCK-
5
ET THRESHOLD.—In the case where the 
6
entire amount of the negotiated price of an 
7
individual claim for an applicable drug 
8
with respect to an applicable beneficiary 
9
does not fall entirely below or entirely 
10
above the annual out-of-pocket threshold 
11
specified in section 1860D–2(b)(4)(B)(i) 
12
for the year, the manufacturer of the ap-
13
plicable drug shall provide the discounted 
14
price— 
15
‘‘(I) in accordance with subpara-
16
graph (A)(i) on the portion of the ne-
17
gotiated price of the applicable drug 
18
that falls below such threshold; and 
19
‘‘(II) in accordance with subpara-
20
graph (A)(ii) on the portion of such 
21
price of such drug that falls at or 
22
above such threshold. 
23
‘‘(5) MANUFACTURER.—The term ‘manufac-
24
turer’ means any entity which is engaged in the pro-
25
17:03 Apr 19, 2022
H7497
125 
•HR 7497 IH
duction, preparation, propagation, compounding, 
1
conversion, or processing of prescription drug prod-
2
ucts, either directly or indirectly by extraction from 
3
substances of natural origin, or independently by 
4
means of chemical synthesis, or by a combination of 
5
extraction and chemical synthesis. Such term does 
6
not include a wholesale distributor of drugs or a re-
7
tail pharmacy licensed under State law. 
8
‘‘(6) NEGOTIATED
PRICE.—The term ‘nego-
9
tiated price’ has the meaning given such term in sec-
10
tion 423.100 of title 42, Code of Federal Regula-
11
tions (or any successor regulation) and, with respect 
12
to an applicable drug, such negotiated price shall in-
13
clude any dispensing fee and, if applicable, any vac-
14
cine administration fee for the applicable drug. 
15
‘‘(7) QUALIFIED RETIREE PRESCRIPTION DRUG 
16
PLAN.—The term ‘qualified retiree prescription drug 
17
plan’ has the meaning given such term in section 
18
1860D–22(a)(2). 
19
‘‘SEC. 1860D–14D. SELECTED DRUG SUBSIDY PROGRAM. 
20
‘‘With respect to covered part D drugs that would 
21
be applicable drugs (as defined in section 1860D– 
22
14C(g)(2)) but for the application of subparagraph (B) 
23
of such section, the Secretary shall provide a process 
24
whereby, in the case of an applicable beneficiary (as de-
25
17:03 Apr 19, 2022
H7497
126 
•HR 7497 IH
fined in section 1860D–14C(g)(1)) who, with respect to 
1
a year, is enrolled in a prescription drug plan or is enrolled 
2
in an MA–PD plan, has not incurred costs that are equal 
3
to or exceed the annual out-of-pocket threshold specified 
4
in section 1860D–2(b)(4)(B)(i), and is dispensed such a 
5
drug the Secretary (periodically and on a timely basis) 
6
provides the PDP sponsor or the MA organization offering 
7
the plan, a subsidy with respect to such drug that is equal 
8
to 10 percent of the negotiated price (as defined in section 
9
1860D–14C(g)(6)) of such drug.’’. 
10
(2) SUNSET OF MEDICARE COVERAGE GAP DIS-
11
COUNT PROGRAM.—Section 1860D–14A of the So-
12
cial Security Act (42 U.S.C. 1395–114a) is amend-
13
ed— 
14
(A) in subsection (a), in the first sentence, 
15
by striking ‘‘The Secretary’’ and inserting 
16
‘‘Subject to subsection (h), the Secretary’’; and 
17
(B) by adding at the end the following new 
18
subsection: 
19
‘‘(h) SUNSET OF PROGRAM.— 
20
‘‘(1) IN
GENERAL.—The program shall not 
21
apply with respect to applicable drugs dispensed on 
22
or after January 1, 2024, and, subject to paragraph 
23
(2), agreements under this section shall be termi-
24
nated as of such date. 
25
17:03 Apr 19, 2022
H7497
127 
•HR 7497 IH
‘‘(2) CONTINUED APPLICATION FOR APPLICA-
1
BLE
DRUGS
DISPENSED
PRIOR
TO
SUNSET.—The 
2
provisions of this section (including all responsibil-
3
ities and duties) shall continue to apply on and after 
4
January 1, 2024, with respect to applicable drugs 
5
dispensed prior to such date.’’. 
6
(3) INCLUSION OF ACTUARIAL VALUE OF MANU-
7
FACTURER DISCOUNTS IN BIDS.—Section 1860D–11 
8
of the Social Security Act (42 U.S.C. 1395w–111) 
9
is amended— 
10
(A) in subsection (b)(2)(C)(iii)— 
11
(i) by striking ‘‘assumptions regarding 
12
the reinsurance’’ and inserting ‘‘assump-
13
tions regarding— 
14
‘‘(I) the reinsurance’’; and 
15
(ii) by adding at the end the fol-
16
lowing: 
17
‘‘(II) for 2024 and each subse-
18
quent year, the manufacturer dis-
19
counts provided under section 1860D– 
20
14C subtracted from the actuarial 
21
value to produce such bid; and’’; and 
22
(B) in subsection (c)(1)(C)— 
23
17:03 Apr 19, 2022
H7497
128 
•HR 7497 IH
(i) by striking ‘‘an actuarial valuation 
1
of the reinsurance’’ and inserting ‘‘an ac-
2
tuarial valuation of— 
3
‘‘(i) the reinsurance’’; 
4
(ii) in clause (i), as inserted by clause 
5
(i) of this subparagraph, by adding ‘‘and’’ 
6
at the end; and 
7
(iii) by adding at the end the fol-
8
lowing: 
9
‘‘(ii) for 2024 and each subsequent 
10
year, the manufacturer discounts provided 
11
under section 1860D–14C;’’. 
12
(e) CONFORMING AMENDMENTS.— 
13
(1) Section 1860D–2 of the Social Security Act 
14
(42 U.S.C. 1395w–102) is amended— 
15
(A) in subsection (a)(2)(A)(i)(I), by strik-
16
ing ‘‘, or an increase in the initial’’ and insert-
17
ing ‘‘or, for a year preceding 2024, an increase 
18
in the initial’’; 
19
(B) in subsection (c)(1)(C)— 
20
(i) in the subparagraph heading, by 
21
striking ‘‘AT
INITIAL
COVERAGE
LIMIT’’; 
22
and 
23
(ii) by inserting ‘‘for a year preceding 
24
2024 or the annual out-of-pocket threshold 
25
17:03 Apr 19, 2022
H7497
129 
•HR 7497 IH
specified in subsection (b)(4)(B) for the 
1
year for 2024 and each subsequent year’’ 
2
after ‘‘subsection (b)(3) for the year’’ each 
3
place it appears; and 
4
(C) in subsection (d)(1)(A), by striking ‘‘or 
5
an initial’’ and inserting ‘‘or, for a year pre-
6
ceding 2024, an initial’’. 
7
(2) Section 1860D–4(a)(4)(B)(i) of the Social 
8
Security Act (42 U.S.C. 1395w–104(a)(4)(B)(i)) is 
9
amended by striking ‘‘the initial’’ and inserting ‘‘for 
10
a year preceding 2024, the initial’’. 
11
(3) Section 1860D–14(a) of the Social Security 
12
Act (42 U.S.C. 1395w–114(a)) is amended— 
13
(A) in paragraph (1)— 
14
(i) in subparagraph (C), by striking 
15
‘‘The continuation’’ and inserting ‘‘For a 
16
year preceding 2024, the continuation’’; 
17
(ii) in subparagraph (D)(iii), by strik-
18
ing ‘‘1860D–2(b)(4)(A)(i)(I)’’ and insert-
19
ing ‘‘1860D–2(b)(4)(A)(i)(I)(aa)’’; and 
20
(iii) in subparagraph (E), by striking 
21
‘‘The elimination’’ and inserting ‘‘For a 
22
year preceding 2024, the elimination’’; and 
23
(B) in paragraph (2)— 
24
17:03 Apr 19, 2022
H7497
130 
•HR 7497 IH
(i) in subparagraph (C), by striking 
1
‘‘The continuation’’ and inserting ‘‘For a 
2
year preceding 2024, the continuation’’; 
3
and 
4
(ii) in subparagraph (E), by striking 
5
‘‘1860D–2(b)(4)(A)(i)(I)’’ and inserting 
6
‘‘1860D–2(b)(4)(A)(i)(I)(aa)’’. 
7
(4) Section 1860D–21(d)(7) of the Social Secu-
8
rity Act (42 U.S.C. 1395w–131(d)(7)) is amended 
9
by striking ‘‘section 1860D–2(b)(4)(B)(i)’’ and in-
10
serting ‘‘section 1860D–2(b)(4)(C)(i)’’. 
11
(5) Section 1860D–22(a)(2)(A) of the Social 
12
Security Act (42 U.S.C. 1395w–132(a)(2)(A)) is 
13
amended— 
14
(A) by striking ‘‘the value of any discount’’ 
15
and inserting the following: ‘‘the value of— 
16
‘‘(i) for years prior to 2024, any dis-
17
count’’; 
18
(B) in clause (i), as inserted by subpara-
19
graph (A) of this paragraph, by striking the pe-
20
riod at the end and inserting ‘‘; and’’; and 
21
(C) by adding at the end the following new 
22
clause: 
23
17:03 Apr 19, 2022
H7497
131 
•HR 7497 IH
‘‘(ii) for 2024 and each subsequent 
1
year, any discount provided pursuant to 
2
section 1860D–14C.’’. 
3
(6) Section 1860D–41(a)(6) of the Social Secu-
4
rity Act (42 U.S.C. 1395w–151(a)(6)) is amended— 
5
(A) by inserting ‘‘for a year before 2024’’ 
6
after ‘‘1860D–2(b)(3)’’; and 
7
(B) by inserting ‘‘for such year’’ before the 
8
period. 
9
(7) Section 1860D–43 of the Social Security 
10
Act (42 U.S.C. 1395w–153) is amended— 
11
(A) in subsection (a)— 
12
(i) by striking paragraph (1) and in-
13
serting the following: 
14
‘‘(1) participate in— 
15
‘‘(A) for 2011 through 2023, the Medicare 
16
coverage gap discount program under section 
17
1860D–14A; and 
18
‘‘(B) for 2024 and each subsequent year, 
19
the manufacturer discount program under sec-
20
tion 1860D–14C;’’; 
21
(ii) by striking paragraph (2) and in-
22
serting the following: 
23
‘‘(2) have entered into and have in effect— 
24
17:03 Apr 19, 2022
H7497
132 
•HR 7497 IH
‘‘(A) for 2011 through 2023, an agreement 
1
described in subsection (b) of section 1860D– 
2
14A with the Secretary; and 
3
‘‘(B) for 2024 and each subsequent year, 
4
an agreement described in subsection (b) of sec-
5
tion 1860D–14C with the Secretary; and’’; and 
6
(iii) by striking paragraph (3) and in-
7
serting the following: 
8
‘‘(3) have entered into and have in effect, under 
9
terms and conditions specified by the Secretary— 
10
‘‘(A) for 2011 through 2023, a contract 
11
with a third party that the Secretary has en-
12
tered into a contract with under subsection 
13
(d)(3) of section 1860D–14A; and 
14
‘‘(B) for 2024 and each subsequent year, 
15
a contract with a third party that the Secretary 
16
has entered into a contract with under sub-
17
section (d)(3) of section 1860D–14C.’’; and 
18
(B) by striking subsection (b) and insert-
19
ing the following: 
20
‘‘(b) EFFECTIVE DATE.—Paragraphs (1)(A), (2)(A), 
21
and (3)(A) of subsection (a) shall apply to covered part 
22
D drugs dispensed under this part on or after January 
23
1, 2011, and before January 1, 2024, and paragraphs 
24
(1)(B), (2)(B), and (3)(B) of such subsection shall apply 
25
17:03 Apr 19, 2022
H7497
133 
•HR 7497 IH
to covered part D drugs dispensed under this part on or 
1
after January 1, 2024.’’. 
2
(8) Section 1927 of the Social Security Act (42 
3
U.S.C. 1396r–8) is amended— 
4
(A) in subsection (c)(1)(C)(i)(VI), by in-
5
serting before the period at the end the fol-
6
lowing: ‘‘or under the manufacturer discount 
7
program under section 1860D–14C’’; and 
8
(B) in subsection (k)(1)(B)(i)(V), by in-
9
serting before the period at the end the fol-
10
lowing: ‘‘or under section 1860D–14C’’. 
11
(f) IMPLEMENTATION FOR 2024 AND 2025.—Not-
12
withstanding any other provision of this section, the Sec-
13
retary shall implement this section, including the amend-
14
ments made by this section, for 2024 and 2025 by pro-
15
gram instruction or otherwise. 
16
(g) FUNDING.—In addition to amounts otherwise 
17
available, there are appropriated to the Centers for Medi-
18
care & Medicaid Services, out of any money in the Treas-
19
ury not otherwise appropriated, $44,000,000 for fiscal 
20
year 2022, $38,000,000 for fiscal year 2023, and 
21
$32,000,000 for each of fiscal years 2024 through 2031, 
22
to remain available until expended, to carry out the provi-
23
sions of, including the amendments made by, this section. 
24
17:03 Apr 19, 2022
H7497
134 
•HR 7497 IH
SEC. 302. MAXIMUM MONTHLY CAP ON COST-SHARING PAY-
1
MENTS UNDER PRESCRIPTION DRUG PLANS 
2
AND MA–PD PLANS. 
3
(a) IN GENERAL.—Section 1860D–2(b) of the Social 
4
Security Act (42 U.S.C. 1395w–102(b)), as amended by 
5
section 301, is amended— 
6
(1) in paragraph (2)— 
7
(A) in subparagraph (A), by striking ‘‘and 
8
(D)’’ and inserting ‘‘, (D), and (E)’’; and 
9
(B) by adding at the end the following new 
10
subparagraph: 
11
‘‘(E) MAXIMUM MONTHLY CAP ON COST- 
12
SHARING PAYMENTS.— 
13
‘‘(i) IN GENERAL.—For plan years be-
14
ginning on or after January 1, 2025, each 
15
PDP sponsor offering a prescription drug 
16
plan and each MA organization offering an 
17
MA–PD plan shall provide to any enrollee 
18
of such plan, including an enrollee who is 
19
a subsidy eligible individual (as defined in 
20
paragraph (3) of section 1860D–14(a)), 
21
the option to elect with respect to a plan 
22
year to pay cost-sharing under the plan in 
23
monthly amounts that are capped in ac-
24
cordance with this subparagraph. 
25
17:03 Apr 19, 2022
H7497
135 
•HR 7497 IH
‘‘(ii) DETERMINATION
OF
MAXIMUM 
1
MONTHLY
CAP.—For each month in the 
2
plan year for which an enrollee in a pre-
3
scription drug plan or an MA–PD plan has 
4
made an election pursuant to clause (i), 
5
the PDP sponsor or MA organization shall 
6
determine a maximum monthly cap (as de-
7
fined in clause (iv)) for such enrollee. 
8
‘‘(iii) BENEFICIARY
MONTHLY
PAY-
9
MENTS.—With respect to an enrollee who 
10
has made an election pursuant to clause 
11
(i), for each month described in clause (ii), 
12
the PDP sponsor or MA organization shall 
13
bill such enrollee an amount (not to exceed 
14
the maximum monthly cap) for the out-of- 
15
pocket costs of such enrollee in such 
16
month. 
17
‘‘(iv) MAXIMUM
MONTHLY
CAP
DE-
18
FINED.—In this subparagraph, the term 
19
‘maximum monthly cap’ means, with re-
20
spect to an enrollee— 
21
‘‘(I) for the first month for which 
22
the enrollee has made an election pur-
23
suant to clause (i), an amount deter-
24
mined by calculating— 
25
17:03 Apr 19, 2022
H7497
136 
•HR 7497 IH
‘‘(aa) the annual out-of- 
1
pocket 
threshold 
specified 
in 
2
paragraph (4)(B) minus the in-
3
curred costs of the enrollee as de-
4
scribed in paragraph (4)(C); di-
5
vided by 
6
‘‘(bb) the number of months 
7
remaining in the plan year; and 
8
‘‘(II) for a subsequent month, an 
9
amount determined by calculating— 
10
‘‘(aa) the sum of any re-
11
maining out-of-pocket costs owed 
12
by the enrollee from a previous 
13
month that have not yet been 
14
billed to the enrollee and any ad-
15
ditional out-of-pocket costs in-
16
curred by the enrollee; divided by 
17
‘‘(bb) the number of months 
18
remaining in the plan year. 
19
‘‘(v) ADDITIONAL
REQUIREMENTS.— 
20
The following requirements shall apply 
21
with respect to the option to make an elec-
22
tion pursuant to clause (i) under this sub-
23
paragraph: 
24
17:03 Apr 19, 2022
H7497
137 
•HR 7497 IH
‘‘(I) SECRETARIAL RESPONSIBIL-
1
ITIES.—The Secretary shall provide 
2
information to part D eligible individ-
3
uals on the option to make such elec-
4
tion through educational materials, in-
5
cluding through the notices provided 
6
under section 1804(a). 
7
‘‘(II) TIMING OF ELECTION.—An 
8
enrollee in a prescription drug plan or 
9
an MA–PD plan may make such an 
10
election— 
11
‘‘(aa) prior to the beginning 
12
of the plan year; or 
13
‘‘(bb) in any month during 
14
the plan year. 
15
‘‘(III) PDP SPONSOR
AND
MA 
16
ORGANIZATION
RESPONSIBILITIES.— 
17
Each PDP sponsor offering a pre-
18
scription drug plan or MA organiza-
19
tion offering an MA–PD plan— 
20
‘‘(aa) may not limit the op-
21
tion for an enrollee to make such 
22
an election to certain covered 
23
part D drugs; 
24
17:03 Apr 19, 2022
H7497
138 
•HR 7497 IH
‘‘(bb) shall, prior to the plan 
1
year, notify prospective enrollees 
2
of the option to make such an 
3
election in promotional materials; 
4
‘‘(cc) shall include informa-
5
tion on such option in enrollee 
6
educational materials; 
7
‘‘(dd) shall have in place a 
8
mechanism to notify a pharmacy 
9
during the plan year when an en-
10
rollee incurs out-of-pocket costs 
11
with respect to covered part D 
12
drugs that make it likely the en-
13
rollee may benefit from making 
14
such an election; 
15
‘‘(ee) shall provide that a 
16
pharmacy, after receiving a noti-
17
fication described in item (dd) 
18
with respect to an enrollee, in-
19
forms the enrollee of such notifi-
20
cation; 
21
‘‘(ff) shall ensure that such 
22
an election by an enrollee has no 
23
effect on the amount paid to 
24
pharmacies (or the timing of 
25
17:03 Apr 19, 2022
H7497
139 
•HR 7497 IH
such payments) with respect to 
1
covered part D drugs dispensed 
2
to the enrollee; and 
3
‘‘(gg) shall have in place a 
4
financial reconciliation process to 
5
correct inaccuracies in payments 
6
made by an enrollee under this 
7
subparagraph with respect to 
8
covered part D drugs during the 
9
plan year. 
10
‘‘(IV) FAILURE TO PAY AMOUNT 
11
BILLED.—If an enrollee fails to pay 
12
the amount billed for a month as re-
13
quired under this subparagraph, the 
14
election of the enrollee pursuant to 
15
clause (i) shall be terminated and the 
16
enrollee shall pay the cost-sharing 
17
otherwise applicable for any covered 
18
part D drugs subsequently dispensed 
19
to the enrollee up to the annual out- 
20
of-pocket threshold specified in para-
21
graph (4)(B). 
22
‘‘(V) CLARIFICATION REGARDING 
23
PAST DUE AMOUNTS.—Nothing in this 
24
subparagraph shall be construed as 
25
17:03 Apr 19, 2022
H7497
140 
•HR 7497 IH
prohibiting a PDP sponsor or an MA 
1
organization from billing an enrollee 
2
for an amount owed under this sub-
3
paragraph. 
4
‘‘(VI) TREATMENT
OF
UNSET-
5
TLED BALANCES.—Any unsettled bal-
6
ances with respect to amounts owed 
7
under this subparagraph shall be 
8
treated as plan losses and the Sec-
9
retary shall not be liable for any such 
10
balances outside of those assumed as 
11
losses estimated in plan bids.’’; and 
12
(2) in paragraph (4)— 
13
(A) in subparagraph (C), by striking ‘‘in 
14
subparagraph (E)’’ and inserting ‘‘in subpara-
15
graph (E) and subject to subparagraph (F)’’; 
16
and 
17
(B) by adding at the end the following new 
18
subparagraph: 
19
‘‘(F) INCLUSION OF COSTS PAID UNDER 
20
MAXIMUM MONTHLY CAP OPTION.—In applying 
21
subparagraph (A), with respect to an enrollee 
22
who has made an election pursuant to clause (i) 
23
of paragraph (2)(E), costs shall be treated as 
24
incurred if such costs are paid by a PDP spon-
25
17:03 Apr 19, 2022
H7497
141 
•HR 7497 IH
sor or an MA organization under the option 
1
provided under such paragraph.’’. 
2
(b) APPLICATION TO ALTERNATIVE PRESCRIPTION 
3
DRUG COVERAGE.—Section 1860D–2(c) of the Social Se-
4
curity Act (42 U.S.C. 1395w–102(c)) is amended by add-
5
ing at the end the following new paragraph: 
6
‘‘(4) SAME MAXIMUM MONTHLY CAP ON COST- 
7
SHARING.—For plan years beginning on or after 
8
January 1, 2025, the maximum monthly cap on 
9
cost-sharing payments under the option provided 
10
under subsection (b)(2)(E) shall apply to such cov-
11
erage.’’. 
12
(c) IMPLEMENTATION
FOR 2025.—The Secretary 
13
shall implement this section, including the amendments 
14
made by this section, for 2025 by program instruction or 
15
otherwise. 
16
(d) FUNDING.—In addition to amounts otherwise 
17
available, there are appropriated to the Centers for Medi-
18
care & Medicaid Services, out of any money in the Treas-
19
ury not otherwise appropriated, $1,000,000 for each of fis-
20
cal years 2022 through 2031, to remain available until ex-
21
pended, to carry out the provisions of, including the 
22
amendments made by, this section. 
23
17:03 Apr 19, 2022
H7497
142 
•HR 7497 IH
TITLE IV—REPEAL OF CERTAIN 
1
PRESCRIPTION 
DRUG 
RE-
2
BATE RULE 
3
SEC. 401. PROHIBITING IMPLEMENTATION OF RULE RELAT-
4
ING TO ELIMINATING THE ANTI-KICKBACK 
5
STATUTE SAFE HARBOR PROTECTION FOR 
6
PRESCRIPTION DRUG REBATES. 
7
Beginning January 1, 2026, the Secretary of Health 
8
and Human Services shall not implement, administer, or 
9
enforce the provisions of the final rule published by the 
10
Office of the Inspector General of the Department of 
11
Health and Human Services on November 30, 2020, and 
12
titled ‘‘Fraud and Abuse; Removal of Safe Harbor Protec-
13
tion for Rebates Involving Prescription Pharmaceuticals 
14
and Creation of New Safe Harbor Protection for Certain 
15
Point-of-Sale Reductions in Price on Prescription Phar-
16
maceuticals and Certain Pharmacy Benefit Manager Serv-
17
ice Fees’’ (85 Fed. Reg. 76666). 
18
TITLE V—MISCELLANEOUS 
19
SEC. 501. APPROPRIATE COST-SHARING FOR CERTAIN IN-
20
SULIN PRODUCTS UNDER MEDICARE PART D. 
21
(a) IN GENERAL.—Section 1860D–2 of the Social 
22
Security Act (42 U.S.C. 1395w–102) is amended— 
23
(1) in subsection (b)— 
24
17:03 Apr 19, 2022
H7497
143 
•HR 7497 IH
(A) in paragraph (1)(A), by striking ‘‘The 
1
coverage’’ and inserting ‘‘Subject to paragraph 
2
(8), the coverage’’; 
3
(B) in paragraph (2)(A), by striking ‘‘and 
4
(D)’’ and inserting ‘‘and (D) and paragraph 
5
(8)’’; 
6
(C) in paragraph (3)(A), by striking ‘‘and 
7
(4)’’ and inserting ‘‘(4), and (8)’’; 
8
(D) in paragraph (4)(A)(i), by striking 
9
‘‘The coverage’’ and inserting ‘‘Subject to para-
10
graph (8), the coverage’’; and 
11
(E) by adding at the end the following new 
12
paragraph: 
13
‘‘(8) TREATMENT OF COST-SHARING FOR CER-
14
TAIN INSULIN PRODUCTS.— 
15
‘‘(A) IN GENERAL.—For plan years begin-
16
ning on or after January 1, 2023, the following 
17
shall apply with respect to insulin products (as 
18
defined in subparagraph (B)): 
19
‘‘(i) NO
APPLICATION
OF
DEDUCT-
20
IBLE.—The deductible under paragraph 
21
(1) shall not apply with respect to such in-
22
sulin products. 
23
‘‘(ii) APPLICATION
OF
COST-SHAR-
24
ING.— 
25
17:03 Apr 19, 2022
H7497
144 
•HR 7497 IH
‘‘(I) PLAN YEAR 2023.—For plan 
1
year 2023, the coverage provides ben-
2
efits for such insulin products, regard-
3
less of whether an individual has 
4
reached the initial coverage limit 
5
under paragraph (3) or the out-of- 
6
pocket threshold under paragraph (4), 
7
with cost-sharing that is equal to the 
8
applicable copayment amount. 
9
‘‘(II) PLAN YEAR 2024 AND SUB-
10
SEQUENT
PLAN
YEARS.—For plan 
11
year 2024 and subsequent plan years, 
12
the coverage provides benefits for 
13
such insulin products, prior to an in-
14
dividual reaching the out-of-pocket 
15
threshold under paragraph (4), with 
16
cost-sharing that is equal to the appli-
17
cable copayment amount. 
18
‘‘(III) APPLICABLE
COPAYMENT 
19
AMOUNT.—For 
purposes 
of 
this 
20
clause, the term ‘applicable copayment 
21
amount’ means, with respect to an in-
22
sulin product under a prescription 
23
drug plan or an MA–PD plan, an 
24
amount that is not more than $35. 
25
17:03 Apr 19, 2022
H7497
145 
•HR 7497 IH
‘‘(B) INSULIN PRODUCT.—For purposes of 
1
this paragraph, the term ‘insulin product’ 
2
means an insulin product that is approved 
3
under section 505 of the Federal Food, Drug, 
4
and Cosmetic Act or licensed under section 351 
5
of the Public Health Service Act and marketed 
6
pursuant to such approval or licensure, includ-
7
ing any insulin product that has been deemed 
8
to be licensed under section 351 of the Public 
9
Health 
Service 
Act 
pursuant 
to 
section 
10
7002(e)(4) of the Biologics Price Competition 
11
and Innovation Act of 2009 and marketed pur-
12
suant to such section.’’; and 
13
(2) in subsection (c), by adding at the end the 
14
following new paragraph: 
15
‘‘(4) TREATMENT OF COST-SHARING FOR INSU-
16
LIN PRODUCTS.—The coverage is provided in accord-
17
ance with subsection (b)(8).’’. 
18
(b) CONFORMING AMENDMENTS TO COST-SHARING 
19
FOR LOW-INCOME INDIVIDUALS.—Section 1860D–14(a) 
20
of the Social Security Act (42 U.S.C. 1395w–114(a)) is 
21
amended— 
22
(1) in paragraph (1)— 
23
(A) in subparagraph (D)(iii), by adding at 
24
the end the following new sentence: ‘‘For plan 
25
17:03 Apr 19, 2022
H7497
146 
•HR 7497 IH
year 2023 and subsequent plan years, the co-
1
payment amount applicable under the preceding 
2
sentence to an insulin product (as defined in 
3
section 1860D–2(b)(8)(B)) furnished to the in-
4
dividual may not exceed the applicable copay-
5
ment amount for the product under the pre-
6
scription drug plan or MA–PD plan in which 
7
the individual is enrolled.’’; and 
8
(B) in subparagraph (E), by inserting the 
9
following before the period at the end ‘‘or under 
10
section 1860D–2(b)(8) in the case of an insulin 
11
product (as defined in subparagraph (B) of 
12
such section)’’; and 
13
(2) in paragraph (2)— 
14
(A) in subparagraph (D), by adding at the 
15
end the following new sentence: ‘‘For plan year 
16
2023 and subsequent plan years, the amount of 
17
the coinsurance applicable under the preceding 
18
sentence to an insulin product (as defined in 
19
section 1860D–2(b)(8)(B)) furnished to the in-
20
dividual may not exceed the applicable copay-
21
ment amount for the product under the pre-
22
scription drug plan or MA–PD plan in which 
23
the individual is enrolled.’’; and 
24
17:03 Apr 19, 2022
H7497
147 
•HR 7497 IH
(B) in subparagraph (E), by adding at the 
1
end the following new sentence: ‘‘For plan year 
2
2023, the amount of the copayment or coinsur-
3
ance applicable under the preceding sentence to 
4
an insulin product (as defined in section 
5
1860D–2(b)(8)(B)) furnished to the individual 
6
may not exceed the applicable copayment 
7
amount for the product under the prescription 
8
drug plan or MA–PD plan in which the indi-
9
vidual is enrolled.’’. 
10
(c) IMPLEMENTATION.—The Secretary shall imple-
11
ment this section for plan years 2023 and 2024 by pro-
12
gram instruction or otherwise. 
13
SEC. 502. COVERAGE OF ADULT VACCINES RECOMMENDED 
14
BY THE ADVISORY COMMITTEE ON IMMUNI-
15
ZATION PRACTICES UNDER MEDICARE PART 
16
D. 
17
(a) ENSURING TREATMENT OF COST-SHARING IS 
18
CONSISTENT WITH TREATMENT OF VACCINES UNDER 
19
MEDICARE PART B.—Section 1860D–2 of the Social Se-
20
curity Act (42 U.S.C. 1395w–102), as amended by section 
21
501, is further amended— 
22
(1) in subsection (b)— 
23
17:03 Apr 19, 2022
H7497
148 
•HR 7497 IH
(A) in paragraph (1)(A), by striking 
1
‘‘paragraph (8)’’ and inserting ‘‘paragraphs (8) 
2
and (9)’’; 
3
(B) in paragraph (2)(A), by striking 
4
‘‘paragraph (8)’’ and inserting ‘‘paragraphs (8) 
5
and (9)’’; 
6
(C) in paragraph (3)(A), by striking ‘‘and 
7
(8)’’ and inserting ‘‘(8), and (9)’’; 
8
(D) in paragraph (4)(A)(i), by striking 
9
‘‘paragraph (8)’’ and inserting ‘‘paragraphs (8) 
10
and (9)’’; and 
11
(E) by adding at the end the following new 
12
paragraph: 
13
‘‘(9) 
TREATMENT
OF
COST-SHARING
FOR 
14
ADULT VACCINES RECOMMENDED BY THE ADVISORY 
15
COMMITTEE
ON
IMMUNIZATION
PRACTICES
CON-
16
SISTENT
WITH
TREATMENT
OF
VACCINES
UNDER 
17
PART B.— 
18
‘‘(A) IN GENERAL.—For plan years begin-
19
ning on or after January 1, 2024, the following 
20
shall apply with respect to an adult vaccine rec-
21
ommended by the Advisory Committee on Im-
22
munization Practices (as defined in subpara-
23
graph (B)): 
24
17:03 Apr 19, 2022
H7497
149 
•HR 7497 IH
‘‘(i) NO
APPLICATION
OF
DEDUCT-
1
IBLE.—The deductible under paragraph 
2
(1) shall not apply with respect to such 
3
vaccine. 
4
‘‘(ii) NO
APPLICATION
OF
COINSUR-
5
ANCE
OR
ANY
OTHER
COST-SHARING.— 
6
There shall be no coinsurance or other 
7
cost-sharing under this part with respect 
8
to such vaccine, regardless of whether for 
9
costs below, at, or above the initial cov-
10
erage limit under paragraph (3) or the 
11
out-of-pocket threshold under paragraph 
12
(4). 
13
‘‘(B) ADULT VACCINES RECOMMENDED BY 
14
THE ADVISORY COMMITTEE ON IMMUNIZATION 
15
PRACTICES.—For purposes of this paragraph, 
16
the term ‘adult vaccine recommended by the 
17
Advisory Committee on Immunization Prac-
18
tices’ means a covered part D drug that is a 
19
vaccine licensed under section 351 of the Public 
20
Health Service Act for use by adult populations 
21
and administered in accordance with rec-
22
ommendations of the Advisory Committee on 
23
Immunization Practices of the Centers for Dis-
24
ease Control and Prevention.’’; and 
25
17:03 Apr 19, 2022
H7497
150 
•HR 7497 IH
(2) in subsection (c), by adding at the end the 
1
following new paragraph: 
2
‘‘(5) 
TREATMENT
OF
COST-SHARING
FOR 
3
ADULT VACCINES RECOMMENDED BY THE ADVISORY 
4
COMMITTEE
ON
IMMUNIZATION
PRACTICES.—The 
5
coverage is in accordance with subsection (b)(9).’’. 
6
(b) CONFORMING AMENDMENTS TO COST-SHARING 
7
FOR LOW-INCOME INDIVIDUALS.—Section 1860D–14(a) 
8
of the Social Security Act (42 U.S.C. 1395w–114(a)), as 
9
amended by section 501, is further amended— 
10
(1) in paragraph (1)(D), in each of clauses (ii) 
11
and (iii), by striking ‘‘In the case’’ and inserting 
12
‘‘Subject to paragraph (6), in the case’’; 
13
(2) in paragraph (2)— 
14
(A) in subparagraph (B), by striking ‘‘A 
15
reduction’’ and inserting ‘‘Subject to paragraph 
16
(6), a reduction’’; 
17
(B) in subparagraph (D), by striking ‘‘The 
18
substitution’’ and inserting ‘‘Subject to para-
19
graph (6), the substitution’’; and 
20
(C) in subparagraph (E), by striking ‘‘sub-
21
section (c)’’ and inserting ‘‘paragraph (6) and 
22
subsection (c)’’; and 
23
(3) by adding at the end the following new 
24
paragraph: 
25
17:03 Apr 19, 2022
H7497
151 
•HR 7497 IH
‘‘(6) NO APPLICATION OF COST-SHARING FOR 
1
ADULT VACCINES RECOMMENDED BY THE ADVISORY 
2
COMMITTEE
ON
IMMUNIZATION
PRACTICES.—For 
3
plan years beginning on or after January 1, 2024, 
4
there shall be no cost-sharing under this section, in-
5
cluding no annual deductible applicable under this 
6
section, with respect to an adult vaccine rec-
7
ommended by the Advisory Committee on Immuniza-
8
tion Practices (as defined in subparagraph (B) of 
9
such section).’’. 
10
(c) RULE OF CONSTRUCTION.—Nothing in this sec-
11
tion shall be construed as limiting coverage under part D 
12
of title XVIII of the Social Security Act for vaccines that 
13
are not recommended by the Advisory Committee on Im-
14
munization Practices. 
15
(d) IMPLEMENTATION
FOR 2024.—The Secretary 
16
shall implement this section, including the amendments 
17
made by this section, for 2024 by program instruction or 
18
otherwise. 
19
SEC. 503. PAYMENT FOR BIOSIMILAR BIOLOGICAL PROD-
20
UCTS DURING INITIAL PERIOD. 
21
Section 1847A(c)(4) of the Social Security Act (42 
22
U.S.C. 1395w–3a(c)(4)) is amended— 
23
(1) in each of subparagraphs (A) and (B), by 
24
redesignating clauses (i) and (ii) as subclauses (I) 
25
17:03 Apr 19, 2022
H7497
152 
•HR 7497 IH
and (II), respectively, and moving such subclauses 2 
1
ems to the right; 
2
(2) by redesignating subparagraphs (A) and 
3
(B) as clauses (i) and (ii) and moving such clauses 
4
2 ems to the right; 
5
(3) by striking ‘‘UNAVAILABLE.—In the case’’ 
6
and inserting ‘‘UNAVAILABLE.— 
7
‘‘(A) IN
GENERAL.—Subject to subpara-
8
graph (B), in the case’’; and 
9
(4) by adding at the end the following new sub-
10
paragraph: 
11
‘‘(B) LIMITATION
ON
PAYMENT
AMOUNT 
12
FOR BIOSIMILAR BIOLOGICAL PRODUCTS DUR-
13
ING
INITIAL
PERIOD.—In the case of a bio-
14
similar biological product furnished on or after 
15
July 1, 2023, during the initial period described 
16
in subparagraph (A) with respect to the bio-
17
similar biological product, the amount payable 
18
under this section for the biosimilar biological 
19
product is the lesser of the following: 
20
‘‘(i) The amount determined under 
21
clause (ii) of such subparagraph for the 
22
biosimilar biological product. 
23
17:03 Apr 19, 2022
H7497
153 
•HR 7497 IH
‘‘(ii) The amount determined under 
1
subsection (b)(1)(B) for the reference bio-
2
logical product.’’. 
3
SEC. 504. TEMPORARY INCREASE IN MEDICARE PART B 
4
PAYMENT FOR CERTAIN BIOSIMILAR BIO-
5
LOGICAL PRODUCTS. 
6
Section 1847A(b)(8) of the Social Security Act (42 
7
U.S.C. 1395w–3a(b)(8)) is amended— 
8
(1) by redesignating subparagraphs (A) and 
9
(B) as clauses (i) and (ii), respectively, and moving 
10
the margin of each such redesignated clause 2 ems 
11
to the right; 
12
(2) by striking ‘‘PRODUCT.—The amount’’ and 
13
inserting the following: ‘‘PRODUCT.— 
14
‘‘(A) IN
GENERAL.—Subject to subpara-
15
graph (B), the amount’’; and 
16
(3) by adding at the end the following new sub-
17
paragraph: 
18
‘‘(B) TEMPORARY PAYMENT INCREASE.— 
19
‘‘(i) IN GENERAL.—In the case of a 
20
qualifying biosimilar biological product 
21
that is furnished during the applicable 5- 
22
year period for such product, the amount 
23
specified in this paragraph for such prod-
24
uct with respect to such period is the sum 
25
17:03 Apr 19, 2022
H7497
154 
•HR 7497 IH
determined under subparagraph (A), ex-
1
cept that clause (ii) of such subparagraph 
2
shall be applied by substituting ‘8 percent’ 
3
for ‘6 percent’. 
4
‘‘(ii) APPLICABLE 5-YEAR PERIOD.— 
5
For purposes of clause (i), the applicable 
6
5-year period for a qualifying biosimilar bi-
7
ological product is— 
8
‘‘(I) in the case of such a product 
9
for which payment was made under 
10
this paragraph as of March 31, 2022, 
11
the 5-year period beginning on April 
12
1, 2022; and 
13
‘‘(II) in the case of such a prod-
14
uct for which payment is first made 
15
under this paragraph during a cal-
16
endar quarter during the period be-
17
ginning April 1, 2022, and ending 
18
March 31, 2027, the 5-year period be-
19
ginning on the first day of such cal-
20
endar quarter during which such pay-
21
ment is first made. 
22
‘‘(iii) QUALIFYING
BIOSIMILAR
BIO-
23
LOGICAL
PRODUCT
DEFINED.—For pur-
24
poses of this subparagraph, the term 
25
17:03 Apr 19, 2022
H7497
155 
•HR 7497 IH
‘qualifying biosimilar biological product’ 
1
means a biosimilar biological product de-
2
scribed in paragraph (1)(C) with respect to 
3
which— 
4
‘‘(I) in the case of a product de-
5
scribed in clause (ii)(I), the average 
6
sales price under paragraph (8)(A)(i) 
7
for a calendar quarter during the 5- 
8
year period described in such clause is 
9
not more than the average sales price 
10
under paragraph (4)(A) for such 
11
quarter for the reference biological 
12
product; and 
13
‘‘(II) in the case of a product de-
14
scribed in clause (ii)(II), the average 
15
sales price under paragraph (8)(A)(i) 
16
for a calendar quarter during the 5- 
17
year period described in such clause is 
18
not more than the average sales price 
19
under paragraph (4)(A) for such 
20
quarter for the reference biological 
21
product.’’. 
22
SEC. 505. IMPROVING ACCESS TO ADULT VACCINES UNDER 
23
MEDICAID AND CHIP. 
24
(a) MEDICAID.— 
25
17:03 Apr 19, 2022
H7497
156 
•HR 7497 IH
(1) REQUIRING COVERAGE OF ADULT VACCINA-
1
TIONS.— 
2
(A) IN GENERAL.—Section 1902(a)(10)(A) 
3
of 
the 
Social 
Security 
Act 
(42 
U.S.C. 
4
1396a(a)(10)(A)) is amended in the matter pre-
5
ceding clause (i) by inserting ‘‘(13)(B),’’ after 
6
‘‘(5),’’. 
7
(B) 
MEDICALLY
NEEDY.—Section 
8
1902(a)(10)(C)(iv) of such Act (42 U.S.C. 
9
1396a(a)(10)(C)(iv)) is amended by inserting ‘‘, 
10
(13)(B),’’ after ‘‘(5)’’. 
11
(2) NO COST-SHARING FOR VACCINATIONS.— 
12
(A) 
GENERAL
COST-SHARING
LIMITA-
13
TIONS.—Section 1916 of the Social Security 
14
Act (42 U.S.C. 1396o) is amended— 
15
(i) in subsection (a)(2)— 
16
(I) in subparagraph (G), by in-
17
serting a comma after ‘‘State plan’’; 
18
(II) in subparagraph (H), by 
19
striking ‘‘; or’’ and inserting a 
20
comma; 
21
(III) in subparagraph (I), by 
22
striking ‘‘; and’’ and inserting ‘‘, or’’; 
23
and 
24
17:03 Apr 19, 2022
H7497
157 
•HR 7497 IH
(IV) by adding at the end the fol-
1
lowing new subparagraph: 
2
‘‘(J) 
vaccines 
described 
in 
section 
3
1905(a)(13)(B) and the administration of such 
4
vaccines; and’’; and 
5
(ii) in subsection (b)(2)— 
6
(I) in subparagraph (G), by in-
7
serting a comma after ‘‘State plan’’; 
8
(II) in subparagraph (H), by 
9
striking ‘‘; or’’ and inserting a 
10
comma; 
11
(III) in subparagraph (I), by 
12
striking ‘‘; and’’ and inserting ‘‘, or’’; 
13
and 
14
(IV) by adding at the end the fol-
15
lowing new subparagraph: 
16
‘‘(J) 
vaccines 
described 
in 
section 
17
1905(a)(13)(B) and the administration of such 
18
vaccines; and’’. 
19
(B) APPLICATION TO ALTERNATIVE COST- 
20
SHARING.—Section 1916A(b)(3)(B) of the So-
21
cial Security Act (42 U.S.C. 1396o–1(b)(3)(B)) 
22
is amended by adding at the end the following 
23
new clause: 
24
17:03 Apr 19, 2022
H7497
158 
•HR 7497 IH
‘‘(xiv) Vaccines described in section 
1
1905(a)(13)(B) and the administration of 
2
such vaccines.’’. 
3
(3) INCREASED FMAP FOR ADULT VACCINES.— 
4
Section 1905(b) of the Social Security Act (42 
5
U.S.C. 1396d(b)) is amended— 
6
(A) by striking ‘‘and (5)’’ and inserting 
7
‘‘(5)’’; 
8
(B) by striking ‘‘services and vaccines de-
9
scribed in subparagraphs (A) and (B) of sub-
10
section (a)(13), and prohibits cost-sharing for 
11
such services and vaccines’’ and inserting ‘‘serv-
12
ices described in subsection (a)(13)(A), and 
13
prohibits cost-sharing for such services’’; 
14
(C) by striking ‘‘medical assistance for 
15
such services and vaccines’’ and inserting ‘‘med-
16
ical assistance for such services’’; and 
17
(D) by inserting ‘‘, and (6) during the first 
18
8 fiscal quarters beginning on or after the effec-
19
tive date of this clause, in the case of a State 
20
which, as of the date of enactment of the Act 
21
titled ‘An Act to provide for reconciliation pur-
22
suant to title II of S. Con. Res. 14’, provides 
23
medical assistance for vaccines described in 
24
subsection (a)(13)(B) and their administration 
25
17:03 Apr 19, 2022
H7497
159 
•HR 7497 IH
and prohibits cost-sharing for such vaccines, the 
1
Federal medical assistance percentage, as deter-
2
mined under this subsection and subsection (y), 
3
shall be increased by 1 percentage point with 
4
respect to medical assistance for such vaccines’’ 
5
before the first period. 
6
(b) CHIP.— 
7
(1) REQUIRING COVERAGE OF ADULT VACCINA-
8
TIONS.—Section 2103(c) of the Social Security Act 
9
(42 U.S.C. 1397cc(c)) is amended by adding at the 
10
end the following paragraph: 
11
‘‘(12) REQUIRED
COVERAGE
OF
APPROVED, 
12
RECOMMENDED ADULT VACCINES AND THEIR AD-
13
MINISTRATION.—Regardless of the type of coverage 
14
elected by a State under subsection (a), if the State 
15
child health plan or a waiver of such plan provides 
16
child health assistance or pregnancy-related assist-
17
ance (as defined in section 2112) to an individual 
18
who is 19 years of age or older, such assistance shall 
19
include coverage of vaccines described in section 
20
1905(a)(13)(B) and their administration.’’. 
21
(2) NO
COST-SHARING
FOR
VACCINATIONS.— 
22
Section 
2103(e)(2) 
of 
such 
Act 
(42 
U.S.C. 
23
1397cc(e)(2)) is amended by inserting ‘‘vaccines de-
24
scribed in subsection (c)(12) (and the administration 
25
17:03 Apr 19, 2022
H7497
160 
•HR 7497 IH
of such vaccines),’’ after ‘‘in vitro diagnostic prod-
1
ucts described in subsection (c)(10) (and administra-
2
tion of such products),’’. 
3
(c) EFFECTIVE DATE.—The amendments made by 
4
this section take effect on the 1st day of the 1st fiscal 
5
quarter that begins on or after the date that is 1 year 
6
after the date of enactment of this Act and shall apply 
7
to expenditures made under a State plan or waiver of such 
8
plan under title XIX of the Social Security Act (42 U.S.C. 
9
1396 through 1396w–6) or under a State child health plan 
10
or waiver of such plan under title XXI of such Act (42 
11
U.S.C. 1397aa through 1397mm) on or after such effec-
12
tive date. 
13
TITLE VI—ADDITIONAL INSULIN 
14
15
SEC. 601. ERISA REQUIREMENTS WITH RESPECT TO COST- 
16
SHARING FOR CERTAIN INSULIN PRODUCTS. 
17
(a) IN GENERAL.—Subpart B of part 7 of subtitle 
18
B of title I of the Employee Retirement Income Security 
19
Act of 1974 (29 U.S.C. 1185 et seq.) is amended by add-
20
ing at the end the following: 
21
‘‘SEC. 726. REQUIREMENTS WITH RESPECT TO COST-SHAR-
22
ING FOR CERTAIN INSULIN PRODUCTS. 
23
‘‘(a) IN GENERAL.—For plan years beginning on or 
24
after January 1, 2023, a group health plan or health in-
25
17:03 Apr 19, 2022
H7497
161 
•HR 7497 IH
surance issuer offering group health insurance coverage 
1
shall provide coverage of selected insulin products, and 
2
with respect to such products, shall not— 
3
‘‘(1) apply any deductible; or 
4
‘‘(2) impose any cost-sharing in excess of the 
5
lesser of, per 30-day supply— 
6
‘‘(A) $35; or 
7
‘‘(B) the amount equal to 25 percent of 
8
the negotiated price of the selected insulin prod-
9
uct net of all price concessions received by or on 
10
behalf of the plan or coverage, including price 
11
concessions received by or on behalf of third- 
12
party entities providing services to the plan or 
13
coverage, such as pharmacy benefit manage-
14
ment services. 
15
‘‘(b) DEFINITIONS.—In this section: 
16
‘‘(1) SELECTED INSULIN PRODUCTS.—The term 
17
‘selected insulin products’ means at least one of each 
18
dosage form (such as vial, pump, or inhaler dosage 
19
forms) of each different type (such as rapid-acting, 
20
short-acting, intermediate-acting, long-acting, ultra 
21
long-acting, and premixed) of insulin (as defined 
22
below), when available, as selected by the group 
23
health plan or health insurance issuer. 
24
17:03 Apr 19, 2022
H7497
162 
•HR 7497 IH
‘‘(2) INSULIN
DEFINED.—The term ‘insulin’ 
1
means insulin that is licensed under subsection (a) 
2
or (k) of section 351 of the Public Health Service 
3
Act (42 U.S.C. 262) and continues to be marketed 
4
under such section, including any insulin product 
5
that has been deemed to be licensed under section 
6
351(a) of such Act pursuant to section 7002(e)(4) 
7
of the Biologics Price Competition and Innovation 
8
Act of 2009 (Public Law 111–148) and continues to 
9
be marketed pursuant to such licensure. 
10
‘‘(c) OUT-OF-NETWORK
PROVIDERS.—Nothing in 
11
this section requires a plan or issuer that has a network 
12
of providers to provide benefits for selected insulin prod-
13
ucts described in this section that are delivered by an out- 
14
of-network provider, or precludes a plan or issuer that has 
15
a network of providers from imposing higher cost-sharing 
16
than the levels specified in subsection (a) for selected insu-
17
lin products described in this section that are delivered 
18
by an out-of-network provider. 
19
‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall 
20
not be construed to require coverage of, or prevent a group 
21
health plan or health insurance coverage from imposing 
22
cost-sharing other than the levels specified in subsection 
23
(a) on, insulin products that are not selected insulin prod-
24
ucts, to the extent that such coverage is not otherwise re-
25
17:03 Apr 19, 2022
H7497
163 
•HR 7497 IH
quired and such cost-sharing is otherwise permitted under 
1
Federal and applicable State law. 
2
‘‘(e) APPLICATION
OF
COST-SHARING
TOWARDS 
3
DEDUCTIBLES
AND OUT-OF-POCKET MAXIMUMS.—Any 
4
cost-sharing payments made pursuant to subsection (a)(2) 
5
shall be counted toward any deductible or out-of-pocket 
6
maximum that applies under the plan or coverage.’’. 
7
(b) CLERICAL AMENDMENT.—The table of contents 
8
in section 1 of the Employee Retirement Income Security 
9
Act of 1974 (29 U.S.C. 1001 et seq.) is amended by in-
10
serting after the item relating to section 725 the following: 
11
‘‘Sec. 726. Requirements with respect to cost-sharing for certain insulin prod-
ucts.’’. 
SEC. 602. PUBLIC HEALTH SERVICE ACT REQUIREMENTS 
12
WITH RESPECT TO COST-SHARING FOR INSU-
13
LIN PRODUCTS. 
14
(a) IN GENERAL.—Part D of title XXVII of the Pub-
15
lic Health Service Act (42 U.S.C. 300gg–111 et seq.) is 
16
amended by adding at the end the following: 
17
‘‘SEC. 2799A–11. REQUIREMENTS WITH RESPECT TO COST- 
18
SHARING FOR CERTAIN INSULIN PRODUCTS. 
19
‘‘(a) IN GENERAL.—For plan years beginning on or 
20
after January 1, 2023, a group health plan or health in-
21
surance issuer offering group or individual health insur-
22
ance coverage shall provide coverage of selected insulin 
23
products, and with respect to such products, shall not— 
24
17:03 Apr 19, 2022
H7497
164 
•HR 7497 IH
‘‘(1) apply any deductible; or 
1
‘‘(2) impose any cost-sharing in excess of the 
2
lesser of, per 30-day supply— 
3
‘‘(A) $35; or 
4
‘‘(B) the amount equal to 25 percent of 
5
the negotiated price of the selected insulin prod-
6
uct net of all price concessions received by or on 
7
behalf of the plan or coverage, including price 
8
concessions received by or on behalf of third- 
9
party entities providing services to the plan or 
10
coverage, such as pharmacy benefit manage-
11
ment services. 
12
‘‘(b) DEFINITIONS.—In this section: 
13
‘‘(1) SELECTED INSULIN PRODUCTS.—The term 
14
‘selected insulin products’ means at least one of each 
15
dosage form (such as vial, pump, or inhaler dosage 
16
forms) of each different type (such as rapid-acting, 
17
short-acting, intermediate-acting, long-acting, ultra 
18
long-acting, and premixed) of insulin (as defined 
19
below), when available, as selected by the group 
20
health plan or health insurance issuer. 
21
‘‘(2) INSULIN
DEFINED.—The term ‘insulin’ 
22
means insulin that is licensed under subsection (a) 
23
or (k) of section 351 and continues to be marketed 
24
under such section, including any insulin product 
25
17:03 Apr 19, 2022
H7497
165 
•HR 7497 IH
that has been deemed to be licensed under section 
1
351(a) pursuant to section 7002(e)(4) of the Bio-
2
logics Price Competition and Innovation Act of 2009 
3
and continues to be marketed pursuant to such li-
4
censure. 
5
‘‘(c) OUT-OF-NETWORK
PROVIDERS.—Nothing in 
6
this section requires a plan or issuer that has a network 
7
of providers to provide benefits for selected insulin prod-
8
ucts described in this section that are delivered by an out- 
9
of-network provider, or precludes a plan or issuer that has 
10
a network of providers from imposing higher cost-sharing 
11
than the levels specified in subsection (a) for selected insu-
12
lin products described in this section that are delivered 
13
by an out-of-network provider. 
14
‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall 
15
not be construed to require coverage of, or prevent a group 
16
health plan or health insurance coverage from imposing 
17
cost-sharing other than the levels specified in subsection 
18
(a) on, insulin products that are not selected insulin prod-
19
ucts, to the extent that such coverage is not otherwise re-
20
quired and such cost-sharing is otherwise permitted under 
21
Federal and applicable State law. 
22
‘‘(e) APPLICATION
OF
COST-SHARING
TOWARDS 
23
DEDUCTIBLES
AND OUT-OF-POCKET MAXIMUMS.—Any 
24
cost-sharing payments made pursuant to subsection (a)(2) 
25
17:03 Apr 19, 2022
H7497
166 
•HR 7497 IH
shall be counted toward any deductible or out-of-pocket 
1
maximum that applies under the plan or coverage.’’. 
2
(b) NO EFFECT ON OTHER COST-SHARING.—Section 
3
1302(d)(2) of the Patient Protection and Affordable Care 
4
Act (42 U.S.C. 18022(d)(2)) is amended by adding at the 
5
end the following new subparagraph: 
6
‘‘(D) SPECIAL RULE RELATING TO INSU-
7
LIN COVERAGE.—The exemption of coverage of 
8
selected insulin products (as defined in section 
9
2799A–11(b) of the Public Health Service Act) 
10
from the application of any deductible pursuant 
11
to section 2799A–11(a)(1) of such Act, section 
12
726(a)(1) of the Employee Retirement Income 
13
Security Act of 1974, or section 9826(a)(1) of 
14
the Internal Revenue Code of 1986 shall not be 
15
considered when determining the actuarial value 
16
of a qualified health plan under this sub-
17
section.’’. 
18
(c) COVERAGE
OF CERTAIN INSULIN PRODUCTS 
19
UNDER CATASTROPHIC PLANS.—Section 1302(e) of the 
20
Patient Protection and Affordable Care Act (42 U.S.C. 
21
18022(e)) is amended by adding at the end the following: 
22
‘‘(4) COVERAGE
OF
CERTAIN
INSULIN
PROD-
23
UCTS.— 
24
17:03 Apr 19, 2022
H7497
167 
•HR 7497 IH
‘‘(A) IN GENERAL.—Notwithstanding para-
1
graph (1)(B)(i), a health plan described in 
2
paragraph (1) shall provide coverage of selected 
3
insulin products, in accordance with section 
4
2799A–11 of the Public Health Service Act, for 
5
a plan year before an enrolled individual has in-
6
curred cost-sharing expenses in an amount 
7
equal to the annual limitation in effect under 
8
subsection (c)(1) for the plan year. 
9
‘‘(B) TERMINOLOGY.—For purposes of 
10
subparagraph (A)— 
11
‘‘(i) the term ‘selected insulin prod-
12
ucts’ has the meaning given such term in 
13
section 2799A–11(b) of the Public Health 
14
Service Act; and 
15
‘‘(ii) the requirements of section 
16
2799A–11 of such Act shall be applied by 
17
deeming each reference in such section to 
18
‘individual health insurance coverage’ to be 
19
a reference to a plan described in para-
20
graph (1).’’. 
21
SEC. 603. IRC REQUIREMENTS WITH RESPECT TO COST- 
22
SHARING FOR CERTAIN INSULIN PRODUCTS. 
23
(a) IN GENERAL.—Subchapter B of chapter 100 is 
24
amended by adding at the end the following new section: 
25
17:03 Apr 19, 2022
H7497
168 
•HR 7497 IH
‘‘SEC. 9826. REQUIREMENTS WITH RESPECT TO COST-SHAR-
1
ING FOR CERTAIN INSULIN PRODUCTS. 
2
‘‘(a) IN GENERAL.—For plan years beginning on or 
3
after January 1, 2023, a group health plan shall provide 
4
coverage of selected insulin products, and with respect to 
5
such products, shall not— 
6
‘‘(1) apply any deductible; or 
7
‘‘(2) impose any cost-sharing in excess of the 
8
lesser of, per 30-day supply— 
9
‘‘(A) $35; or 
10
‘‘(B) the amount equal to 25 percent of 
11
the negotiated price of the selected insulin prod-
12
uct net of all price concessions received by or on 
13
behalf of the plan, including price concessions 
14
received by or on behalf of third-party entities 
15
providing services to the plan, such as phar-
16
macy benefit management services. 
17
‘‘(b) DEFINITIONS.—In this section: 
18
‘‘(1) SELECTED INSULIN PRODUCTS.—The term 
19
‘selected insulin products’ means at least one of each 
20
dosage form (such as vial, pump, or inhaler dosage 
21
forms) of each different type (such as rapid-acting, 
22
short-acting, intermediate-acting, long-acting, ultra 
23
long-acting, and premixed) of insulin (as defined 
24
below), when available, as selected by the group 
25
health plan. 
26
17:03 Apr 19, 2022
H7497
169 
•HR 7497 IH
‘‘(2) INSULIN
DEFINED.—The term ‘insulin’ 
1
means insulin that is licensed under subsection (a) 
2
or (k) of section 351 of the Public Health Service 
3
Act (42 U.S.C. 262) and continues to be marketed 
4
under such section, including any insulin product 
5
that has been deemed to be licensed under section 
6
351(a) of such Act pursuant to section 7002(e)(4) 
7
of the Biologics Price Competition and Innovation 
8
Act of 2009 (Public Law 111–148) and continues to 
9
be marketed pursuant to such licensure. 
10
‘‘(c) OUT-OF-NETWORK
PROVIDERS.—Nothing in 
11
this section requires a plan that has a network of providers 
12
to provide benefits for selected insulin products described 
13
in this section that are delivered by an out-of-network pro-
14
vider, or precludes a plan that has a network of providers 
15
from imposing higher cost-sharing than the levels specified 
16
in subsection (a) for selected insulin products described 
17
in this section that are delivered by an out-of-network pro-
18
vider. 
19
‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall 
20
not be construed to require coverage of, or prevent a group 
21
health plan from imposing cost-sharing other than the lev-
22
els specified in subsection (a) on, insulin products that are 
23
not selected insulin products, to the extent that such cov-
24
erage is not otherwise required and such cost-sharing is 
25
17:03 Apr 19, 2022
H7497
170 
•HR 7497 IH
otherwise permitted under Federal and applicable State 
1
law. 
2
‘‘(e) APPLICATION
OF
COST-SHARING
TOWARDS 
3
DEDUCTIBLES
AND OUT-OF-POCKET MAXIMUMS.—Any 
4
cost-sharing payments made pursuant to subsection (a)(2) 
5
shall be counted toward any deductible or out-of-pocket 
6
maximum that applies under the plan.’’. 
7
(b) CLERICAL AMENDMENT.—The table of sections 
8
for subchapter B of chapter 100 is amended by adding 
9
at the end the following new item: 
10
‘‘Sec. 9826. Requirements with respect to cost-sharing for certain insulin prod-
ucts.’’. 
Æ 
17:03 Apr 19, 2022
H7497
